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Background: Placental malaria (PM) has been associated with an increased risk of malaria during 
infancy in observational studies suggesting that effective intermittent preventive treatment of 
malaria in pregnancy (IPTp) may reduce the risk of malaria in infants. However, there are no 
randomised controlled trials that have shown that improved IPTp leads to less malaria during 
infancy. To address this knowledge gap, this thesis aimed to: 1) compare the incidence of malaria 
in infants during the first year of life among infants born to mothers with PM detected by 
histology and infants born to mothers without PM; 2) compare the incidence of malaria during 
the first year of life among infants born to mothers randomised to receive monthly IPTp with 
sulfadoxine-pyrimethamine (SP) versus those born to mothers randomised to receive monthly 
IPTp with dihydroartemisinin-piperaquine (DP); and 3) evaluate the effect of PM and IPTp on 
cord blood levels of IgG antibodies to Plasmodium falciparum malaria antigens in infants born 
to mothers enrolled in the trial. 
Methods: Infants born to HIV-uninfected pregnant mothers who participated in a double-blind, 
randomised trial of monthly IPTp with SP or DP in Busia, Uganda were followed from birth to 12 
months of age. The primary outcome was the incidence of malaria measured by passive 
surveillance during the first year of life. PM was categorised as: 1) no PM (no parasites or 
pigment), 2) active PM (presence of parasites), 3) mild-moderate past PM (>0-20% high powered 
fields [HPFs] with pigment), and 4) severe past PM (>20% HPFs with pigment). Cord blood IgG 
antibody levels to P. falciparum antigens: apical membrane antigen-1 (AMA1), erythrocyte 
binding antigen-140 (EBA140), EBA175, EBA181, glutamate-rich protein (GLURP), merozoite 
surface protein-1 (MSP1), reticulocyte-binding protein homologue-2 (Rh2), Rh4, and Rh5 were 
measured using a multiplex antibody bead assay.  
Results: Between December 9, 2016 and December 7, 2017, 678 infants were born into the 
cohort, including 339 to mothers receiving IPTp-DP and 339 to mothers receiving IPTp-SP. A total 
of 581 infants (85.7%) were followed to 12 months of age. There were 1131 malaria episodes 
diagnosed in infants during follow-up. Compared to infants born to mothers with no PM, the 
incidence of malaria was higher among infants born to mothers with active PM (adjusted 
incidence rate ratio [aIRR] 1.30, 95% CI 1.00-1.71, p=0.05) and those born to mothers with 
severe past PM (aIRR 1.28, 95% CI 0.89-1.83, p=0.18), but the differences were not statistically 
significant. When the analysis was stratified by infant sex, the incidence of malaria was higher 
in male infants born to mothers with severe past PM than in those born to mothers with no PM 
(aIRR 2.17, 95% CI 1.45-3.25, p<0.001), but not in female infants (aIRR 0.74, 95% CI 0.46-1.20, 
p=0.22). The association between IPTp and malaria incidence in infants was modified by infant 
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sex. Compared to IPTp-SP, IPTp-DP was associated with a lower incidence of malaria among male 
infants (IRR 0·75, 95% CI 0·58-0·98, p=0·03), but not female infants (IRR 0.99, 95% CI 0.79-1.24, 
p=0.93). There was no significant difference in the cord blood levels of IgG antibodies to 
Plasmodium falciparum among infants born to mothers with active PM, mild-moderate past PM, 
or severe past PM compared to infants born to mothers with no PM, and among infants born to 
mothers who received IPTp-DP compared to those born to mothers who received IPTp-SP. 
Conclusion: Severe past PM was associated with a higher incidence of malaria among male 
infants. IPTp-DP was associated with a lower incidence of malaria among male infants compared 
to IPTp-SP. PM and IPTp did not affect cord blood P. falciparum IgG antibody levels. These 
findings suggest that severe past PM may negatively impact antimalarial immunity in male 
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CHAPTER 1 INTRODUCTION 
1.1 Epidemiology and burden of Plasmodium falciparum malaria in 
pregnancy 
Plasmodium falciparum malaria is a major global public health problem. In 2018, 228 million 
cases of malaria were estimated to have occurred globally, 96.7% of which were due to P. 
falciparum [1]. In sub-Saharan Africa, where most areas are endemic for P. falciparum, pregnant 
women and young children bear the greatest burden of malaria. Eleven million pregnant women 
were estimated to be at risk of P. falciparum infection in 2018 [1]. In areas of moderate to high 
malaria transmission intensity, young children are usually at higher risk of malaria than older 
children and adults because they have less immunity to malaria [2]. Immunity to P. falciparum 
is gradually acquired through repeated infection and exposure to parasites [3-5]. By adulthood, 
most residents of endemic areas have developed partial immunity such that P. falciparum 
infections are primarily asymptomatic. 
P. falciparum infection, unlike other Plasmodium species that cause malaria in humans, is 
associated with severe disease in non-immune individuals mainly due to its unique ability to 
attach to microvascular endothelium leading to sequestration of parasites in body organs 
including lungs, brain, and placenta. P. vivax has been also shown to cause severe disease [6, 7] 
and is associated with adverse birth outcomes including low birth weight and preterm delivery 
[8, 9]. However, the risk of developing severe disease and adverse birth outcomes is lower with 
P. vivax infection than P. falciparum infection [10]. Pregnant women are at higher risk of P. 
falciparum infection than non-pregnant women. The reasons for this are not well understood, 
but hormonal and immunological changes during pregnancy [11, 12], and increased 
attractiveness of pregnant women to mosquitoes, have been suggested as possible explanations 
[13]. The course of P. falciparum infection in pregnant women depends on maternal antimalarial 
immunity, which is determined by malaria endemicity. In areas of low transmission intensity, 
pregnant women typically have little or no immunity to P. falciparum and susceptibility to 
infection is not dependent on maternal gravidity. P. falciparum infection in pregnant women 
with little antimalarial immunity is frequently symptomatic, severe, and is associated with a high 
risk of maternal mortality and foetal loss [14]. In areas of moderate or high malaria transmission 
intensity, pregnant women, like non-pregnant adults, have acquired partial immunity to malaria 
and primigravidae and secundigravidae women are more susceptible to P. falciparum infection 
than multigravidae women [15]. P. falciparum infection in partially immune pregnant women is 




known as placental malaria (PM), which is associated with maternal anaemia and adverse birth 
outcomes such as preterm delivery, low birth weight and stillbirths [16, 17]. In 2018, 11 million 
pregnant women were estimated to have been exposed to malaria in sub-Saharan Africa, and 
872,000 infants suffered from low birth weight as a result [1]. 
In malaria endemic areas, primigravidae and secundigravidae women are more vulnerable to P. 
falciparum infection and its harmful effects because they lack antimalarial immunity specific to 
parasites that infect the placenta [18]. Immunity to P. falciparum is developed by acquisition of 
antibodies to parasite proteins important for attachment of parasites to host tissue receptors 
including chondroitin sulfate A (CSA) which are abundant in the placenta. Parasites isolated from 
placental specimens are immunologically distinct from those isolated from non-pregnant 
individuals, and predominantly express the variant surface antigen 2-CSA (var2CSA) gene, which 
encodes proteins for binding to placental CSA receptors [19, 20]. Immunity to malaria in 
pregnancy is developed by the acquisition of antibodies to CSA binding parasite proteins and 
primigravidae and secundigravidae women are at high risk because they lack these antibodies 
[18, 21]. Also, reduced cell-mediated immune responses have been suggested to play a role in 
the susceptibility of primigravidae and secundigravidae women to PM. This is supported by 
evidence of reduced cell-mediated immune responses in first pregnancies [22] which improve 
over subsequent pregnancies [23]. Together, the lack of antibody mediated immunity and the 
reduced cell-mediated immunity to PM, makes primigravidae and secundigravidae women at 
higher risk of PM and adverse birth outcomes than multigravidae women in malaria endemic 
areas. 
1.2 Placental malaria and its associated pathological changes 
P. falciparum expresses proteins on the membrane of infected erythrocytes which include P. 
falciparum erythrocyte membrane protein (PfEMP) 1, sequestrin, and histidine-rich protein 1 
and 2 [24, 25]. These membrane proteins expressed on infected erythrocytes bind to host 
receptors including vascular cell adhesion molecule-1, intercellular adhesion molecule-1 (ICAM-
1), platelet glycoprotein 4 (CD36), and CSA [24]. Of the P. falciparum membrane proteins 
expressed, PfEMP-1 is a key protein which binds a wide range of receptors including CD36, ICAM-
1, and CD31 that have been implicated in the pathogenesis of both severe and uncomplicated 
malaria [26]. The binding of infected erythrocytes to the endothelium of microvasculature helps 
the parasites evade clearance by the spleen which removes infected erythrocytes [27, 28].  
In pregnant women, the placenta is a preferred site for sequestration of P. falciparum infected 
erythrocytes. P. falciparum infected erythrocytes sequester in the placenta by binding to 




[30] even though parasites may not be detectable in the maternal peripheral blood [31]. P. 
falciparum isolates from the placenta have been shown to have a high affinity for binding to CSA 
receptors, but very low affinity for binding to CD36 and ICAM-1, the receptors commonly bound 
by PfEMP1 in non-pregnant individuals [20, 32] suggesting that parasites with high CSA binding 
affinity are selected for in pregnant women [33]. Sequestration of infected erythrocytes in the 
placenta leads to pathological changes including massive infiltration with inflammatory cells, 
presence of parasites, deposition of haemozoin (malaria pigment), a by-product of haemoglobin 
digestion by malaria parasites, and perivillous fibrin deposition [34], which are associated with 
maternal morbidity and adverse birth outcomes. Without treatment, some women can clear 
placental P. falciparum infection leaving only malaria pigment as evidence of past infection. 
Diagnosis of PM is made at delivery by detection of parasites in placental blood or detection of 
pathological changes in placental tissue by histology. Detection of parasites in placental blood is 
done by microscopic exam of thick blood smears, rapid diagnostic tests [35], or by detecting 
parasite DNA using loop-mediated isothermal amplification (LAMP) [36, 37] or quantitative 
polymerase chain reaction (qPCR) [38]. Detection of PM by histology is done by microscopically 
examining placental tissue sections for the presence of parasites, inflammatory changes, and 
malaria pigment in fibrin or monocytes. Detection of parasites in placental blood by microscopy 
[39], rapid diagnostic tests or LAMP have lower sensitivity for the detection of PM [36, 37] than 
histology. Quantitative PCR has been suggested to have a higher sensitivity than placental 
histology [38], but fails to detect malaria pigment, a sign of past infection. Different methods, 
based on histological findings have been suggested for categorising PM including the Bulmer 
classification [40], the modified Bulmer classification suggested by Ismail et al [41], and the 
Rogerson criteria [42], which are summarised in table 1.1 In addition, a useful semiquantitative 
method for grading inflammation (presence of mononuclear cells graded qualitatively) and 
malaria pigment deposition in fibrin in intervillous space (proportion of high-power fields [HPF] 













Table 1.1: Classification of placental malaria based on histological findings 
Placental malaria category Description 
Bulmer classification [40] 
Not infected No parasites or pigment in monocytes or fibrin 
Active infection Parasites detected with pigment in monocytes but not in 
fibrin 
Active chronic infection Parasites detected with pigment in fibrin 
Past chronic infection No parasites, pigment in fibrin or cells within fibrin 
Modified Bulmer classification [41] 
No infection No parasites or malaria pigment 
Active-acute  Presence of parasites with minimal or no pigment 
Active chronic Presence of parasites with considerable pigment 
Past Presence of pigment with no parasites 
Rogerson criteria [42] 
Class 1 Presence of parasites without pigment in monocytes or fibrin 
Class 2 Parasites present, pigment in monocytes ± fibrin 
Class 3 Parasites present, pigment in fibrin 
Class 4 Presence of pigment only without parasites (past infection) 
Class 5 No parasites or pigment (No infection) 
 
1.3 Association between placental malaria pathological changes and 
adverse birth outcomes 
Different pathological findings associated with PM have been shown to be associated with 
maternal morbidity and adverse birth outcomes. The presence of inflammatory cells in the 
intervillous spaces has been associated with maternal anaemia [42] and low birth weight [42, 
44]. The presence of infected erythrocytes and perivillous fibrin deposition was shown to be 
associated with preterm delivery [44], while presence of pigment deposition in monocytes and 
fibrin has been associated with low birth weight [42]. 
The exact mechanism by which PM leads to adverse birth outcomes is not well known, but 
several possible mechanisms have been suggested including maternal anaemia, inhibition of 
trophoblast invasion, and disruptions in maternal and placental hormones [45]. PM is thought 
to cause adverse birth outcomes through its association with maternal anaemia [46, 47] and 
maternal anaemia is independently associated with adverse birth outcomes including low birth 
weight and preterm birth [48]. Inhibition of trophoblast invasion by PM may lead to poor 
development of the placental vascular system leading to foetal growth restriction [49]. 
Disruptions in placental and maternal hormones have also been suggested as possible 
explanations for PM related foetal growth restriction. PM was reported to be associated with 
reduced levels of insulin-like growth hormone-1 in maternal and cord blood, which was found 




1.4 Effects of malaria in pregnancy on foetal immunity 
There is mounting evidence that P. falciparum infection during pregnancy may affect foetal 
immune responses, which may alter risk of infectious diseases in the newborn later in life [51-
55]. Evidence from laboratory studies shows that cord blood mononuclear cells (CBMCs) from 
newborns of mothers with peripheral malaria parasitaemia or PM have increased production of 
anti-inflammatory cytokines and reduced production of pro-inflammatory cytokines following 
stimulation with non-malaria specific antigens [56-58], and malaria specific antigens [56, 59-61], 
indicating a bias towards immune tolerance. In Gambia, following stimulation with P. falciparum 
antigens, CBMCs of infants born to mothers with placental parasitaemia had increased 
production of interleukin (IL)-10 and reduced production of interferon gamma (IFN-γ) compared 
to CBMCs of infants born to mothers without placental parasitaemia [56]. Fievet et al reported 
increased production of IL-10, following stimulation with synthetic haemozoin, in CBMCs from 
infants born to mothers with malaria pigment in placental tissue compared to those born to 
mothers without malaria pigment in the placenta [57]. In Benin, maternal P. falciparum infection 
at delivery (defined as parasites detected in placental or maternal blood) was associated with 
increased production of IL-10 following toll-like receptor (TLR)-3, 7/8 mediated stimulation of 
CBMCs with non-malaria specific antigens which was associated with increased risk of malaria 
during infancy [58]. In another study, γδ T- cells from CBMCs of infants born to mothers with 
malaria in pregnancy who were treated, demonstrated increased non-specific antigen-driven 
production of IFN-γ and tumour necrosis factor-α compared to CBMCs from infants born to 
untreated mothers [62] suggesting that treatment of malaria in pregnancy may improve immune 
responses in newborns. Together, these studies suggest that PM biases foetal immune 
responses towards tolerance to both malaria and non-malaria specific antigens, which may 
affect the infant’s risk of infections later in life, and treatment of malaria in pregnancy may 
reduce this effect. 
Malaria in pregnancy may also affect acquisition of antibodies by the newborn in-utero or later 
in life. Placental malaria has been associated with reduced maternal-foetal transfer of 
immunoglobulin G (IgG) antibodies to infectious diseases including herpes simplex type 1, 
respiratory syncytial virus and varicella zoster [63], tetanus [64, 65], measles [66], streptococcus 
[66] and P. falciparum malaria [67, 68] which may affect the risk to common infections during 
infancy [69]. Active PM has been associated with reduced maternal-foetal transfer of IgG 
antibodies to P. falciparum antigens including merozoite surface protein (MSP) 1-19, apical 
membrane antigen (AMA)-1 and glutamate rich protein [67]. But this reduction in transfer of 




malaria infection in the first 6 months of life [67]. In Kenya, PM was associated with reduced 
levels of IgG antibodies to P. falciparum antigens (circumsporozoite protein, MSP, rhoptry 
associated protein-1, and erythrocyte binding antigen-175) in infants 4-12 months of age [70] 
suggesting that PM may reduce acquisition of malaria-specific antibodies in infants. However, 
this study did not show a statistically significant association between the risk of malaria 
parasitaemia and reduced acquisition of malaria-specific antibodies, possibly due to small 
sample size. These studies suggest that PM may reduce maternal-foetal transfer of antibodies 
to P. falciparum and other non-malaria pathogens, but whether this affects the risk of malaria 
and non-malaria illnesses during infancy remains to be determined. 
1.5 Association between malaria in pregnancy and malaria risk in infants 
Several studies have reported an association between malaria in pregnancy and a higher risk of 
malaria in infancy. Infants born to mothers with PM detected by microscopy or histology were 
reported to have a higher risk of malaria, compared to those born to mothers without PM, in 
studies conducted in Malawi, Uganda, Benin, Gabon, Tanzania, and Cameroon [71-76]. 
However, these studies had two major limitations. First, in most studies PM was defined as 
detection of parasites in placental blood by microscopy which is less sensitive than placental 
histology [39] and is therefore likely to lead to misclassification and underestimation of the 
effect of PM on infant malaria risk. Secondly, most were observational studies and did not adjust 
for possible confounding by malaria transmission which is shared by both the mother and her 
infant [77]. One study, conducted in Benin, which did adjust for possible confounding by malaria 
transmission intensity, reported an increased risk of malaria in infants born to mothers with PM 
detected by microscopy compared to infants born to mothers without PM [73]. However, this 
effect was only observed in infants who slept in homes with mosquito bed nets and not in those 
who did not have bed nets. Further evaluation of the association between malaria in pregnancy 
and the risk of malaria in infants is needed, including randomised trials using highly efficacious 
interventions for prevention of malaria in pregnancy that significantly reduce malaria parasite 
burden in pregnancy and PM. 
1.6 Prevention of malaria in pregnancy  
To prevent placental malaria and improve birth outcomes for pregnant women residing in 
moderate to high malaria transmission intensity settings, the World Health Organization (WHO) 
recommends that all pregnant women sleep under an insecticide treated bed net (ITN). HIV-
uninfected pregnant women should also take intermittent preventive treatment of malaria in 




trimester and given at every antenatal visit at least a month apart [78]. Previously, IPTp-SP was 
shown to reduce the risk of maternal anaemia, PM, and low birth weight among primigravidae 
and multigravidae women [79-81]. However, currently, widespread antifolate parasite 
resistance [82] threatens the effectiveness of IPTp-SP necessitating alternative drugs and 
strategies for IPTp.  
P. falciparum antifolate resistance develops by mutations in the parasite genes for two 
important enzymes in the parasite DNA synthesis: dihydrofolate reductase (Pfdhfr) and 
dihydropteroate synthase (Pfdhps). A combination of five gene mutations referred to as the 
quintuple mutations, consisting of three mutations in the Pfdhfr gene (N51I, C59R, S108N), and 
two mutations in the Pfdhps gene (A437G, G540E), has been associated with a higher risk of SP 
treatment failure in children [83] and reduced parasite clearance and failure to prevent new 
infections in pregnant women [84-86]. In most parts of East Africa, the prevalence of Pfdhps 
G540E, a proxy marker of the quintuple mutations has been reported to be over 50% [87]. But, 
despite the wide-spread quintuple mutations, a meta-analysis of data from studies conducted 
in sub-Saharan Africa showed that ≥3 doses of IPTp-SP compared to 2 doses, prevent low birth 
weight even in areas with high prevalence of quintuple mutations [88]. In West Africa, where in 
most areas the prevalence of quintuple mutations remains low [89], IPTp-SP remains effective 
at preventing low birth weight [90]. A sixth gene mutation in addition to the quintuple 
mutations, the Pfdhps A581G sextuple mutation, which is associated with complete resistance 
of parasites to SP [91] is emerging in East Africa [87]. In areas where prevalence of the sextuple 
gene is >10%, IPTp-SP has been reported to fail to prevent low birth weight [92] highlighting an 
urgent need for alternative drugs for IPTp. 
Several studies have evaluated alternative drugs and strategies for IPTp, but these studies did 
not show superiority of the alternative regimens and some drugs were poorly tolerated. In 
Ghana, IPTp with amodiaquine (AQ) or IPTp with SP-AQ combination were not superior to IPTp-
SP in preventing low birth weight and PM in HIV-uninfected pregnant women [93]. In addition, 
AQ-based regimens were associated with a higher risk of adverse events compared to IPTp-SP. 
Mefloquine (MQ) for IPTp in HIV-uninfected pregnant women was poorly tolerated and was not 
associated with a reduced risk of low birth weight or PM compared to IPTp-SP, despite 
association with a lower risk of malaria parasitaemia and clinical malaria during pregnancy [94]. 
A multicentre trial, conducted in Uganda, Tanzania, Malawi, Kenya, and Benin, of IPTp with fixed 
dose azithromycin-chloroquine (AZ-CQ) compared to IPTp-SP showed a slightly higher risk of 
adverse birth outcomes (abortion, preterm delivery, low birth weight) among mothers receiving 
IPTp-AZ-CQ and no difference in the risk of PM [95]. Furthermore, AZ-CQ was not well tolerated. 




highly effective artemisinin combination therapy, has also been evaluated for prevention of 
malaria in pregnancy. Delivery of DP has been evaluated using intermittent screening and 
treatment (IST) and IPTp, although the results for the IST approach have been disappointing. In 
studies conducted in Kenya and Malawi, compared to IPTp-SP, IST-DP was associated with a 
higher risk of maternal parasitaemia and PM [96, 97], and higher risk of abortions or stillbirths 
[97]. In contrast to IST-DP, IPTp-DP has shown promising results. In East Africa, IPTp-DP was 
shown to be associated with a lower risk of maternal parasitaemia and incidence of clinical 
malaria during pregnancy, and a lower risk of PM compared to IPTp-DP in HIV-uninfected 
pregnant women [36, 96]. However, despite the reduction in the burden of maternal malaria 
parasitaemia and PM, there was no significant improvement in birth outcomes observed in 
pregnant women who received IPTp-DP compared to those who received SP [37, 98]. 
1.7 Malaria burden and prevention in infants 
Infants residing in areas of moderate-high malaria transmission intensity are one of the groups 
most at risk of malaria and its adverse effects. During the first 3 months of life, infants are 
partially protected from malaria by maternal IgG antibodies to P. falciparum acquired in utero 
[99, 100]. Infants older than 3 months of age are more likely to be admitted due to malaria and 
have a high risk of mortality if they develop severe malaria [2, 101]. As infants grow, the risk of 
malaria infection and clinical malaria increases from three months of age [102] as the levels of 
maternal IgG antibodies to P. falciparum begin to wane [103, 104]. Immunity to malaria after 
three months of life is acquired through repeated malaria infections. 
To prevent and control malaria in infants, the main interventions include sleeping under 
insecticide treated nets, intermittent preventive treatment during infancy (IPTi) with SP [105], 
and seasonal malaria chemoprevention with SP in areas where malaria transmission is not 
perennial [106]. However, these interventions have limitations. The spread of vector resistance 
to pyrethroids, the insecticide used in bed nets [107], and the wide-spread antifolate resistance 
of malaria parasites especially in East and Central Africa [90] is threatening the effectiveness of 
these interventions. Additional ways of preventing and controlling malaria in infants are needed.  
1.8 Effects of prevention of malaria in pregnancy on the risk of malaria in 
infants 
Although PM has been reported to be associated with a higher risk of malaria during infancy [71-
76] suggesting that prevention of malaria in pregnancy may have a protective effect against 
malaria during infancy, evidence of the impact of IPTp on the risk of malaria in infants is limited. 




and alternative regimens have not shown a clear difference in effect. Compared to infants born 
to mothers receiving IPTp-SP, the incidence of malaria was similar among infants born to 
mothers randomised to IPTp-MQ [108] or IST with artemether lumefantrine (AL) [109]. 
However, these studies were limited by the failure of the alternative interventions (IPTp-MQ 
and IST-AL) to show a significant difference in the risk of PM compared to IPTp-SP [94, 110]. 
There is need to evaluate the impact of IPTp on the risk of malaria in infants in randomised trials 
using highly efficacious alternative drugs for IPTp. 
In Uganda, a recent study compared the incidence of malaria in a birth cohort of infants born to 
mothers randomised to monthly IPTp-DP versus 2 monthly IPTp-DP versus 2 monthly IPTp-SP 
[111]. Surprisingly, in this birth cohort, monthly IPTp-DP was associated with a higher incidence 
of malaria in infants during the first year of life compared to 2 monthly IPTp-SP, but only in 
female infants. In male infants, monthly IPTp-DP was associated with a lower incidence of 
malaria compared to IPTp-SP, but the difference was not statistically significant. However, this 
study had several limitations. The sample size was small, infants received DP every three months 
for intermittent preventive treatment of malaria during infancy, and over the course of the study 
successful implementation of indoor residual spraying in the district substantially reduced 
malaria transmission [112]. Thus, there is need to evaluate the impact of IPTp-DP compared to 
SP on the risk of infants who are not taking drugs for malaria prevention in a high malaria 
transmission setting. 
1.9 Thesis rationale 
P. falciparum infection during pregnancy remains a major public health burden, which mainly 
affects pregnant women and children in malaria endemic areas. In pregnant women residing in 
areas of moderate to high malaria transmission intensity, P. falciparum infection is often 
asymptomatic but can lead to PM which is associated with maternal morbidity and adverse birth 
outcomes including preterm delivery, low birth weight and stillbirths [16, 17]. Furthermore, 
increasing evidence mainly from observational studies suggests that PM is associated with an 
increased risk of malaria in infancy [71-73, 75]. This suggests that prevention of malaria in 
pregnancy may lower the risk of malaria in infancy. 
The WHO recommends IPTp-SP for pregnant women residing in areas of moderate-high malaria 
transmission intensity to prevent adverse effects of PM in both the mother and child [78]. 
However, the effectiveness of IPTp is threatened by wide-spread antifolate resistance [82]. 
Recent studies have shown DP to be a promising alternative to SP for IPTp. Compared to IPTp-




pregnancy and a lower risk of PM in HIV-uninfected pregnant women, but this did not 
significantly reduce the risk of adverse birth outcomes compared IPTp-SP [36, 96]. Because IPTp-
DP reduces the risk of PM which has been reportedly associated with a higher risk of malaria 
infancy, it is hypothesised that IPTp with DP may have the additional benefit of reducing the risk 
of malaria in infants. However, evidence to support this hypothesis is currently limited. 
This thesis further explores the association between PM and the incidence of malaria in infants; 
evaluates the impact of IPTp on the risk of malaria in infancy by comparing the incidence of 
malaria during the first year of life in infants born to HIV-uninfected mothers who were 
randomised to monthly IPTp with DP versus SP for prevention of malaria in pregnancy; and 
finally evaluates the impact of IPTp and PM on total cord blood P. falciparum IgG antibody levels.  
1.10 Research questions 
This thesis aimed to answer the following questions: 
1) Is PM associated with a higher incidence of malaria during infancy? 
2) Does preventing malaria in pregnancy with IPTp with DP, a highly efficacious 
antimalarial, protect against malaria during infancy more effectively than IPTp-SP? 
3) What is the impact of PM and IPTp on total P. falciparum-specific IgG antibodies in cord 
blood? 
1.11 Specific thesis objectives  
1) To compare the incidence of malaria in infants during the first year of life among infants 
born to mothers with PM detected by histology and infants born to mothers without 
PM detected by histology. 
2) To compare the incidence of malaria during the first year of life in infants born to 
mothers who were randomised to receive monthly IPTp-DP versus monthly IPTp-SP. 
3) To evaluate the effect of PM and IPTp on cord blood levels of IgG antibodies to P. 
falciparum malaria antigens. 
1.12 Study structure 
This study was part of double-blind, randomised, controlled trial of monthly IPTp with DP versus 
SP for prevention of malaria in HIV-uninfected pregnant women and infants born to these 
women. The trial involved two phases: the pregnancy and infant phases. In the pregnancy phase, 




phase of the study was to compare the risk of a composite birth outcome (preterm delivery [<37 
weeks of gestation], low birth weight [<2500g], or small for gestation age) among mothers who 
received IPTp-DP and mothers who received IPTp-SP. The findings of the pregnancy phase of the 
study have been published [37] and are not a subject of this thesis.  
The infant phase, which is the focus of this thesis, involved follow-up of all live births to mothers 
who took part in the randomised trial to one year of age. The primary objective of the infant 
phase of the study was to compare the incidence of malaria during the first year of life among 
infants born to mothers randomised to monthly IPTp-DP with those born to mothers 
randomised to monthly IPTp-SP. 
1.13 Thesis structure 
Chapter 1 provides thesis introduction, thesis rationale, study questions, thesis objectives and a 
summary of the study structure. Chapter 2 presents a systematic review of the literature on the 
impact of P. falciparum malaria and intermittent preventive treatment of malaria in pregnancy 
on the risk of malaria in infants which was published in the Malaria Journal in September 2019 
and an update of literature published since then. Chapter 3 presents the study design and 
methodology including study procedures and statistical methods. In Chapter 4, a manuscript 
reporting the association between PM and the incidence of malaria in infants is presented. This 
manuscript was published in the Malaria Journal. Chapter 5 presents a manuscript reporting the 
impact of IPTp-DP vs IPTp SP on the incidence of malaria in infants. This manuscript was 
published in the BMC Medicine journal. Chapter 6 resents a manuscript on the effect of IPTp 
and PM on cord blood P. falciparum IgG antibody levels and the relationship between cord blood 
IgG antibody levels and the incidence of malaria during the first year of life. Lastly, Chapter 7 
discusses the research findings, their implications, and highlights areas for future research. 
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CHAPTER 2 LITERATURE REVIEW 
2.1 Introduction 
This chapter presents a systematic review of the literature on the impact of P. falciparum malaria 
and intermittent preventive treatment of malaria in pregnancy on the risk of malaria in infants 
which was published in Malaria Journal in September 2019. At the end of the chapter, an update 
of the recent published literature on the same subject and a conclusion are presented. 
2.2 Systematic review paper 
Below is the research paper cover sheet for the published systematic review, followed by the 

















Background: Studies of the association between malaria in pregnancy (MiP) and malaria during 
infancy have provided mixed results. A systematic review was conducted to evaluate available 
evidence on the impact of Plasmodium falciparum malaria infection during pregnancy, and 
intermittent preventive treatment of malaria during pregnancy (IPTp), on the risk of clinical 
malaria or parasitaemia during infancy.  
Methods: MEDLINE, EMBASE, Global Health, and Malaria in Pregnancy Library databases were 
searched from inception to 22 May 2018 for articles published in English that reported on 
associations between MiP and malaria risk in infancy. Search terms included malaria, 
Plasmodium falciparum, pregnancy, placenta, maternal, prenatal, foetal, newborn, infant, child 
or offspring or preschool. Randomised controlled trials and prospective cohort studies, which 
followed infants for at least 6 months, were included if any of the following outcomes were 
reported: incidence of clinical malaria, prevalence of parasitaemia, and time to first episode of 
parasitaemia or clinical malaria. Substantial heterogeneity between studies precluded meta-
analysis. Thus, a narrative synthesis of included studies was conducted. 
Results: The search yielded 14 published studies, 10 prospective cohort studies and four 
randomised trials; all were conducted in sub-Saharan Africa. Infants born to mothers with 
parasitaemia during pregnancy were at higher risk of malaria in three of four studies that 
assessed this association. Placental malaria detected by microscopy or histology was associated 
with a higher risk of malaria during infancy in nine of 12 studies, but only one study adjusted for 
malaria transmission intensity. No statistically significant associations between the use of IPTp 




Conclusion: Evidence of an association between MiP and IPTp and risk of malaria in infancy is 
limited and of variable quality. Most studies did not adequately adjust for malaria transmission 
intensity shared by mothers and their infants. Further research is needed to confirm or exclude 
an association between MiP and malaria in infancy. Randomised trials evaluating highly effective 
interventions aimed at preventing MiP, such as IPTp with dihydroartemisinin-piperaquine, may 
help to establish a causal association between MiP and malaria in infancy. 
Keywords: Malaria, pregnancy, infants, intermittent preventive treatment 
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In sub-Saharan Africa, an estimated 30 million pregnant women are at risk of Plasmodium 
falciparum infection every year [1]. In areas of moderate to high malaria transmission intensity, 
like most parts of sub-Saharan Africa, P. falciparum infection in pregnant women is usually 
asymptomatic because adults are usually partially immune to malaria infection. However, P. 
falciparum infection during pregnancy can lead to placental malaria (PM). At delivery, 25% of 
pregnant women in sub-Saharan Africa were estimated to have PM detected by microscopy in 
2007 [2]. Infection with P. falciparum during pregnancy has been associated with maternal 
morbidity such as maternal anaemia [3] and adverse birth outcomes including abortions, 
stillbirths, preterm delivery, and low birth weight [4-7].  
The effects of P. falciparum infection during pregnancy on the infant may extend beyond the 
neonatal period [8]. Studies have shown that in utero foetal exposure to malaria antigens may 
negatively affect development of immunity to infectious diseases, including malaria in the 
newborn [9-11]. Foetal exposure to P. falciparum antigens has been shown to induce malaria 
specific immune responses that are biased towards tolerance to malaria antigens [12-14], while 
treatment of malaria in pregnancy (MiP) was shown to be associated with pro-inflammatory 
responses toward malaria specific antigens [15], suggesting that infants exposed to malaria in 
utero may have a higher risk of malaria during early childhood, and treatment of MiP may 
improve antimalarial immunity in infants. However, studies evaluating the association between 
MiP and malaria in infancy have shown mixed results. Some studies have reported an increased 
risk of clinical malaria or parasitaemia in infants born to mothers with placental malaria (PM) 
[16-18], while others have reported no difference in the risk of malaria in infants born to 
mothers with and without PM at delivery [19, 20]. One study has suggested that infants born to 
primigravid mothers with PM have a lower risk of malaria [21].  
Intermittent preventive treatment of MiP (IPTp) with sulfadoxine-pyrimethamine (SP), remains 
one of the main interventions recommended by the World Health Organization in areas of 
moderate to high malaria transmission intensity mainly to improve birth outcomes [22], despite 
widespread resistance of malaria parasites to antifolate drugs [23]. Although IPTp-SP still 
improves birth outcomes in settings with antifolate resistance [24], its impact on PM and 
maternal parasitaemia remains minimal [25, 26]. This continues to expose the foetus to malaria 
antigens which may negatively affect the health of the infant even after delivery [27]. 
Intermittent preventive treatment has been shown to be associated with improved infant 
outcomes beyond delivery, such as perinatal mortality [28], but the impact of IPTp on the risk of 




such as dihydroartemisinin piperaquine (DP), which markedly reduces both the risk of malaria 
parasitaemia and incidence of clinical malaria during pregnancy, and reduces the prevalence of 
PM at delivery but does not clearly improve birth outcomes compared to IPTp-SP [25, 26, 29], 
possible additional benefits of IPTp to the newborn including reducing the risk of malaria in 
infancy may have IPTp policy implications. Understanding the impact of IPTp on the risk of 
malaria in infants is important in order to maximise the benefits of malaria prevention in 
pregnancy. 
To better understand the effect of maternal parasitaemia, PM, and IPTp on the risk of malaria 
in infants, which may have potential to guide policy on the choice of alternative drugs for IPTp, 
a systematic review was conducted to examine and summarize published studies evaluating the 
impact of P. falciparum parasitaemia in pregnancy and PM, and the effect of IPTp, on the risk of 
clinical malaria or parasitaemia in infants. 
Methods 
This systematic review was conducted following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) guidelines [30]. The protocol for this systematic review 
was developed and registered with PROSPERO register (Registration number: CRD42018088869) 
prior to conducting the review. 
Selection criteria 
Original research studies were included if they were published in English and evaluated 
associations between P. falciparum infection during pregnancy or IPTp and the risk of 
parasitaemia or incidence of malaria in infants born to HIV-uninfected pregnant women. Only 
randomised controlled trials (RCTs) and prospective cohort studies in which infants were 
followed up for at least 6 months were included. Studies involving only HIV-exposed infants, 
animal studies, and studies of non-falciparum malaria were excluded. 
Information sources and search strategy 
MEDLINE, EMBASE, Global Health, and Malaria in Pregnancy (MiP) Library [31] databases were 
searched from inception to 22 May 2018. All review authors participated in developing the 
search strategy and AK conducted the search. MEDLINE, EMBASE and Global Health databases 
were searched via the Ovid interface using Medical Subject Headings (MeSH) of key search 
terms. The MiP library [31] was searched using key search terms, including malaria, Plasmodium 




born, infant, child, offspring, and preschool. The search was limited to journal articles reporting 
human studies and published in the English language. Additional studies were identified by 
scrutinising reference lists of studies that met the inclusion criteria and relevant review articles. 
A bibliography of included studies was shared with other experts in the field of MiP to assess 
whether all the relevant articles had been retrieved.  
Study selection 
Lists of titles and abstracts of retrieved articles were exported to Endnote and duplicates were 
removed. Retrieved titles and abstracts were assessed for eligibility at the level of titles and 
abstracts by the corresponding author. Full articles and abstracts of potentially relevant articles 
and those where there was uncertainty about whether to include or exclude the article were 
retrieved and assessed for eligibility by two independent reviewers (AK and DC). Where there 
was disagreement, it was resolved by discussing with the rest of the authors.  
Data extraction process 
Data were extracted by one reviewer (AK) and verified by a second reviewer (DC). A data 
extraction matrix in an Excel spreadsheet was developed and piloted prior to data extraction. 
The Excel spreadsheet included the following variables: author and year of publication, country 
where the study was done, study period (dates of fieldwork), transmission intensity as measured 
by entomological inoculation rate, study design (considered RCT if IPTp was randomised, 
otherwise defined as an observational study), length of follow-up, follow-up schedule, study 
objectives, study population, sample size, long-lasting insecticide treated net (ITN) coverage 
among study participants, whether IPTp was given, type and frequency of IPTp regimen, 
whether maternal peripheral malaria parasitaemia was measured, timing of measurement of 
maternal peripheral malaria parasitaemia and how it was measured, PM detection, PM case 
definition, when and how clinical malaria or parasitaemia were detected in the infant, study 
outcomes, proportion of infants born to mothers with peripheral malaria parasitaemia or PM, 
adjustment for potential confounding factors, losses to follow-up, proportion of infants with 
outcomes of interest, results including effect sizes with confidence intervals and p-values, and 
study strengths and limitations. Disagreements between the two reviewers were resolved by 
discussion. Unresolved disagreements were settled by a third reviewer (either SS or GD or SR). 
Corresponding authors of included studies were contacted by email for any missing or unclear 
information. Corresponding authors who did not respond to the first email contact were 
contacted two more times and if they did not respond at the third contact, they were not 




Assessment of risk of bias  
The risk of bias in individual studies was assessed by two reviewers using the Newcastle-Ottawa 
quality assessment scale for cohort studies [32], and the Cochrane Collaboration tool for 
randomised controlled trials [33]. Details of how the risk of bias was assessed in cohort studies 
were published in the systematic review protocol (PROSPERO Registration number: 
CRD42018088869). Studies were rated on the following categories: selection, comparability, and 
outcome. For the selection category, studies were rated on the following items: 
representativeness of the exposed group (whether the exposed cohort was truly representative 
of the average from the community), selection of the non-exposed group, measurement of the 
exposure (if the exposed and the unexposed were from the same community), and 
demonstration that the outcome was not present at the start of follow-up. For the comparability 
category, studies were assessed based on whether the study adjusted for malaria transmission 
or controlled for malaria prevention during pregnancy using IPTp or ITNs. In the outcome 
category, studies were rated on the following items: ascertainment of outcome, whether follow-
up was long enough for outcomes to occur (follow-up of six months was considered adequate), 
and completeness of follow-up (proportion of infants lost to follow-up, and whether 
characteristics of those lost to follow-up were reported). Each item in the selection and outcome 
categories was awarded a maximum of one point. The comparability category was awarded a 
maximum of two points. Studies were awarded a maximum of nine points. Studies that had a 
score of 9 were rated as having medium risk of bias while those with a score of ≤8 were rated as 
high risk.  
Data synthesis 
A systematic narrative synthesis of the included studies was conducted. A meta-analysis was not 
conducted because studies had substantial variation in the definition of malaria exposure during 
pregnancy, type of IPTp given, length of follow-up, and determination of primary outcome. 
Results were summarised using tables and in text. Tables with summary descriptions of study 
design, MiP exposure measurement, follow-up time, outcome measurement and results were 
generated. Studies were grouped in clusters according to the type of exposure (maternal 
peripheral malaria during pregnancy, or PM or IPTp), and outcome of interest (incidence of 
malaria in infants, prevalence of malaria parasitaemia, time to first malaria parasitaemia or first 








Overall, 2084 titles and abstracts were identified and retrieved from searches of electronic 
databases. An additional 2 records were identified from searching lists and contacting experts 
in the field (figure 2.1). Of the 2086 records, 461 duplicates were removed, and 1625 records 
were screened. Of these, 1582 records were excluded after review of the title and abstract, and 
29 were excluded for various reasons after reviewing full text articles. Only 14 articles were 





Figure 2.1 Study Selection results 
 
Characteristics of included studies  
All 14 studies were conducted in sub-Saharan Africa (Table 2.1); 10 prospective cohort studies 
and four RCTs. Of the 10 cohort studies, IPTp-SP was given in seven studies, and IPTp was not 
given in two [17, 34] because they were conducted before implementation of the WHO 
recommendation on IPTp. Malaria transmission data in form of entomological inoculation rate 
(number of infectious mosquito bites per person per year) was reported in half of the included 




of infants ranged from one year to five years. In 10 studies, infants were followed up from birth 
to one year of age [16, 18-21, 34-38]. Maternal malaria exposure was determined by 1) 
microscopy (N=5) [18, 36, 37, 39] or DNA PCR of maternal blood [40], 2) microscopy of placental 
blood only (N=6) [17, 18, 21, 34, 35, 37], or 3) histology of placental tissue (N=5) [16, 19, 36, 40, 
41]. Malaria infection during infancy was measured as malaria parasitaemia (prevalence of 
parasitaemia, N=7; time to first parasitaemia, N=4), and clinical malaria (incidence of clinical 
malaria, N=5; time to first clinical malaria, N=2). Malaria parasitaemia was assessed during 
weekly [35], fortnightly [21], or monthly [18, 37] routine visits. Clinical malaria was assessed by 
active surveillance in three studies [21, 35, 36] and by passive surveillance in 11 of the studies 
[16-20, 34, 37-41]. ITN use in infants was not reported in half of the studies. In five studies, ITN 
use was reported as 100% [20, 41], 51% [21], 73% [19], and 95% [18]. In one study, 66% of infants 
were from families that owned at least an ITN at enrolment [35] while in another study, all 
infants did not have ITNs [34]. The median number of infants born to mothers with maternal 
parasitaemia was 224 (range 28-236). The median number of infants born to mothers with PM 
detected by microscopy or histology was 59 (range 15-445). Out of 11 studies which assessed 
association between PM and the risk of malaria in infants, there were three studies with ≥100 






Table 2.1 Characteristics of included studies 









Measures of malaria in pregnancy 








Parasitaemia Clinical malaria 
Tassi Yunga, 2018. Cameroon [34]  80 cohort None 1 year      
Boudova, 2017. Malawi [40]  473 
RCT SP vs CQ vs CQ 
prophylaxis 
2 years 
     
Ruperez, 2016. Benin, Gabon, Tanzania, 
Mozambique [38] 
4247 RCT SP vs MQ 
1 year 
     
Sylvester, 2016. Tanzania [41]  206 cohort Not reported 2 years      
De Beaudrap, 2016. Uganda [37] 832 cohort SP 1 year      
Awine, 2016. Ghana [19] 988 RCT SP vs ISTp-AL 1 year      
Apinjoh, 2015. Cameroon [36] 415 cohort SP 1 year      
Ndibazza, 2013. Uganda [39] 2289 cohort SP 5 years      
Borgella, 2013. Benin [18] 194 cohort SP 1 year      
Asante, 2013. Ghana [20] 1855 cohort SP 1 year      
Le Port, 2011. Benin [35] 550 cohort SP 1 year      
Bardaji, 2011.Mozambique [16] 997 RCT SP vs placebo 1 year      
Schwarz, 2008. Gabon [17] 527 cohort None 2.5 years      
Mutabingwa, 2005. Tanzania [21] 453 cohort SP 1 year      
aMalaria detected in maternal blood by microscopy or PCR,  
bPlacental malaria detected in placental blood by microscopy,  
cPlacental malaria detected in placental tissue by histology 
Abbreviations: AL-artemether lumefantrine CQ-chloroquine, IPTp intermittent preventive treatment of malaria in pregnancy, ISTp intermittent screening and treatment of malaria 






Table 2.2 Association between maternal parasitaemia and malaria risk in infancy stratified by outcome measure 
Author, year of 
publication 
(ref)  
Timing of measurement 
of maternal parasitaemia 
Method used to detect 
maternal parasitaemia 
Exposure groups (n) 
Measure of association (95% CI), p-
value 
Confounders adjusted for 
Prevalence of parasitaemia 
Boudova, 2017 
[40] 
2nd and 3rd trimester PCR 
Unexposed (n=184) reference 
OR=1.5 (0.5-4.4), p=0.45 
Maternal age, gestation age at delivery, 
IPTp arm Exposed (n=28) 
De Beaudrap, 
2016 [37] 
2nd and 3rd trimester Microscopy or RDT 
Unexposed (n=626) reference 
RR=2.97 (1.37-6.42), p=NR 
Gravidity, birth season, haemoglobin 
genotype, residence Exposed (n=198) 
Borgella, 2013 
[18] 
1st trimester Microscopy 
Unexposed (n=NA) reference 
OR=1.12 (0.23-5.45), p=0.89 
Residence near the lake, birth season 
Exposed (n=NA) 
2nd trimester Microscopy 
Unexposed (n=142) reference 
OR=0.87 (0.35-2.09), p=0.75 Exposed (n=52) 
3rd trimester Microscopy 
Unexposed (n=121) reference 
OR=4.16 (1.64-10.54), p=0.003 Exposed (n=73) 
Time to first parasitaemia 
Borgella, 2013 
[18] 
1st trimester Microscopy 
Unexposed (n=NA) reference 
HR=1.00 (0.42-2.39), p=0.99 
Residence near the lake, birth season 
Exposed (n=NA) 
2nd trimester Microscopy 
Unexposed (n=142) reference 
HR=1.14 (0.62-2.12), p=0.68 Exposed (n=52) 
3rd trimester Microscopy 
Unexposed (n=121) reference 
HR=2.95(1.58-5.50), p=0.001 Exposed (n=73) 
Time to first clinical malaria 
Borgella, 2013 
[18] 
1st trimester Microscopy 
Unexposed (n=NA) reference 
HR=0.97 (0.32-2.92), p=0.95 
Residence near the lake, birth season 
Exposed (n=NA) 
2nd trimester Microscopy 
Unexposed (n=142) reference 
HR=1.15 (0.58-2.28), p=0.70 Exposed (n=52) 
3rd trimester Microscopy 
Unexposed (n=121) reference 
HR=3.19 (1.59-6.38), p=0.001 Exposed (n=73) 
Incidence of clinical malaria 
Ndibazza, 2013 
[39] 
Baseline and delivery Microscopy 
Unexposed (n=2053) reference 
HR=1.23 (1.01-1.51), p=0.04 
Maternal age, ITN possession, parity, 
education, social economic status, 
residence, mother’s HIV status 
Exposed (n=236) 
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; IPTp, intermittent preventive treatment of malaria in pregnancy; ITN, insecticide treated net; 




Association between maternal parasitaemia and the risk of malaria in infancy 
The association between maternal parasitaemia and malaria risk in infancy was assessed in three 
cohort studies [18, 37, 39] and one RCT of IPTp-SP versus IPTp with chloroquine (CQ) versus CQ 
prophylaxis conducted in Malawi [40] (Table 2.2). In Malawi, infants born to mothers with 
malaria parasitaemia detected during the 2nd or 3rd trimester had higher odds of parasitaemia 
compared to infants born to mothers without parasitaemia during pregnancy, but the difference 
was not statistically significant [40]. In a cohort study conducted in Uganda, infants born to 
mothers with any parasitaemia detected by microscopy during pregnancy had a higher risk of 
parasitaemia during the first year of life compared to infants born to mothers without 
parasitaemia during pregnancy adjusted for gravidity, birth season, haemoglobin genotype, and 
residence (risk ratio [RR] 2.97; 95 % confidence interval [CI] 1.37-6.42) [37]. In Benin [18], infants 
born to mothers having parasitaemia in the 3rd trimester had higher prevalence of parasitaemia 
(odds ratio [OR] 4.16; 95% CI 1.64-10.54), shorter time to first clinical malaria (hazard ratio [HR] 
3.19; 95% CI 1.59-6.38) and shorter time to first parasitaemia (HR 2.95; 95% CI 1.58-5.5) 
compared to those born to mothers without parasitaemia in the 3rd trimester after adjusting for 
birth season and residence near the lake (Table 2.2). In the same study, maternal parasitaemia 
detected during 1st or 2nd trimester was not associated with an increased risk of malaria during 
infancy [18]. In another cohort study conducted in Uganda, infants born to mothers with malaria 
parasitaemia at enrolment or at delivery had a higher incidence of clinical malaria during the 
first five years of life compared to infants born to mothers without parasitaemia (HR 1.23; 95% 
CI 1.01-1.51) [39].  
Association between placental malaria and risk of malaria in infants 
Six studies evaluating the association between PM detected by microscopy only and the risk of 
malaria in infants produced mixed results (Table2.3). The prevalence of parasitaemia was higher 
in infants born to mothers with PM detected by microscopy compared to those born to mothers 
without PM (RR 10.42; 95 % CI 2.64-41.10) in a cohort study conducted in Uganda [37] while the 
prevalence of parasitaemia and clinical malaria tended to be lower in Benin [18] though this was 
not statistically significant (OR 0.72; 95% CI 0.25-2.11). Compared to infants born to mothers 
without PM, infants born to mothers with PM detected by microscopy had a shorter time to first 
parasitaemia in Cameroon [34], Benin [35] and Tanzania [21], and a shorter time to first clinical 
malaria in Gabon (HR 2.1; 95 % CI 1.2-3.7) [17]. The only study that adjusted for malaria exposure 
among other confounding factors showed an association between PM detected by microscopy 
and time to first parasitaemia but only among infants resident in houses with ITNs (HR 2.13; 95 




association between PM detected by microscopy and time to first parasitaemia (OR 0.68; 95 % 
CI 0.34-1.38) or time to first clinical malaria (HR 0.60; 95 % CI 0.28-1.32) in infants [18].  
Five studies evaluated associations between PM detected by histology and the risk of malaria in 
infancy (table 2.4). Histology detected PM was associated with an increase in the odds of clinical 
malaria in Malawi (OR 3.9; 95% CI 1.2-13.0) [40], Tanzania (OR 4.79; 95% 2.21-10.38) [41], and 
Mozambique (OR 4.63; 95% CI 2.10-10.24) [16] while one study in Cameroon did not find a 
statistically significant association between histologically detected PM and prevalence of 
malaria in infants (OR 0.72; 95% CI 0.40-1.28) [36]. Histologically detected PM was associated 
with a higher incidence of malaria in Malawi (unadjusted incident rate ratio [IRR] 2.3; 95% CI 




Table 2.3. Association between placental malaria detected by microscopy and the risk of malaria in infancy stratified by outcome. 
Author, year of 
publication (ref) 
PM exposure  
group (n) 
Measure of association (95% CI),  
p-value 
Confounders adjusted for 
Prevalence of parasitaemia 
De Beaudrap, 2016 
[37] 
Unexposed (475) reference 
RR=10.42 (2.64-41.10), p=NR 
Gravidity, maternal age, residence, level of education, season, 
maternal HIV status, ITN use Exposed (15) 
Borgella, 2013 [18] 
Unexposed (154 reference 
OR=0.72 (0.25-2.11), P=0.55 
Residence near the lake, birth season 
Exposed (36) 
Time to first parasitaemia 
 
Tassi Yunga, 2018a [34] 
No PM (36) reference 
Gravidity, birth season Hb genotype, residence PM Lo (18) HR=2.6 (1.3-4.8) 
PM Hi (18) HR=1.5 (0.7-3.7) 
Borgella, 2013 [18] 
Unexposed (154) reference 
HR=0.68 (0.34-1.38), p=0.29 
Residence near the lake, birth season 
Exposed (36) 
Le Port, 2011 [35] 
Unexposed (485) reference 
HR=1.62 (1.08-2.43), p=0.02 
Unadjusted 
Exposed (59) 
Le Port, 2011 [35] 
Unexposed, had ITN (321) Reference 
HR= 2.13 (1.24-3.67) p<0.01 
Exposure to anopheles, season, antenatal care, severe anaemia 
Exposed, had ITN (34) 
Unexposed, no ITN (158) Reference 
HR=1.18 (0.60-2.33), p=0.62 Exposed, no ITN (25) 
Mutabingwa, 2005 
[21] 
Unexposed (384) reference 
HR=1.41 (1.01-1.99), p=NR 
Gravidity, residence, transmission season at birth, and bed net 
usage Exposed (69) 
Time to first clinical malaria 
Borgella, 2013 [18]  
Unexposed (154) reference 
HR=0.60 (0.28-1.32), p=0.21 
Residence near the lake, birth season 
Exposed (36) 
Schwarz, 2008 [17] 
Unexposed (477) reference 
HR=2.1 (1.2-3.7), p=NR 
Gravidity, residence, birth season, IPTi, bed net use 
Exposed (50) 
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; IPTi, intermittent preventive treatment of malaria in infancy; ITN, 
insecticide treated net; NR, Not reported; OR, odds ratio; PM, placental malaria; RR, risk ratio. 





Table 2.4 Association between placental malaria detected by histology and the risk of malaria in infancy stratified by outcome. 
Author, year of 
publication (ref) 
Placental malaria 
exposure group (n) 
Measure of association (95% CI), p-
value 
Confounders adjusted for  
Clinical malaria 
Boudova, 2017 [40] 
Unexposed (184) reference 
OR=3.9 (1.2-13.0), p=0.03 
Maternal age, gestation age at delivery, IPTp arm 
Exposed (67) 
Boudova, 2017 [40] 
Unexposed (184) reference 
Unadjusted 
Exposed (67) IRR=2.3 (1.1-4.8), p=NR 
Sylvester, 2016 [41] 
Unexposed (165) reference 
OR=4.79 (2.21-1O.38), p<0.05 
Gravidity, season of birth, infant birth weight, maternal age 
Exposed (41) 
Awine, 2016 [19] 
Unexposed (484) reference ITN use, gender, social economic status, living near an irrigated 
area, infant age, maternal baseline parasitaemia Exposed (202) IRR=0.86 (0.54-1.37), p=0.52 
Apinjoh, 2015 [36] 
Unexposed (n=237) reference 
OR=0.72 (0.40-1.28), p=0.26 
Not indicated 
Exposed (n=166) 
Bardaji, 2011 [16] 
Unexposed (424) reference 
Residence near the lake, birth season 
Past infection (321) OR=3.06 (1.94-4.82), p<0.001 
Acute infection (42) OR=4.63 (2.10-10.24), p<0.001 
Chronic infection (82) OR=3.95 (2.07-10.24), p<0.001 
Prevalence of parasitaemia 
Boudova, 2017 [40] 
Unexposed (184) reference 
OR=2.5 (1.0-6.3), p=0.06 
Maternal age, gestation age at delivery, IPTp arm 
Exposed (67) 
Abbreviations: CI, confidence interval; IPTp, intermittent preventive treatment of malaria in pregnancy; IRR; incident rate ratio; ITN, insecticide treated net; NR, 




Impact of IPTp on the risk of malaria in infants 
Four studies evaluated the impact of IPTp on the risk of malaria in infants (Table 2.5). Of these, 
three were RCTs and one was an observational study where some women received IPTp-SP and 
others received no IPTp. There was no significant difference in the incidence of malaria among 
infants born to mothers randomised to IPTp-MQ vs IPTp-SP (IRR 0.95; 95% CI 0.81-1.13) in a 
multicentre RCT conducted in Benin, Gabon, Tanzania, and Mozambique [38] and among infants 
born to mothers randomised to intermittent screening and treatment of MiP (ISTp) with 
artemether-lumefantrine (AL) vs IPTp-SP (IRR 0.94; 95% CI 0.68-1.59) conducted in Ghana [19]. 
In a cohort study conducted in Ghana, the risk of malaria was higher in infants born to mothers 
who did not receive IPTp compared to infants born to mothers who received IPTp-SP, but this 
difference was also not statistically significant [20]. In Mozambique, the odds of clinical malaria 
in infants born to mothers who were randomised to IPTp-SP were higher, but not statistically 
significantly so, than in infants born to mothers randomised to placebo (OR 1.28; 95% CI 0.90-




Table 2.5 Impact of IPTp on the risk of malaria in infancy 




IPTp arm (n) Measure of association (95% 
CI), p-value 
Confounders adjusted for  
Ruperez, 2016 [38] Yes 
IPTp-SP (1432) reference 
IRR=0.95 (0.81-1.13), p=0.60 
Country 
IPTP-MQ (2815) 
Awine, 2016 [19] Yes 
IPTp-SP (495) reference 
IRR=0.94 (0.68-1.59), p=0.76 
Gender, social economic status, residence, irrigated area, season, 
ITN use, baseline parasitaemia, maternal haemoglobin ISTp-AL (493) 
Asante, 2013 [20] No 
IPTp-SP (1755) reference 
HR=1.23 (0.93-1.59), p=0.15 
Unadjusted 
No IPTp (97) 




OR=1.28 (0.90-1.83), p=0.17 
Unadjusted 
Abbreviations: AL-artemether lumefantrine; CI, confidence interval; IPTp, intermittent preventive treatment of malaria in pregnancy; IRR, incident rate ratio; ISTp 




Table 2.6 Assessment of risk of bias for observational studies using the Newcastle Ottawa scale 
Author, year of publication (ref) Selection comparability Outcome Total Overall risk of 
bias REC SNEC ME DON AME AI AO FL CF 
Tassi Yunga, 2018 [34] * * * * - - * * * 7 high 
Boudova, 2017 [40] * * * * - * * * - 7 high 
Sylvester, 2016 [41] * * * * - - * * - 6 high 
De Beaudrap, 2016 [37] * * * * - * * * * 8 high 
Apinjoh, 2015 [36] * * * * - - * * - 6 high 
Ndibazza, 2013 [39] * * * * - * * * * 8 high 
Borgella, 2013 [18] * * * * - * * * * 8 high 
Asante, 2013 [20] * * * * * * * * * 9 medium 
Le Port, 2011 [35] * * * * * * * * * 9 medium 
Schwarz, 2008 [17] * * * * - * * * - 7 high 
Mutabingwa, 2005 [21] * * * * - * * * * 8 high 
Abbreviations: REC, Representativeness of the exposed cohort; SNEC, selection of the non-exposed cohort, ME, measurement of exposure to malaria during 
pregnancy; DON, demonstration that the outcome of interest was not present at the start of the study; AME, adjusted for malaria transmission exposure, AI, 
Adjusted for IPTp or insecticide treated net use; AO, assessment of the outcome, FL, follow-up long enough for outcome to occur; CF; completeness of follow-up. 




Assessment of risk of bias in individual studies 
Risk of bias in individual studies was assessed using the Newcastle Ottawa scale for 
observational studies (Table 2.6) and the Cochrane Collaboration tool for RCTs (Table 2.7). One 
study where IPTp was randomised was assessed using the Newcastle Ottawa Scale for assessing 
risk of bias in observational studies because the study only assessed an association between MiP 
(and not IPTp regimens) and the risk of clinical malaria or parasitaemia in the infant [40]. All 
cohort studies had a representative exposed cohort, selected the non-exposed comparison 
group adequately and measured malaria exposure during pregnancy, and demonstrated that 
the outcome was not present at the beginning of follow-up. Most of the studies adjusted for 
IPTp and ITN use but only two studies [20, 35] adjusted for malaria exposure. In three of the 
studies, the number of participants lost to follow-up or the reasons for losses to follow-up were 
not reported [16, 36, 41]. Three studies had >20% losses to follow-up [17, 36, 40]. The overall 
risk of bias in cohort studies was rated as high in nine studies [17, 18, 21, 34, 36, 37, 39-41] and 
medium in two studies [20, 35]. In all the RCTs, allocation concealment was adequate, and no 
trial was stopped before completion. Overall, the risk of bias in all three RCTs was low. 
Table 2.7 Assessment of risk of bias in randomised trials comparing the risk of malaria 
among infants who received different IPTp regimens 
Criterion 
Studies 




Allocation concealment Yes Yes Yes 
Trial stopped early No No No 
Participants blinded No No Yes 
Study staff blinded No No Yes 
Infant malaria assessed blinded Yes Yes Yes 
Proportion of infants lost to follow-up 972/4247 (22.9%) NR NR 
Overall risk of bias Low Low Low 
Abbreviations: NR, not reported 
Discussion  
This systematic review assessed evidence evaluating the associations between MiP or IPTp and 
the risk of malaria infection or illness during infancy. Overall, the available evidence is of 
insufficient quality to confirm or rule out an association between maternal malaria infection and 
the risk of malaria during infancy. Most studies had small numbers of exposed infants and failed 
to control for possible confounding by malaria transmission intensity shared between mothers 
and their infants. Only one study that examined the association between malaria in pregnancy 
and the risk of malaria in infants controlled for malaria transmission at the level of the household 
[35]. In this study, time to first parasitaemia in infants born to mothers with PM was shorter in 




possible that household use of ITNs reflects underlying malaria transmission intensity, with 
households exposed to higher transmission more likely to use ITNs, and mothers and infants in 
such households at higher risk of malaria. However, secondary data analysis of the study did not 
find an association between PM and the risk of subsequent clinical malaria episodes [42]. This 
suggests that the effect of PM on the risk of malaria in infants wanes over time. 
The majority of the studies included in this review showed an increased risk of clinical malaria 
or parasitaemia in infants born to mothers with maternal peripheral parasitaemia [37, 39], 
infants born to mothers with PM detected by microscopy [17, 21, 34, 35, 37] and in infants born 
to mothers with PM detected by histology [16, 40, 41]. These results could possibly be explained 
by confounding due to differences in malaria transmission intensity. Infants born to mothers 
with maternal peripheral parasitaemia during pregnancy or PM at delivery could be at higher 
risk of clinical malaria or parasitaemia because they live in an environment with higher risk of 
malaria transmission just like their mothers [43]. 
Because it would not be ethical and feasible to randomise pregnant women to exposure to MiP, 
alternative study designs are needed, such as randomising pregnant women to IPTp 
interventions with different efficacies and comparing the risks of parasitaemia and clinical 
malaria in the different sets of infants born to mothers who received different IPTp 
interventions. In this systematic review, three RCTs which evaluated the association between 
IPTp and the risk of malaria during infancy showed no difference in the risk of malaria among 
infants born to mothers who received IPTp-MQ vs IPTp-SP [38], ISTp-AL vs IPTp-SP [19], and IPTp-
SP vs placebo [16]. These studies were possibly limited by the failure of the alternative 
intervention to significantly reduce the burden of malaria, especially PM, during pregnancy [44, 
45]. The prevalence of PM was not significantly different among mothers randomised to IPTp-
MQ (4.6%) compared to IPTp-SP (5.4%, p=0.19) in the multicentre trial [44], and was similar 
among mothers randomised to IPTp-SP (24.5%) compared to ISTp-AL (24.2%) in the Ghana trial 
[45]. In the Mozambique trial, the prevalence of any PM detected by histology or microscopy 
was similar among mothers on IPTp-SP (52%) or placebo (52%) [46]. Although in the same trial, 
the prevalence of PM detected by microscopy was higher among women on placebo (14%) 
compared to women on IPTp-SP (7%) [46], the risk of clinical malaria did not differ among infants 
born to mothers in the two IPTp arms [16]. This could possibly be due to few malaria outcomes 
during infancy, which limited the power of the study. 
There is currently a promising alternative drug combination for IPTp which substantially reduces 
the burden of malaria during pregnancy including PM compared to SP. Although SP remains the 




resistance [47]. In East Africa, IPTp-DP has been shown to markedly reduce the incidence of 
clinical malaria and the prevalence of parasitaemia during pregnancy, and the prevalence of PM 
at delivery compared to IPTp-SP [25, 26, 29]. One study has evaluated the impact of IPTp-DP on 
malaria during infancy in Uganda. In this randomised controlled trial, which examined infants 
receiving DP for malaria prevention, the incidence of malaria during the first two years of life 
was higher in infants born to pregnant women who received IPTp with DP (given monthly) than 
in those born to women who received IPTp with SP (given every two months). This effect was 
magnified in female infants [48]. The reason for this finding is unclear but may be due to lower 
blood levels of piperaquine, which were observed in female infants born to mothers who 
received IPTp with DP [48]. Lower piperaquine levels have been associated with a higher risk of 
malaria in children taking DP for malaria prevention [49], but the reason why female infants 
born to mothers receiving IPTp with DP would have lower levels of piperaquine is unknown. 
Several studies have suggested immune tolerance [9, 12, 14, 50] as one of the potential 
mechanisms for the observed association between MiP and the risk of malaria in infants. 
Evidence from laboratory studies shows that in-utero exposure to malaria antigens is associated 
with a bias of foetal immune responses to P. falciparum specific [12-14] or non-malaria specific 
[12, 50] antigens towards anti-inflammatory responses suggesting that exposure to malaria in-
utero may not only affect development of malaria-specific immunity in the foetus, but may also 
affect non-malaria specific immunity. Indeed, one study has reported an increased risk of non-
malaria febrile illnesses in infants born to mothers with PM compared to infants born to mothers 
without PM [51]. Also, PM has been associated with a reduced maternal-foetal transfer of 
antibodies to P. falciparum [52, 53], but this was not associated with an increased risk of malaria 
in infants [52, 53]. 
This systematic review had several limitations. Substantial heterogeneity in included studies was 
found. Studies varied in the duration of follow-up, detection of malaria exposure during 
pregnancy, and approaches to measuring the outcome in infants and to data analysis. Also, 
important raw data like the number of malaria episodes in each malaria exposure group during 
pregnancy was not presented in majority of the studies. Majority of studies included in this 
systematic review used PM as a proxy measure of MiP, but PM may not be a good proxy measure 
of MiP because some mothers with peripheral malaria parasitaemia may clear their parasites 
especially with highly efficacious IPTp drugs. However, the majority of the included studies used 
IPTp-SP, which is not highly effective at clearing parasites [54]. Only studies published in English 
were included in this systematic review. However, a search not limiting the language to English 




This could have limited the number of studies with null findings which are less likely to be 
published. 
In conclusion, the results of this systematic review suggest that there is insufficient evidence to 
confirm or exclude a causal association between MiP and the risk of malaria during infancy. Also, 
evidence on the impact of IPTp on the risk of malaria in infancy is inconclusive. There is need to 
better understand the association between MiP and malaria in infants in order to minimise the 
effects of MiP on malaria during infancy. Future studies of new IPTp interventions should 
consider not only evaluating the impact of IPTp on birth outcomes but also the potential impact 
of the intervention on the risk of clinical malaria or parasitaemia in infancy. This could have 
important policy implications on the choice of future drugs for IPTp. 
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2.4 Updates to the systematic review literature 
In this section, I review more recent literature including systematic reviews and original research 
articles reporting on the impact of MiP and IPTp on the risk of malaria in infants published since 
my systematic review was completed. Considering this additional literature, the conclusions of 
my systematic review are still valid. 
2.1.4 Other systematic reviews on the impact of malaria in pregnancy on the risk of malaria 
in infants 
One additional systematic review and meta-analysis was published in March 2020 [1]. The 
objective of this new systematic review was to quantify the risk of malaria in children born to 
mothers who had malaria during pregnancy. In this review, the authors included cohort studies, 
case control studies, and studies with follow-up period of at least 3 months, and conducted 
meta-analyses. This new review differed from my review in 3 important ways: 1) only 
prospective cohort studies were included in my analysis while the new systematic review 
included case-control, and retrospective cohort studies in addition to prospective cohort 
studies; 2) only studies with a follow-up period of at least 6 months were considered in my 
review while studies with shorter follow-up periods were included in this new systematic review; 
and 3) a meta-analysis was not conducted in my review due to substantial heterogeneity in 
studies while in this new review, a meta-analysis was conducted. The new review identified 19 
published articles, two of which were from the same birth cohort study [2, 3] conducted in 
Tanzania, which reported on the impact of MiP on the risk of malaria in children. Thirteen of the 
studies included in this new systematic review were also included in my review. 
The five of the six additional studies which were not included in my review did not show 
evidence of a significant association between MiP and malaria in children. The birth cohort 
conducted in Tanzania [2] reported a non-significant higher risk of severe malaria during 4 years 
of follow-up in children born to secundi or multigravidae mothers with PM (HR 1.86, 95% CI 
0.92-3.77, p=0.08) and those born to primigravidae mothers with PM (HR 1.12, 95% CI 0.44-2.82, 
p=0.81) compared to those born to primigravidae mothers without PM. In a cohort study 
conducted in Kenya [4], there was no difference in the risk of parasitaemia detected by 
microscopy during one year of follow-up among infants born to mothers with PM (15.6%) 
compared to those born to mothers without PM (14.7%). A cohort study conducted in Cameroon 
[5, 6] reported a higher prevalence of parasitaemia from 4-18 months of age, among children 
born to mothers with PM detected by microscopy, compared to those born to mothers without 




there was no difference in the odds of parasitaemia during the first 3 months of life among 
infants born to mothers with PM detected by microscopy compared to those born to mothers 
without PM (unadjusted OR 1.1, 95% CI 0.7-1.9, p=0.71) [7]. The sixth study, conducted in Kenya 
by Malhotra et al [8] reported a higher risk of malaria parasitaemia during the first 3 years of life 
in infants born to mothers with parasitaemia or PM, compared to those born to mothers without 
maternal parasitaemia or PM (RR 1.61, 95% CI 1.10-2.43, p=0.024), after adjusting for repeated 
measures, time, and location. Moreover, these infants were found to be immune tolerant 
following stimulation of cord blood mononuclear cells with malaria antigens suggesting that in-
utero malaria exposure may lead to bias of immune responses to malaria towards tolerance 
which may increase the risk of malaria in later life. 
In this new review, meta-analyses were conducted despite the substantial heterogeneity 
between studies as demonstrated by the Higgin’s I-squared values of >50% [1]. The authors 
pooled infant results if the exposure was maternal parasitaemia or PM (regardless of how PM 
was detected) and the effect measure in the studies included was identical. The results of the 
meta-analysis showed that maternal parasitaemia or PM were associated with non-significant 
higher odds of parasitaemia (pooled odds ratio [OR], 1.94, 95% confidence interval [CI] 0.93-
4.07), and a significantly higher risk of first parasitaemia (pooled hazard ratio [HR] 1.46, 95% CI 
1.07-2.00). Similarly, maternal parasitaemia or PM were associated with higher odds of clinical 
malaria (pooled OR 2.82, 95% CI 1.82-4.38), and a higher risk of first clinical malaria (pooled HR 
1.31, 95% CI 0.96-1.79), although this was not significant. The authors concluded that overall, 
MiP was associated with a higher risk of malaria in children but acknowledged that most of the 
included studies failed to control for the potential confounding effects of malaria transmission 
intensity, which was a major limitation. 
2.2.4 Other studies on the impact of malaria in pregnancy or IPTp on the risk of malaria in 
infants 
I repeated the literature search using the same strategy applied in my systematic review and 
found two additional birth cohort studies, one conducted in Benin, published in December 2018 
[9], and another from Burkina Faso, published in September 2018 [10], which examined the 
impact of maternal parasitaemia or PM on the risk of malaria in infants. The birth cohort 
conducted in Benin [9], was part of a multicentre randomised controlled trial in which HIV-
uninfected pregnant women were randomised to IPTp with SP versus MQ (15mg/kg given in one 
day) versus split dose MQ (15mg/Kg given over two days) conducted in Benin, Gabon, 
Mozambique, and Tanzania [11] and were followed-up to delivery. A subset of infants born to 




malaria during the first year of life were compared among infants born to mothers with 
parasitaemia or PM at delivery detected by microscopy and those born to mothers with no 
parasitaemia or PM at delivery adjusting for factors including small for gestation age, maternal 
age, social economic status, and exposure to mosquitoes. The authors found that compared to 
no parasitaemia or PM at delivery, parasitaemia or PM at delivery was associated with higher 
odds of parasitaemia among infants during the first 6 months (aOR 2.18, 95% CI 0.95-4.95, 
p=0.07), and between 6-12 months of life (aOR 1.31, 95% CI 0.62-2.78, p=0.48) [9], but the 
differences were not significant. Parasitaemia or PM at delivery was also associated with higher 
odds of clinical malaria during the first 6 months of life (aOR 1.62, 95% CI 0.84-3.58, p=0.13), and 
lower odds of clinical malaria between 6-12 months of life (aOR 0.91, 95% CI 0.39-2.14, p=0.83) 
compared to no parasitaemia or PM at delivery, but the differences were not statistically 
significant. 
The second birth cohort in Burkina Faso [10] was part of the COSMIC study, a multicentre cluster 
randomised trial conducted in Burkina Faso, Benin, and the Gambia, where villages were 
randomised to one of two treatment arms, 1) a combination of monthly community-scheduled 
screening and treatment of malaria in pregnancy (CSST) with rapid diagnostic tests and 
artemether-lumefantrine (AL) plus IPTp with SP (CSST/IPTp-SP), and 2) monthly IPTp-SP alone 
[12]. Pregnant women from the participating villages were then followed-up to delivery. Infants 
born to mothers in Burkina Faso were then followed-up from birth to one year of age; the risk 
of malaria in infancy was compared between infants born to mothers with PM detected by 
histology and those born to mothers without PM. The authors found that PM was associated 
with a lower risk of clinical malaria among infants between 0-6 months of age, but a higher risk 
of malaria among infants between 6-12 months of age, although effect estimates (hazard ratios) 
were not reported [10]. 
Another publication from the same Burkina Faso birth cohort described above, was also 
retrieved. In this publication, the effect of in-utero malaria exposure and the impact of monthly 
CSST/IPTp-SP on the risk of first malaria episode among infants were assessed [13]. Compared 
to infants born to uninfected mothers (no maternal or PM), after adjusting for gravidity, low 
birth weight, and birth season, infants born to mothers with peripheral parasitaemia (adjusted 
HR [aHR] 1.62, 95% CI 1.12-2.32, p=0.009) and those born to mothers with past PM (aHR 1.42, 
95% CI 1.06-1.91, p=0.02) had a higher risk of first malaria episode. Infants born to mothers with 
active PM had a higher risk of first malaria episode compared to those born to uninfected 
mothers, but this finding was not significant (aHR 1.30, 95% CI 0.89-1.91, p=0.18). Monthly 
CSST/IPTp-SP was associated with a modest 12% lower risk of first malaria episode among 




0.88, 95% CI 0.73-1.07, p=0.21). There was no association between monthly CSST/IPTp-SP and 
the incidence of malaria in infants (adjusted IRR 0.95, 95% CI 0.82-1.10, p=0.46). 
2.3.4 Summary 
In summary, the recent systematic review and meta-analysis [1], and the additional COSMIC 
publications identified [10, 13] showed that maternal peripheral parasitaemia and PM were 
associated with an increased risk of malaria in infants. Like my review, the recent review and 
meta-analysis was largely limited by the heterogeneity of included studies, most of which were 
also limited by the failure to adjust for potential confounding by malaria exposure. The birth 
cohort in Burkina Faso did not find that adding community scheduled screening and treatment 
with RDTs and AL to IPTp reduced the risk of malaria in infants born over IPTp-SP alone. 
Considering this, the conclusions of my systematic review remain valid. Evidence to confirm or 
exclude a causal association between MiP, or the prevention of MiP, and the risk of malaria in 
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CHAPTER 3 OBJECTIVES, AND METHODS 
3.1 Introduction 
In this chapter, the thesis objectives, the respective hypotheses, and the study methods used to 
answer the thesis questions and objectives are presented, including the study design, study 
participants, follow-up of study participants, laboratory procedures, study outcomes and 
statistical analyses performed. 
3.2 Study objectives and hypotheses 
1) To compare the incidence of malaria in infants during the first year of life among infants 
born to mothers with PM detected by microscopy, LAMP, or histology and those born 
to mothers without PM. 
Hypothesis: Infants born to mothers with PM detected by microscopy, LAMP, or histology will 
have a higher incidence of malaria in the first year of life compared to infants born to mothers 
without PM. 
2) To compare the incidence of malaria during the first year of life in infants born to 
mothers who were randomised to receive monthly IPTp-DP versus monthly IPTp-SP. 
Hypothesis: Infants born to mothers randomised to receive monthly IPTp-DP will have a lower 
incidence of malaria during the first year of life compared to infants born to mothers randomised 
to receive monthly IPTp-SP. 
3) To evaluate the effect of IPTp and PM on cord blood levels of IgG antibodies to P. 
falciparum malaria antigens. 
Hypothesis 1: Infants born to mothers with PM detected by microscopy, LAMP, or histology will 
have lower mean blood levels of IgG antibodies to P. falciparum antigens at birth compared to 
those born to mothers without PM. 
Hypothesis 2: Compared to infants born to mothers randomised to monthly IPTp-SP, infants 
born to mothers randomised to monthly IPTp-DP will have higher mean blood levels of IgG 






3.1.3 Study design 
This study was part of a completed double-blind, randomised, controlled trial (RCT) 
(ClinicalTrials.gov: NCT02793622) of monthly IPTp with DP or SP for the prevention of malaria in 
HIV-uninfected pregnant women and their infants. The trial involved two phases: the pregnancy 
and infant phases. The pregnancy phase of the study involved enrolment and follow-up of 
pregnant women through delivery. The main objective of the pregnancy phase of the study was 
to compare the risk of a composite adverse birth outcome (preterm delivery [< 37 weeks of 
gestation], low birth weight [< 2500g], or small for gestation age [< 10th percentile based on 
reference population]) among mothers who received IPTp-DP and mothers who received IPTp-
SP, and the findings, which are not the subject of this thesis, were published [1]. The infant 
phase, which is the focus of this thesis, involved follow up of all live births to mothers who took 
part in the RCT, from birth to one year of age. The study was conducted from September 2016 
to December 2018. 
3.2.3 Study area 
This study was conducted in Busia district, Uganda. Busia district, an area of high malaria 
endemicity, is located on the border between Kenya and Uganda and is bordered to the south 
by Lake Victoria (Figure 3.1).  
 





Participants of the pregnancy phase of the study were pregnant women of all gravidities. 
Pregnant women were enrolled if they fulfilled the following criteria: 1) a viable intrauterine 
pregnancy confirmed by ultrasound; 2) estimated gestational age between 12-20 weeks; 3) 
confirmed HIV- uninfected status by rapid test; 4) 16 years of age or older; 5) residing in Busia 
District, Uganda; 6) agreement to come to the study clinic for any febrile episode or other illness 
and avoid medications given outside the study protocol; 7) plan to deliver in the hospital; 8) no 
history of a serious adverse event related to DP or SP; and 9) provision of informed consent for 
themselves and their unborn infants. Participants of the infant phase of the study were live 
births of pregnant women who were enrolled in the trial. 
3.3.3 Randomisation and study drug administration 
At enrolment, pregnant women were randomised to receive IPTp-DP or IPTp-SP in a ratio of 1:1. 
A randomisation list consisting of permuted blocks of 4 or 8 was computer generated by a staff 
member not involved in patient care. Treatment assignment was done by a study pharmacist 
not involved in patient care. Study drugs were initiated at 16 (for women enrolled at ≤16 weeks 
and one day of gestation) or 20 (for those enrolled at >16 weeks and one day of gestation) weeks 
of gestation and were administered every 4 weeks thereafter. A dose of DP consisted of 3 tablets 
of 40 mg of dihydroartemisinin and 320 mg of piperaquine (Duo-Cotexin, Holley-Cotec, Beijing, 
China) given once a day for 3 days. A dose of SP consisted of 3 tablets of 500 mg of sulfadoxine 
and 25 mg of pyrimethamine (Kamsidar, Kampala Pharmaceutical Industries), given as a single 
dose. In addition, participants randomised to DP received SP placebos, while those randomised 
to SP received DP placebos every 4 weeks to achieve blinding. All doses of study drugs were 
prepackaged by a study pharmacist and dispensed by study nurses blinded to the study 
participant’s treatment regimen. For DP or DP placebo, all 1st daily doses were administered 
directly observed in the clinic. The 2nd and 3rd daily doses were dispensed to the mother for 
self-administration at home. Administration of all SP and SP placebo doses were directly 
observed in the study clinic. 
3.4.3 Follow-up of pregnant women 
At enrolment, a clinical assessment including history and clinical examination was conducted. 
Baseline laboratory tests included a complete blood count (CBC) and the detection of malaria 
parasites by microscopy and quantitative PCR (qPCR). All enrolled women were given a long-




characteristics including the house structure and household possessions among others [2], was 
conducted. Women were followed up for all their medical care in a dedicated study clinic located 
in Masafu General Hospital and were reviewed routinely every 4 weeks. Routine assessments 
included a standardised history and clinical assessment, study drug administration, and 
collection of blood samples (thick blood smear and a capillary blood sample) for detection of 
malaria parasites by microscopy or qPCR. Routine blood smears were read later and were not 
used for the management of pregnant women. At any study visit, pregnant women who were 
febrile (with a history of fever or a tympanic temperature ≥ 38.0˚C) had a finger prick done for 
an urgent thick blood smear for malaria diagnosis. Pregnant women diagnosed with malaria 
were treated using either AL or artesunate according to the Uganda Ministry of Health 
guidelines. Women were encouraged to deliver at Masafu General Hospital. At delivery, babies 
were weighed on standard scales. Maternal, cord, and placental blood, for making dried blood 
spots and thick blood smears for detecting malaria parasites, and placental tissue samples for 
detecting PM by histology were collected. Post-partum visits were conducted in the study clinic 
at 1, and 6 weeks after delivery. 
3.5.3 Follow-up of infants 
All infants born alive were followed up for all their medical care in a dedicated study clinic, open 
daily from 8:00 am - 5:00 pm. Parents/guardians were encouraged to bring their infants to the 
study clinic for routine assessments and any time they were ill. Routine assessments were 
conducted at 1, 4, 6 and 8 weeks of age, and thereafter every 4 weeks until infants reached 52 
weeks of age. The 4 weekly routine assessments included a standardised history taking, a clinical 
exam, and collection of thick blood smears for detection of malaria parasitaemia. At 12, 28, and 
52 weeks, blood was drawn for measuring haemoglobin (Hb) level using either a CBC or a 
portable spectrophotometer (HemoCue, Angholm, Sweden), and plasma sample was stored. 
Infants who were febrile (with a history of fever in the past 24 hours or a tympanic temperature 
≥ 38.0˚C) at any clinic visit had an urgent thick blood smear done for malaria parasites and were 
diagnosed with malaria if the urgent smear was positive. Febrile infants with negative urgent 
thick blood smears were treated for non-malaria febrile illness. Infants who were not febrile but 
had a malaria positive routine thick blood smear were not treated for malaria in accordance with 
local guidelines. 
3.6.3 Malaria diagnosis and treatment 
Study participants with fever and a positive thick blood smear were diagnosed with malaria and 




level measurement using a portable spectrophotometer (HemoCue). Malaria episodes were 
classified as uncomplicated, complicated or treatment failure. Uncomplicated malaria was 
diagnosed in participants with fever and without danger signs (≤ 2 convulsions in 24 hours, 
vomiting everything, inability to sit or stand, unable to breastfeed or drink, and lethargy) or 
severe malaria. Complicated malaria was diagnosed in participants with danger signs or severe 
malaria. Treatment failure was defined as a malaria episode preceded by another malaria 
episode in the last 14 days. A new malaria episode was defined as a malaria episode not 
preceded by another malaria episode in the last 14 days. All infants diagnosed with malaria were 
treated according to the Uganda Ministry of Health guidelines. New episodes of uncomplicated 
malaria were treated with artemether lumefantrine (AL). Children with complicated malaria 
were treated with artesunate and those with a new episode of malaria who were less than 4 
months of age or <5kg of weight, were treated with quinine. Those diagnosed with treatment 
failures within 14 days following treatment with AL were treated with quinine. Patients with 
treatment failure within 14 days following treatment with quinine or artesunate were treated 
with quinine plus clindamycin or artesunate.  
3.7.3 Premature withdrawal of study participants 
Participants were prematurely withdrawn if they meet any of the following criteria: 1) 
movement out of study area, 2) inability to be located for > 60 consecutive days, 3) withdrawal 
of informed consent, 4) inability to comply with the study schedule and procedures, 5) at the 
discretion of the site investigator if the study is not in the best interest of the participant, or 6) 
subject or parent/guardian judged by the site investigator to be at significant risk of failing to 
comply with the study protocol as to cause them harm or seriously interfere with the validity of 
study results.  
3.8.3 Laboratory methods 
Thick blood smears were stained with 2% Giemsa for half-hour and examined under a light 
microscope by trained laboratory technicians who were blinded to the mother’s study treatment 
arm. A thick blood smear was declared negative if 100 high power fields were examined without 
showing any asexual parasites. Thin smears were used for parasite species identification. For 
quality control, all blood smears were examined by two independent laboratory technicians and 
smears with discrepant results were examined by a 3rd laboratory technician. 
Quantitative polymerase chain reaction (qPCR) for detection of P. falciparum malaria parasites 




enrolment, and during routine assessment. DNA was extracted from whole blood using PureLink 
DNA extraction kit. Parasites were then detected in the extracted sample by detecting the 
varATS gene. The LAMP assay for detection of malaria parasites from dried placental blood spots 
collected at delivery was performed using LoopampTM MALARIA Pan Detection Kit (Eiken 
Chemical Company, Japan) as previously described [4]. In brief, parasite DNA was extracted from 
placental dried blood spots using chelex extraction method and amplified in reaction tubes, 
which were incubated at 65.0˚C for 40 minutes. Reaction tubes were then visualized in a 
fluorescence visualization unit. Positive samples emitted green light.  
Placental biopsy specimens were assessed for histological evidence of PM as previously 
described [5]. In brief, placental biopsy specimens were embedded in paraffin wax, sectioned 
into 3 μM slices using a rotary microtome, fixed to glass slides, and dehydrated in sequential 
ethanol baths. Separate slides were stained in 0.1% hematoxylin and 1% eosin for 5 and 1 min, 
respectively, or in 2% Giemsa for 30 minutes and then microscopically examined. The presence 
of intervillous parasite-infected erythrocytes and of pigment in monocyte/macrophages or fibrin 
was noted. The quantity of malaria pigment deposited in fibrin, expressed as the proportion of 
high-power fields (HPF) with malaria pigment deposition in fibrin was assessed as described by 
Muelenbach’s et al [6].  
3.9.3 Measurement of P. falciparum IgG antibodies 
Measurement of antibodies to P. falciparum was done on stored maternal and cord plasma 
samples collected at delivery, and on infant plasma samples. All plasma samples were stored at 
-80°C. Levels of antibodies to P. falciparum antigens (including antigens associated with long 
term responses such as MSP 1 and 2, AMA1, and antigens with shorter half-lives such EBA-175, 
Rh-5 were measured using a multiplex antibody bead assay. Luminex bead conjugation was 
performed as previously described [7]. 50 μl thawed plasma, in duplicate (1/200 dilution) were 
co-incubated with microsphere mixtures on a 96-well plate for one hour, washed, stained, and 
incubated with a secondary antibody, then washed and read by the MAGPIX system. Antibody 
levels were expressed in arbitrary units (AUs), calculated by dividing the median fluorescence 
intensity (MFI) of the sample by the MFI plus 3 standard deviations (SD) of samples from North 
Americans never exposed to malaria. Positive control samples from individuals with known 
antibodies to these antigens were placed on each plate. Standard curves were generated 
through serial dilutions of the positive control pool. The qualitative nature of the immune 
response was investigated in infants in each arm by measuring IgG (total & isotype responses) 




3.10.3 Study outcomes 
The primary outcome for objective 1 and 2 was the incidence of malaria in the first 12 months 
of life defined as the number of incident episodes of malaria per person-year at risk. An incident 
episode of malaria was defined as the presence of fever (history of fever in the last 24 hours or 
a tympanic temperature ≥ 38.0˚C) with malaria positive thick blood smear not preceded by 
another episode in the last 14 days. The primary outcome for objective 3 was the mean levels 
of specific P. falciparum IgG antibodies. Secondary outcomes are presented in Table 3.1 below.  
Table 3.1 Secondary outcomes 
Secondary outcome Definition 
Time to first malaria episode Time from birth to first episode of malaria  
Incidence of complicated 
malaria 
Number of malaria episodes with danger signs 
(convulsions, vomiting everything, lethargy) or with 
severe malaria according to the WHO definition 
Prevalence of malaria 
parasitaemia 
Proportion routine thick blood smears with malaria 
parasites detected by microscopy 
Prevalence of anaemia Proportion of haemoglobin measurements done at 12, 
28, and 52 weeks that were <10 g/dL or <8 g/dL 
Incidence of hospital 
admissions 
Number of all cause hospital admissions  
Incidence of non-malaria febrile 
illnesses 
Number of episodes of fever not preceded by another 
episode in the last 7 days (history of fever in the last 24 
hours or a tympanic temperature ≥ 38.0˚C) with a malaria 
negative blood smear  
Infant mortality All cause deaths occurring within 12 months of life 
 
3.11.3 Sample size and power calculation 
An independent estimation of the sample size of the infant phase of the study was not done. 
Instead, the sample size of the infant phase of the study was determined by the estimated 
sample size of the pregnancy phase of the study and the resulting live births. The sample size of 
the pregnancy phase of the study was estimated to be 782 pregnant women and it was assumed 
that 95% would result into live births in which the primary outcome of the pregnancy phase of 
the study was assessed [1]. With the resulting live births, to test the hypothesis that compared 
to IPTp-SP, IPTp-DP is associated with a lower incidence of malaria among infants during the first 
12 months of life, it was assumed that malaria incidence would be 3-5 episodes per person-year 
among infants born to mothers on IPTp-SP (using data from a prior study conducted in the 
adjacent district of Tororo [8]) and that 5% of infants would be lost to follow-up. With these 




23% difference in the incidence of malaria among infants born to mothers on IPTp-DP compared 
to those born to mothers on IPTp-SP.  
3.12.3 Data analysis 
Data were double entered and checked by two trained independent data officers into an Access 
database. Data analyses were conducted using Stata version 14.2. Follow-up period started from 
the birth date and ended on the date the infant was one year old or the date the infant was 
prematurely withdrawn.  
Maternal characteristics at enrolment, during follow-up, and at delivery, and infant 
characteristics at birth were compared among infants born to mothers who received monthly 
IPTp-DP and those born to mothers who received monthly IPTp-SP. Characteristics with simple 
proportions were compared using a chi-squared test, continuous outcomes were analysed using 
a t-test, incidence measures were analysed using negative binomial regression, and repeated 
prevalence measures were analysed using generalized estimating equations with robust 
standard errors. For objective 1, PM detected by microscopy, LAMP or histology, was 
categorised as follows: no PM (absence of parasites or pigment); active PM (parasites detected 
in placental blood or tissue by microscopy LAMP or histology, with or without pigment [9, 10]); 
mild-moderate past PM (>0-20% HPFs with pigment without parasites); or severe past PM (>20% 
HPFs with pigment without parasites). Placental inflammation was not considered in the grading 
PM. Comparisons among infants in different PM categories taking the no PM category as the 
reference group were made adjusting for maternal IPTp arm, gravidity (categorised as 
primigravidae, secundigravidae, or multigravidae), housing construction type (modern or 
traditional), and maternal parasitaemia status detected by microscopy or qPCR at enrolment. 
For objective 2, comparisons were made between infants born to mothers who received 
monthly IPTp-DP and those born to mothers who received monthly IPTp-SP. Because the 
association between IPTp and the risk of malaria in children had been previously reported to 
vary with infant sex [11], assessments for effect modification by infant sex in the analyses were 
made a priori. In all comparisons, negative binomial regression models were used to compare 
incidence measures, Cox proportional hazards models were used for comparisons of first 
malaria episode in infants, and generalised estimating equations with robust standard errors 
were used to compare prevalence outcomes measured repeatedly during infancy. 
To estimate the proportion of the effect of IPTp-DP compared to IPTp-SP on the incidence of 
malaria in infancy was mediated through prevention of PM, mediation analysis using inverse 
odds ratio weighting (IOW) [12] was conducted. The exposure, mediator, and outcome of 




respectively (figure 3.2). Since IPTp was randomised, it was assumed that there was no potential 
confounding in the association between IPTp and PM, and between IPTp and malaria incidence 
in infants. Maternal parasitaemia at enrolment, gravidity, and housing construction type, were 
considered as potential confounders in the association between PM and malaria incidence in 
infants. Three models were used to estimate the total, direct, and indirect (mediated) effects. In 
the first model, treatment weights were generated using logistic regression, by specifying 
treatment as a function of the mediator and potential confounders in the association between 
PM and outcome. The predicted probabilities were obtained from the first model and used to 
generate inverse odds as treatment weights for each maternal-infant pair. In the second model, 
negative binomial regression was used to estimate the effect of IPTp DP versus SP on malaria 
incidence in infants, first for all infants and then stratified by infant sex, this estimated the total 
effect. In the third model, negative binomial regression was used to estimate the direct effect 
by modelling the association between IPTp and incidence of malaria in infancy weighted for the 
inverse odds predicted in the first model above. The mediated effect was then calculated by 
subtracting the direct effect from the total effect. 95% confidence intervals were then calculated 
by bootstrapping using 1,000 simulations. The proportion of the effect mediated by PM was 
calculated using the formula, [ln(IRRindirect effect)])/[ln(IRRtotal effect)]*100, where IRR=incidence rate 
ratio. 
 
Figure 3.2 Causal diagram showing how the relationship between intermittent preventive 
treatment of malaria in pregnancy and infant malaria, is mediated by placental malaria 
 
For objective 3, log transformed mean levels of different P. falciparum IgG antibodies were 
calculated separately for maternal, and cord blood. Using a t-test, log transformed mean levels 
of P. falciparum IgG antibodies in maternal blood were compared among mothers who received 
monthly IPTp-DP and those who received monthly IPTp-SP, and among mothers in different PM 
categories. Using linear regression models, log transformed mean levels of IgG P. falciparum 
antibodies in cord blood were compared among infants born to mothers who received IPTp-DP 




different PM categories. Adjustments for potential confounders including maternal gravidity, 
maternal parasitaemia at enrolment, and housing construction type, were made. Potential 
associations between levels P. falciparum IgG antibodies in cord blood and the incidence of 
malaria were evaluated using negative binomial regression.  
In all analyses, two-tailed p-values of < 0.05 were considered statistically significant. 
3.13.3 Ethical considerations 
Ethical approval was obtained from Makerere University school of Biomedical Sciences Ethics 
Committee, the Uganda National Council of Science and Technology, the University of California 
San Francisco Research Ethics committee, and the Stanford University Institutional Review 
Board. In addition, the PhD part of the study was approved by the London School of Hygiene and 
Tropical Medicine Ethics Committee (Appendices D-H). Written informed consent was obtained 
from all participants before enrolment. 
3.14.3 Summary of the main trial 
The pregnancy phase of the study took place between September 2016 to December 2017 and 
the results have been published [1]. In summary, 782 HIV-uninfected pregnant women residing 
in Busia district, were enrolled between September 2016 and May 2017 and were randomised 
to monthly IPTp-DP (N=391) or monthly IPTp-SP (N=391). The homes of enrolled study 
participants were well- distributed across Busia district (Figure 3.3). A total of 687 (88%) women, 
338 receiving IPTp-SP and 349 receiving IPTp-DP, were followed-up through delivery resulting in 
678 live births between December 2016 and December 2017. At enrolment, 82% of the enrolled 
mothers had parasitaemia detected by microscopy or qPCR. During pregnancy, monthly IPTp-
DP was associated with a 96% (95% CI 88%-99%, p=0.001) lower risk of clinical malaria and 98% 
(95% CI 96%-99%, p<0.0001) lower risk parasitaemia detected by microscopy, compared to IPTp-
SP. At delivery, IPTp-DP was associated with a 97% (75%-99%, p=0.0009), 90% (80%-96%, 
p<0.0001) and 54% (44%-62%, p<0.0001) lower risk of placental malaria detected by 
microscopy, LAMP, or histology, respectively, compared to IPTp-SP. However, there was no 
evidence that infants born mothers receiving IPTp-DP had a lower risk of adverse birth outcomes 
compared to infants born to mothers receiving IPTp-SP [1]. Results of the infant phase of the 
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CHAPTER 4 ASSOCIATION BETWEEN PLACENTAL MALARIA AND 
INCIDENCE OF MALARIA DURING INFANCY 
4.1 Chapter Introduction 
This chapter addresses Objective 1, to compare the incidence of malaria in infants during the 
first year of life among infants born to mothers with PM detected by histology and infants born 
to mothers without PM detected by histology. This manuscript presents results of secondary 
analysis of data from a birth cohort of infants born to HIV-uninfected mothers who took part in 
a double-blind, randomised, controlled trial of monthly IPTp with DP versus SP. The manuscript 
was published in the Malaria Journal. At the end of the manuscript, a table of baseline 
characteristics of study participants stratified by infant sex is presented. 
4.2 Research paper 




















Placental malaria (PM) has been associated with a higher risk of malaria during infancy. 
However, it is unclear whether this association is causal, and is modified by infant sex, and 
whether intermittent preventive treatment in pregnancy (IPTp) can reduce infant malaria by 
preventing PM.  
Methods 
Data from a birth cohort of 656 infants born to HIV-uninfected mothers randomised to IPTp with 
dihydroartemisinin-piperaquine (DP) or sulfadoxine-pyrimethamine (SP) was analysed. PM was 
categorised as no PM, active PM (presence of parasites), mild-moderate past PM (>0-20% high 
powered fields [HPFs] with pigment), or severe past PM (>20% HPFs with pigment). The 
association between PM and incidence of malaria in infants stratified by infant sex was 
examined. Causal mediation analysis was used to test whether IPTp can impact infant malaria 
incidence via preventing PM.  
Results 
There were 1088 malaria episodes diagnosed among infants during 596.6 person years of follow-
up. Compared to infants born to mothers with no PM, the incidence of malaria was higher 
among infants born to mothers with active PM (adjusted incidence rate ratio [aIRR] 1.30, 95% 
CI 1.00-1.71, p=0.05) and those born to mothers with severe past PM (aIRR 1.28, 95% CI 0.89-




infant sex, compared to no PM, severe past PM was associated a higher malaria incidence in 
male (aIRR 2.17, 95% CI 1.45-3.25, p<0.001), but not female infants (aIRR 0.74, 95% CI 0.46-1.20, 
p=0.22). There were no significant associations between active PM or mild-moderate past PM 
and malaria incidence in male or female infants. Male infants born to mothers given IPTp with 
DP had significantly less malaria in infancy than males born to mothers given SP, and 89.7% of 
this effect was mediated through prevention of PM.  
Conclusion 
PM may have more severe consequences for male infants, and interventions which reduce PM 
could mitigate these sex-specific adverse outcomes. More research is needed to better 
understand this sex-bias between PM and infant malaria risk.  
Keywords Placental malaria, pregnancy, infants, Plasmodium falciparum 
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Plasmodium falciparum remains a major public health problem affecting mainly pregnant 
women and young children. In pregnant women infected with P. falciparum, parasitized 
erythrocytes sequester in the placenta, resulting in placental malaria (PM), which is 
characterised by placental inflammation, parasite infiltration, and deposition of malaria 
pigment, a product of digestion of haemoglobin by P. falciparum [1]. Placental malaria is 
associated with adverse effects such as preterm delivery, low birth weight, stillbirth, and 
neonatal mortality [2-4]. Despite the use of preventive measures including insecticide treated 
nets and intermittent preventive therapy during pregnancy (IPTp), the burden of PM among 
pregnant women living in high malaria transmission settings remains high [5]. 
There is evidence that PM may impact infants after birth [6-8]. Several observational studies 
have reported associations between PM and increased risks of malaria, non-malaria febrile 
illnesses, and anaemia in infancy, possibly due to immune tolerance induced by in-utero 
exposure to malaria antigens [9-13]. However, most of these studies defined PM as the 
detection of malaria parasites in placental blood by microscopy which has limited sensitivity and 
does not account for past placental infections characterised by the presence of malaria pigment 
[14]. Furthermore, the severity of malaria pigment deposition in the placenta was recently 
shown to be strongly predictive of adverse birth outcomes including low birth weight and 
preterm birth [15]. Whether the severity of malaria pigment deposition in the placenta is also 
associated with the risk of malaria in infancy is unknown. 
A recent double-blind randomised controlled trial compared the incidence of malaria during 
infancy among infants born to mothers who received monthly IPTp with dihydroartemisinin-
piperaquine (DP) versus sulfadoxine-pyrimethamine (SP). In this trial, infants born to mothers 
receiving IPTp-DP had a lower malaria incidence compared to infants born to mothers receiving 
IPTp-SP. However, this association was observed in male, but not female, infants [16]. To further 
evaluate the association between PM and the incidence of malaria in infants, a secondary and 
mediation analysis of these data was carried out to examine how much of the previously 
observed associations between IPTp and the risk of malaria in infants is mediated through 
prevention of PM. 
Methods 




Data were collected from a birth cohort of infants born to HIV-uninfected pregnant women 
enrolled in a randomized controlled trial of monthly IPTp with DP vs SP (Trial registration, 
ClinicalTrials.gov; NCT02793622) conducted in Busia district, Uganda, an area of perennial high 
malaria transmission intensity. Details of the study have been previously reported [5, 16, 17]. 
Pregnant women were enrolled at 12-20 weeks of gestation and followed through delivery. At 
delivery, placental blood and tissue samples were collected. Following delivery, all live births 
were followed up to 12 months of age. Mothers were encouraged to bring their infants to a 
dedicated study clinic open every day for all their medical care. Routine assessments were 
conducted every 4 weeks for clinical assessment and collection of blood smears for the detection 
of parasites by microscopy. Infants presenting with a history of fever in the past 24 hours or a 
documented tympanic temperature > 38.0˚C had a thick blood smear collected for detection of 
malaria parasites and those diagnosed with malaria were treated according to the Uganda 
Ministry of Health guidelines. Non-malarial illnesses were treated according to the integrated 
management of childhood illnesses guidelines. At 12, 28, and 52 weeks of age, blood was 
collected for haemoglobin measurement. 
Laboratory methods 
Thick blood smears were stained with 2% Giemsa and read by microscopists [5]. Haemoglobin 
measurements were made using a spectrophotometer (Hemocue, Angelholm, Sweden). Malaria 
parasites were detected in placental blood by microscopy and loop-mediated isothermal 
amplification (LAMP) [18]. Placental biopsy specimens were embedded in paraffin wax, 
sectioned using a rotary microtome, fixed on glass slides, and dehydrated in sequential ethanol 
baths [19]. Separate slides were stained in 0.1% hematoxylin and 1% eosin for 5 and 1 min, 
respectively, or in 2% Giemsa for 30 minutes and examined for presence of intervillous parasite-
infected erythrocytes and malaria pigment by two independent readers. The proportion of high-
power fields (HPF) with malaria pigment deposition in fibrin was analysed as described [20].  
Study outcomes 
The primary outcome was the incidence of malaria from birth to 12 months of age. An incident 
episode of malaria was defined as the presence of fever (history of fever in the past 24 hours or 
a tympanic temperature ≥ 38·0˚C) with a positive thick blood smear not preceded by another 
malaria episode in the last 14 days. Secondary outcomes included time to first episode of 
malaria; incidence of complicated malaria (malaria with danger signs or meeting standardised 
criteria for severe malaria), all-cause hospitalisations; and non-malarial febrile illnesses; 
prevalence of malaria parasitaemia during routine visits and anaemia (haemoglobin <10g/dL); 





Data were double entered and verified in Microsoft Access, and statistical analyses conducted 
using Stata (14.2) including all live births with placental histology results. Follow-up began at 
birth and ended at 12 months of age or premature study withdrawal. The primary exposure 
variable, PM, was categorised as follows: no PM (absence of parasites or pigment); active PM 
(parasites detected in placental blood or tissue by microscopy LAMP or histology, with or 
without pigment [9, 21]); or past PM (presence of pigment, without parasites). Relationships 
between past PM and infant malaria incidence were initially evaluated by considering the 
proportion of HPF with pigment as a continuous variable. Given the non-linear nature of this 
relationship, past PM was further characterised into 2 groups based on best fit associations with 
the outcome variable: mild-moderate past PM (>0-20% HPFs with pigment without parasites); 
or severe past PM (>20% HPFs with pigment without parasites). Analyses were stratified by 
infant sex a priori. Associations between PM and the incidence of malaria were performed using 
negative binomial regression and adjusted for maternal parasitaemia status at enrolment, IPTp 
arm, gravidity, housing construction type, and clustering for twin gestation. The cumulative risk 
of any first episode of malaria was compared using a Cox proportional hazards model. For 
secondary outcomes, incident and repeated prevalence measures were compared using 
negative binomial regression model and generalized estimating equations with robust standard 
errors, respectively. Mediation analysis, using inverse odds weighting (IOW) [22], was used to 
estimate what proportion of the reported effect between maternal IPTp regimen and malaria 
incidence in infants [16] was mediated through preventing PM [Supplementary Appendix]. In 
brief, we used three models to conduct IOW mediation analyses. The first model used logistic 
regression to model treatment given mediator (PM) and mediator-outcome confounders. 
Predicted probabilities obtained from this model were then used to calculate treatment IOWs 
for each mother-infant pair. The second and third models used negative binomial regression to 
model the outcome given treatment with and without weights, respectively. The treatment 
coefficient from the model with weights estimated the direct effect, which was then subtracted 
from the treatment coefficient of the model without weights (total effect) to estimate the 
mediated effect. Bias-corrected 95% confidence intervals (CIs) were computed using 
bootstrapping. The proportion mediated by PM was calculated by dividing the mediated effect 
by the total effect. In all analyses, p-values of <0·05 were considered statistically significant. 
Results 




Between September 2016 and May 2017, 782 HIV-uninfected pregnant women were enrolled 
and randomised to receive either IPTp-SP or IPTp-DP, and 687 (87.9%) followed through delivery 
resulting in 678 live births (Figure 4.1) [16]. A total of 656 infants with placental histology results 
were included in the analyses. Mean maternal age at enrolment was 24 years and 23.5% infants 
were born to primigravida mothers. During pregnancy, the incidence of malaria and prevalence 
of malaria parasitaemia were significantly lower among women randomised to IPTp-DP 
compared to those randomised to IPTp-SP. At delivery, women randomised to IPTp-DP had a 
significantly lower prevalence of active PM (2.1% versus 21.7% p<0.001) and severe past PM 
(1.8% versus 12.2%, p<0.001) compared to those randomised to IPTp-SP (Table 4.1).  
Association between placental malaria and the incidence of malaria in infants 
Overall, 1088 incident episodes of malaria were diagnosed over 596.6 person years of follow-up 
(1.82 episodes per person year). Each 1% increase in the proportion of HPF with pigment 
deposition in fibrin was associated with a higher incidence of malaria in infants but the 
difference was not statistically significant (adjusted incidence rate ratio [aIRR] 1.98, 95% CI 0.76-
5.20, p=0.16). However, on stratifying by infant sex, significant interaction was observed (P-
interaction [pint]= 0.03). Among male infants, a 1% increase in HPF with pigment deposition in 
fibrin was associated with over 5 times higher incidence of malaria (aIRR 5.20, 95% CI 1.70-15.94, 
p=0.004). No significant difference in the incidence of malaria was observed in female infants 
(aIRR 0.53, 95% CI 0.13-2.11 p=0.37). Considering PM as a categorical variable, compared to 
infants born to mothers with no PM, the incidence of malaria was higher among infants born to 
mothers with active PM (aIRR 1.30, 95% CI 1.00-1.71, p=0.05) and those born to mothers with 
severe past PM (aIRR 1.28, 95% CI 0.89-1.83, p=0.18, Table 4.2), but the differences were not 
statistically significant. However, effect modification by infant sex was also observed in the 
association between categories of PM and the incidence of malaria in infants (pint = 0.02). 
Compared to no PM, severe past PM was associated with a higher incidence of malaria among 
male infants (aIRR 2.17, 95% CI 1.45-3.25, p<0.001), but not among female infants (Table 4.2) 
There were no significant associations between active PM or mild-moderate past PM and the 
incidence of malaria in male or female infants. There was no significant difference in the overall 
rate of first malaria episode among infants born to mothers with active PM (adjusted hazard 
ratio [aHR] 1.03, 95% CI 0.72-1.47, p=0.88), mild-moderate past PM (aHR 0.92, 95% CI 0.71-1.18, 
p=0.51), or severe past PM (aHR 1.18, 95% CI 0.75-1.86, p=0.47), compared to those born to 
mothers with no PM. However, the association between PM and the rate of first malaria episode 
was also modified by infant sex. Compared to no PM, severe past PM was associated with a 
significantly higher rate of first malaria episode among male infants (aHR 1.99, 95% CI 1.04-3.81, 





Association between placental malaria and other malaria outcomes in infants 
The incidence of complicated malaria was non-significantly higher among infants born to 
mothers with active PM (aIRR 1.72, 95% CI 0.81-3.66, p=0.16), and severe past PM (aIRR 2.44, 
95% CI 0.93-6.37, p=0.07; Table 4.3). The prevalence of parasitaemia detected during routine 
visits was also similar among infants born to mothers with active or past PM compared to infants 
born to mothers with no PM (Table 4.3). However, effect modification by infant sex was also 
observed in the association between PM and other malaria outcomes. Among male infants, 
severe past PM was associated with a nearly four-fold higher incidence of complicated malaria 
(aIRR 3.88, 95% CI 1.14-13.03, p=0.03) and a more than two-fold higher prevalence of malaria 
parasitaemia during routine visits (risk ratio 2.24, 95% CI 1.34-3.74, p=0.002) compared to no 
PM. No significant associations were observed among female infants (Table 4.3).  
Association between placental malaria and non-malarial outcomes in infancy 
There were 16 deaths (2.4% of infants) and 25 all-cause hospitalisations during follow-up. Severe 
past PM was associated with a non-significant higher incidence of all-cause hospitalisations 
among infants (aIRR 2.90, 95% CI 0.59-14.44, p=0.19; Table 4.4) compared to no PM. There were 
no significant differences in the incidence of non-malaria febrile illnesses and prevalence of 
anaemia during routine visits among infants born to mothers in different PM categories 
compared to no PM (Table 4.4).  
Does prevention of PM explain the difference in infant malaria incidence between IPTp-DP 
and IPTp-SP? 
Male infants born to mothers who received IPTp-DP have been previously reported to have a 
lower incidence of malaria in infancy compared to male infants whose mothers received IPTp-
SP [16]. Consistent with this prior analysis, male infants with placental histology results born to 
mothers who received IPTp-DP had 23% less malaria than male infants born to mothers who 
received IPTp-SP (IRR 0.77, 95% CI 0.61-0.99, p=0.049), but this association was not observed in 
female infants (Table 4.5). Mediation analysis showed that among all infants, 43% of IPTp-DP’s 
effect on preventing malaria during infancy than IPTp-SP was attributed to its greater effect on 
preventing PM (IRRmediated 0.95, versus IRRtotal 0.89, Table 4.5). In males, this proportion was 
89.7% (IRRmediated 0.79 versus IRRtotal 0.77). Among female infants, the proportion of mediated 





In this secondary analysis of data from a birth cohort of infants born to women randomised to 
receive monthly IPTp with SP vs DP, infants born to mothers with active PM and severe past PM 
had a non-significant higher incidence of malaria and complicated malaria during the first year 
of life compared to infants born to mothers without PM. However, the association between 
severe past PM and infant malaria was sex-specific. In male, but not female, infants, severe past 
PM was associated with a significantly higher incidence of malaria, a higher rate of first malaria 
episode, a higher incidence of complicated malaria, and a higher prevalence of parasitaemia 
during routine visits, compared to no PM. No sex-specific differences were observed between 
active PM and the incidence of malaria in infancy. Importantly, male infants born to mothers 
given IPTp-DP had significantly less malaria in infancy than males born to mothers given IPTp-
SP, and 89.7% of this effect was mediated through prevention of PM.  
Several prior studies have reported associations between active PM defined as detection of 
parasites in placental blood or tissue and an increased risk of malaria during infancy [9-11, 23-
25]. Active PM detected by microscopy was associated with a higher risk of malaria infection in 
Ugandan infants [23], an increased rate of first parasitaemia in Beninese infants [11], and a 
higher risk of first episode of malaria in Gabonese infants [24]. In Mozambique, active PM 
detected by histology was also associated with higher odds of malaria compared to no PM [9]. 
The results from the current study, although not statistically significant, are consistent with 
these prior studies. The exact mechanisms through which PM might impact on the incidence of 
malaria in infancy are not well understood but may be due to the effects of PM on the foetal 
immune system, including modulation of innate and adaptive cellular immune responses, as well 
as altered maternal-foetal transfer of antibodies to P. falciparum [26]. Alternatively, these 
associations may represent confounding secondary to shared levels of exposure to malaria 
parasites between mothers and their infants. To limit the effect of confounding by malaria 
exposure in the current study, IPTp arm and markers of exposure, including housing structure 
and maternal parasitaemia at enrolment were adjusted for, but the possibility of residual 
confounding persists.  
Importantly, in this study, there was an association between the severity of past PM, defined as 
the proportion of HPF with malaria pigment deposition, with malaria risk, but only in male 
infants. Severity of malaria pigment deposition in the placenta has been previously reported by 
our group, as a strong predictor of adverse birth outcomes [15]. To our knowledge, this is the 
first report to suggest that severity of past PM is also associated with increased risk of malaria 
in infancy, and that infant sex may modify these associations. Although the precise mechanism 
by which infant sex modifies the relationship between PM and infant malaria risk remains 




infectious diseases in infants [27, 28]. While one study in southern Sudan suggested that 
pregnant women who bore female infants were more likely to have PM than those who bore 
male infants [29], several adverse pregnancy outcomes, including stillbirths, have been shown 
to be more common in males than in females [30]. This suggests that in-utero fetal exposures 
may have more severe consequences for male infants than female infants [31]. Furthermore, 
male infants exposed to malaria in-utero have been shown to have higher frequencies of 
regulatory T cells in cord blood compared to female infants with similar exposure [32], 
suggesting that in-utero malaria exposure may differentially induce tolerance to malaria 
antigens in male, but not female, infants. Alternatively, other sex-based differences, including 
malaria-induced responses to toll-like receptor ligands [27, 32], expression of X-chromosome 
encoded genes [33], and/or glucocorticoid receptor expression [34] may be responsible for 
these findings. Future studies are needed to better understand how PM may result in different 
sex-specific outcomes in infants.  
IPTp with highly effective drugs such as DP can reduce the severity of PM, and in this study, IPTp-
DP was associated with a statistically significant lower incidence of malaria among male infants, 
and a non-significant lower incidence of malaria among all infants, compared with IPTp-SP. In 
the mediation analysis, 89.7% of the effect of IPTp-DP vs SP on the incidence of malaria among 
male infants was mediated through prevention of PM. Although this result was not statistically 
significant, possibly due to limited sample size to conduct this stratified mediation analysis, 
these results suggest that in addition to preventing adverse birth outcomes in all infants, 
effective interventions in pregnancy that reduce severe PM may also result in a lower risk of 
malaria in male infants. 
In this study, there was no significant association between PM and the incidence of non-malaria 
febrile illnesses in infancy, contrary to other reports that suggest that in-utero exposure may 
also influence immune responses to non-malarial infections [7, 35]. Furthermore, effective 
prevention of PM with IPTp-DP was not associated with a lower incidence of non-malarial febrile 
illnesses in infancy compared with IPTp-SP [16]. These data suggest that PM may specifically 
impact infant malaria risk, although the possibility that it may impact other non-malaria 
infections cannot be excluded.  
This study had some limitations. This secondary analysis was exploratory in nature and did not 
use categories of PM based on malaria pigment deposition in fibrin used by previous studies [15, 
20]. However, prior studies assessed associations between the severity of placental pigment and 
adverse birth outcomes. To our knowledge, ours is the first study to assess associations between 




come up with a standardized classification system relating the severity of placental pigment 
deposition to infant malaria risk using data from multiple independent studies from different 
epidemiological settings. There were relatively small number of infants in the severe past and 
active PM categories, and our findings should therefore be interpreted with caution. The study 
was conducted in a very high malaria transmission setting and therefore its findings cannot be 
generalized to other malaria transmission settings. Finally, exclusion of infants with missing 
placental histology results (3.2%) and losses to follow-up may have reduced the power of the 
study and introduced bias if the infants excluded and those lost to follow-up were different from 
those who completed follow-up. However, there were no significant differences between 
infants excluded from the analysis, those lost to follow-up, and the infants who completed the 
study.  
Conclusions 
Overall, this study suggests that severe malaria pigment deposition in placental tissue is 
associated with a higher incidence of malaria during the first year of life among infants residing 
in a setting of high malaria transmission intensity; however, this association was seen in only 
male infants. Highly effective interventions which reduce both severe past and active PM could 
be protective in male infants. Future research is needed to evaluate the association between 
PM and the risk of malaria in infancy in larger studies conducted in moderate and high malaria 
transmission settings and to evaluate mechanistic pathways between PM and infant malaria risk.  
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Figure 1. Study profile 
IPTp=intermittent preventive treatment in pregnancy, DP=dihydroartemisinin-piperaquine, 
SP=sulfadoxine-pyrimethamine,  
 
Figure 2. Time to first episode of malaria stratified by infant sex 
Panel A= all infants, panel B= male infants C=female infants 
PM= placental malaria, mild-mod= mild-moderate 
No PM=no parasites or pigment detected; active PM=parasites detected with or without 
pigment 
past PM (mild-mod)= >0-20% of high-power fields with pigment but no parasites; past 






Table 4.1 Characteristics of study participants 
Abbreviations: SP, sulfadoxine-pyrimethamine; DP, dihydroartemisinin-piperaquine; SD, 
standard deviation; PM, placental malaria; ppy, per person year; qPCR, quantitative 
polymerase chain reaction 
aDefined as number of routine positive blood smears divided by total number of routine blood 
smears 
No PM=no parasites or pigment detected; active PM=parasites detected with or without 
pigment 
Past PM (Mild-moderate)= >0-20% of high-power fields with pigment but no parasites; Past 
PM (severe)= >20%-60% of high-power fields with pigment but no parasites  
Characteristic 
Maternal IPTp arm 




Maternal characteristics at enrolment 
Age in years, mean (SD) 24.0 (5.9) 24.0 (5.7) 
Gravidity, n (%)   
 Primigravida/secundigravida 152 (46.5%) 156 (47.4%) 
 Multigravida 175 (53.5%) 173 (52.6) 
House-hold type, n (%)   
 Modern House 77 (23.6%) 71 (21.6%) 
 Traditional House 250 (76.5%) 258 (78.4%) 
Parasite prevalence by microscopy or qPCR, n (%)   
 No parasites 53 (16.2%) 63 (19.2%) 
 Sub-microscopic parasitemia 111 (33.9%) 88 (26.8%) 
 Microscopic parasitemia 163 (49.9%) 178 (54.1%) 
Maternal characteristics during pregnancy 
Parasite prevalence by microscopy, n/N (%)a  797/2212 (36.0%) 355/2260 (15.7%) 
Incidence of malaria (episodes/ppy) 0.59 0.09 
Placental malaria status 
Placental malaria status, n (%)   
 No PM 119 (36.4%) 232 (70.5%) 
Active PM 71 (21.7%) 7 (2.1%) 
Past PM (Mild-moderate pigment) 97 (29.7%) 84 (25.5%) 
Past PM (Severe pigment) 40 (12.2%) 6 (1.8%) 
Characteristics of infants at birth 
Preterm birth, n (%) 25 (7.7%) 17 (5.2%) 
Gestation age in weeks, mean (SD) 39.4 (1.9) 39.6 (1.6) 
Low birth weight, n (%) 33 (10.1%) 25 (7.6%) 
Birth weight in grams, mean (SD) 3055 (505) 3024 (409) 

















IRR (95% CI) p-value IRR (95% CI) p-value 
All 
No PM (351) 574 327.4 1.75 reference group reference group 
Active PM (78) 152 68.9 2.21 1.27 (0.99-1.62) 0.06 1.30 (1.00-1.71) 0.05 
Past PM (mild-mod) (181) 271 157.8 1.72 0.97 (0.79-1.18) 0.74 0.94 (0.76-1.16) 0.55 
Past PM (severe) (46) 91 42.5 2.14 1.22 (0.91-1.63) 0.19 1.28 (0.89-1.83) 0.18 
Male  
No PM (168) 255 154.5 1.65 reference group reference group 
Active PM (45) 86 39.9 2.16 1.31 (0.93-1.87) 0.13 1.27 (0.87-1.84) 0.22 
Past PM (mild-mod) (70) 129 77.7 1.66 0.98 (0.72-1.35) 0.92 1.02 (0.76-1.36) 0.90 
Past PM (severe) (17) 49 15.3 3.20 1.87 (1.29-2.71) 0.001 2.17 (1.45-3.25) <0.001 
Female  
No PM (183) 319 172.9 1.84 reference group reference group 
Active PM (33) 66 29.0 2.28 1.24 (0.89-1.73) 0.21 1.29 (0.87-1.91) 0.21 
Past PM (mild-mod) (91) 142 80.1 1.77 0.96 (0.73-1.24) 0.74 0.81 (0.61-1.08) 0.15 
Past PM (severe) (29) 42 27.1 1.55 0.85 (0.58-1.24) 0.40 0.74 (0.46-1.20) 0.22 
 Abbreviations: CI, confidence interval; IRR, incidence rate ratio; mild-mod, mild-moderate; PM, placental malaria 
 a Episodes of malaria per person year of follow-up 
 bAdjusted for gravidity, maternal IPTp, maternal parasitaemia at enrolment, and household type 
 No PM=no parasites or pigment detected; active PM=parasites detected with or without pigment past PM (mild-mod)= >0-20% of high-power fields with 














 categories (N) 
Number of cases 
(incidence PPY) 
Unadjusted Adjusteda 





No PM (351) 30 (0.092) reference group reference group 
Active PM (78) 12 (0.17) 1.89 (0.93-3.87) 0.08 1.72 (0.81-3.66) 0.16 
Past PM (mild-mod) (181) 14 (0.09) 0.97 (0.52-1.81) 0.91 0.99 (0.52-1.92) 0.98 
Past PM (severe) (46) 9 (0.21) 2.30 (0.97-5.43) 0.06 2.44 (0.93-6.37) 0.07 
Male 
No PM (168) 13 (0.08) reference group reference group 
Active PM (45) 6 (0.04) 1.78 (0.63-5.02) 0.27 1.18 (0.39-3.62) 0.77 
Past PM (mild-mod) (90) 11 (0.14) 1.68 (0.76-3.68) 0.20 1.54 (0.44-3.45) 0.30 
Past PM (severe) (17) 6 (0.39) 4.61 (1.50-14.22) 0.008 3.88 (1.14-13.03) 0.03 
Female 
No PM (183) 17 (0.10) reference group reference group 
Active PM (33) 6 (0.21) 2.09 (0.78-5.64) 0.15 2.60 (0.91-7.44) 0.14 
Past PM (mild-mod) (91) 3 (0.04) 0.38 (0.11-1.29) 0.12 0.44 (0.13-1.54) 0.20 





Placental malaria  
categories 
Prevalence  
 n/N (%) 




No PM (351) 377/4170 (9.0%) reference group reference group 
Active PM (78) 82/858 (9.6%) 1.07 (0.76-1.52) 0.70 1.19 (0.82-1.73) 0.36 
Past PM (mild-mod) (181) 154/1993 (7.7%) 0.85 (0.65-1.12) 0.26 0.86 (0.65-1.14) 0.28 
Past PM (severe) (46) 61/542 (11.3%) 1.22 (0.84-1.77) 0.30 1.38 (0.90-2.10) 0.14 
Male 
No PM (168) 170/1964 (8.7%) reference group reference group 
Active PM (45) 50/498 (10.0%) 1.17 (0.73-1.86) 0.52 1.19 (0.71-2.00) 0.51 
Past PM (mild-mod) (90) 70/976 (7.2%) 0.81 (0.55-1.20) 0.29 0.87 (0.58-1.31) 0.50 
Past PM (severe) (17) 31/191 (16.2%) 1.80 (1.08-2.99) 0.02 2.24 (1.34-3.74) 0.002 
Female 
No PM (183) 207/2206 (9.4%) reference group reference group 
Active PM (33) 32/360 (8.9%) 0.97 (0.57-1.66) 0.91 1.05 (0.61-1.83) 0.85 
Past PM (mild-mod) (91) 84/1017 (8.3%) 0.90 (0.61-1.31) 0.57 0.79 (0.53-1.17) 0.24 
Past PM (severe) (29) 31/351 (8.6%) 0.90 (0.54-1.51) 0.70 0.86 (0.48-1.52) 0.60 
   Abbreviations: CI, confidence interval; IRR, incidence rate ratio; mild-mod, mild-moderate; PM, placental malaria; PPY, per person year 
   aAdjusted for gravidity, maternal IPTp, maternal parasitaemia at enrolment, and household type 
No PM=no parasites or pigment detected; active PM=parasites detected with or without pigment; past PM (mild-mod)= >0-20% of high-power fields with 





Table 4.4. Association between placental malaria and non-malaria outcomes in infants during the first year of life 
Outcome measure 
Placental malaria category 
(N) 
Number of cases 
(incidence PPY) 
unadjusted Adjusteda 




No PM (351) 9 (0.027) reference group reference group 
Active PM (78) 3 (0.044) 1.66 (0.40-7.00) 0.49 1.14 (0.22-5.98) 0.87 
Past PM (mild-mod) (181) 7 (0.044) 1.72 (0.58-5.12) 0.33 1.26 (0.44-3.64) 0.66 




No PM (351) 1128 (3.45) reference group reference group 
Active PM (78) 203 (2.95) 0.86 (0.72-1.03) 0.10 0.84 (0.64-1.10) 0.20 
Past PM (mild-mod) (181) 536 (3.40) 0.98 (0.86-1.13) 0.82 1.03 (0.84-1.25) 0.79 
Past PM (severe (46) 152 (3.58) 1.04 (0.85-1.26) 0.72 1.06 (0.72-1.57) 0.76 
Prevalence measures Categories Prevalence n/N (%) Risk ratio (95% CI) p-value Risk ratio (95% CI) p-value 
Anaemiac 
No PM (351) 227/934 (24.3%) reference group reference group 
Active PM (78) 48/190 (25.3%) 1.07 (0.76-1.50) 0.69 1.00 (0.69-1.47) 0.98 
Past PM (mild-mod) (181) 106/441 (24.0%) 1.01 (0.80-1.29) 0.92 0.94 (0.73-1.22) 0.64 
Past PM (severe (46) 37/118 (31.4%) 1.29 (0.94-1.77) 0.12 1.16 (0.79-1.70) 0.44 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio; mild-mod, mild-moderate; PM, placental malaria 
aAdjusted for gravidity, maternal IPTp, maternal parasitaemia at enrolment, and household type 
b Defined as haemoglobin < 10 g/dL measured routinely at 12, 28, and 52 weeks of age 
No PM=no parasites or pigment detected; active PM=parasites detected with or without pigment; past PM (mild-mod)= >0-20% of high-power fields with 




Table 4.5 Effect of IPTp on malaria incidence in infants that is mediated by preventing placental malaria 
Infant 
category 
Total Effect  Direct effect  Mediated effect % of mediated 
effect* IRR (95% CI) p-value  IRR (95% CI) p-value  IRR (95% CI) p-value 
All sexes 0.89 (0.75-1.04) 0.16  0.94 (0.73-1.17) 0.58  0.95 (0.77-1.16) 0.61 43.5% 
Males 0.77 (0.61-0.99) 0.05  0.97 (0.67-1.36) 0.89  0.79 (0.56-1.09) 0.17 89.7% 
Females 1.01 (0.81-1.26) 0.96  0.92 (0.71-1.22)  0.56  1.09 (0.87-1.38) 0.45 -- 
Abbreviations: CI, confidence intervals and IRR, incidence rate ratio  
Note: IRRs represent the effect of IPTp DP versus SP on the incidence of malaria in infants. Confidence intervals reported here were obtained by 
bootstrapping and may differ from those reported in the primary analysis which used the delta method specifying robust standard errors. 






















Table 4.6 Additional table of characteristics of study participants stratified by infant sex. 
Abbreviations: SP, sulfadoxine-pyrimethamine; DP, dihydroartemisinin-piperaquine; SD, 
standard deviation; PM, placental malaria; ppy, per person year; qPCR, quantitative 
polymerase chain reaction 
aDefined as number of routine positive blood smears divided by total number of routine blood 
smears 
No PM=no parasites or pigment detected; active PM=parasites detected with or without 
pigment 
Past PM (Mild-moderate) = >0-20% of high-power fields with pigment but no parasites; Past 










Maternal characteristics at enrolment 
Age in years, mean (SD) 23.9 (5.8) 24.2 (5.9) 
Gravidity, n (%)   
 Primigravida/secundigravida 152 (47.5%) 156 (46.4%) 
 Multigravida 168 (52.5%) 180 (53.6%) 
House-hold type, n (%)   
 Modern House 88 (27.5%) 60 (17.9%) 
 Traditional House 250 (72.5%) 258 (82.1%) 
Parasite prevalence by microscopy or qPCR, n (%)   
 No parasites 58 (18.1%) 58 (17.3%) 
 Sub-microscopic parasitemia 100 (31.3%) 99 (29.5%) 
 Microscopic parasitemia 162 (50.6%) 179 (53.3%) 
Maternal characteristics during pregnancy 
Parasite prevalence by microscopy, n/N (%)a  544/2176 (25.0%) 608/2296 (26.5%) 
Incidence of malaria (episodes/ppy) 0.33 0.34 
Placental malaria status 
Placental malaria status, n (%)   
 No PM 168 (52.5%) 183 (54.5%) 
Active PM 90 (28.1%) 91 (27.1%) 
Past PM (Mild-moderate pigment) 17 (5.3%) 29 (8.6%) 
Past PM (Severe pigment) 45 (14.1%) 33 (9.8%) 
Characteristics of infants at birth 
Preterm birth, n (%) 17 (5.3%) 25 (7.4%) 
Gestation age in weeks, mean (SD) 39.6 (1.5) 39.4 (2.0) 
Low birth weight, n (%) 21 (6.6%) 37 (11.0%) 




Characteristics of study participants stratified by infant sex 
At enrolment, maternal age was similar between male and female infants. There was no 
significant difference maternal parasite status at enrolment. The proportion of mothers 
residing in traditional households was significantly higher in female infants (82.1%) than male 
infants (72.5%, p=0.003). During pregnancy, maternal parasite prevalence was similar among 
male and female infants. At birth, the mean birth weight was higher for male infants (mean 





CHAPTER 5 IMPACT OF INTERMITTENT PREVENTIVE TREATMENT 
OF MALARIA IN PREGNANCY ON THE INCIDENCE OF MALARIA 
DURING INFANCY 
5.1 Chapter Introduction 
This chapter addresses objective 2, to compare the incidence of malaria during the first year of 
life in infants born to mothers who were randomised to receive monthly IPTp-DP versus monthly 
IPTp-SP. The manuscript presents results from a birth cohort of infants born to HIV-uninfected 
mothers who were randomised to monthly IPTp with DP versus SP, which was published in BMC 
Medicine in August 2020. 
5.2 Research paper 


















Intermittent preventive treatment of malaria during pregnancy (IPTp) with dihydroartemisinin-
piperaquine (DP) significantly reduces the burden of malaria during pregnancy compared to 
sulfadoxine-pyrimethamine (SP), the current standard of care, but its impact on the incidence 
of malaria during infancy is unknown. 
Methods  
We conducted a double-blind, randomised trial to compare the incidence of malaria during 
infancy among infants born to HIV-uninfected pregnant women who were randomised to 
monthly IPTp with either DP or SP. Infants were followed for all their medical care in a dedicated 
study clinic and routine assessments were conducted every 4 weeks. At all visits, infants with 
fever and a positive thick blood smear were diagnosed and treated for malaria. The primary 
outcome was malaria incidence during the first 12 months of life. All analyses were done by 
modified intention to treat. 
Results 
Of the 782 women enrolled, 687 were followed through delivery from December 9, 2016 to 
December 5, 2017 resulting in 678 live births; 339 born to mothers randomised to SP and 339 
born to those randomised to DP. Of these, 581 infants (85.7%) were followed to 12 months of 
age. Overall, the incidence of malaria was lower among infants born to mothers randomised to 




person year, incidence rate ratio (IRR) 0.87, 95% confidence interval (CI) 0.73-1.03, p=0.11). 
Stratifying by infant sex, IPTp with DP was associated with a lower incidence of malaria among 
male infants (IRR 0.75, 95% CI 0.58-0.98, p=0.03) but not female infants (IRR 0.99, 95% CI 0.79-
1.24, p=0.93). 
Conclusion 
Despite the superiority of DP for IPTp, there was no evidence of a difference in malaria incidence 
during infancy in infants born to mothers who received DP compared to those born to mothers 
who received SP. Only male infants appeared to benefit from IPTp-DP suggesting that IPTp-DP 
may provide additional benefits beyond birth. Further research is needed to further explore the 
benefits of DP versus SP for IPTp on health outcomes of infants.  
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Infection with malaria parasites during pregnancy remains a major public health problem, 
especially in sub-Saharan Africa where transmission intensity is highest and Plasmodium 
falciparum the predominant species. In 2018 there were an estimated 39 million pregnancies in 
sub-Saharan Africa, of which over 11 million (29%) were exposed to P. falciparum [1]. The 
majority of women residing in malaria endemic areas of sub-Saharan Africa are partially immune 
and do not develop symptoms when infected with P. falciparum during pregnancy. However, 
even in the absence of symptomatic disease, malaria in pregnancy is associated with maternal 
anaemia and adverse birth outcomes such as low birth weight, preterm delivery, and stillbirth 
[2-4].  
To prevent malaria in pregnancy and improve birth outcomes, the World Health Organization 
(WHO) recommends intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine 
(SP) in pregnant women residing in areas of moderate to high malaria transmission intensity [5]. 
However, the effectiveness of IPTp-SP is threatened by widespread antifolate resistance 
resulting in failure to clear parasites and prevent new infections [6]. Recent studies have shown 
dihydroartemisinin-piperaquine (DP) to be a promising alternative to SP for IPTp. Compared to 
IPTp-SP, IPTp-DP has been shown to be much more effective at reducing the prevalence of 
malaria parasitaemia and incidence of clinical malaria during pregnancy and reducing the risk of 
placental malaria at delivery [7-9]. However, despite significantly reducing the burden of malaria 
during pregnancy, IPTp-DP has not been shown to be superior to IPTp-SP at improving adverse 
birth outcomes [7-9].  
Prevention of malaria during pregnancy may have additional benefits to the infant beyond the 
neonatal period. Studies have shown that intrauterine exposure to P. falciparum may negatively 
affect the development of antimalarial immunity in the infant [10, 11]. Indeed, several 
observational studies have suggested that placental malaria increases the risk of malaria during 
infancy [12-14]. However, these studies could not rule out the possible confounding effect of 
behavioural, environmental, genetic, and social-economic factors shared by the mother and her 
infant on the associations between exposure to malaria parasites during pregnancy and risk of 
malaria during infancy. A more robust method of testing this hypothesis would be to compare 
the impact of a highly effective regimen versus a less effective regimen for IPTp on the risk of 
malaria during infancy in a randomised controlled trial. However, to date clinical trials that have 
evaluated the impact of IPTp on the risk of malaria during infancy have been limited by similar 
efficacy of IPTp regimens [15, 16] or the provision of chemoprevention during infancy, in 




To address this gap in evidence, we compared the incidence of malaria during the first year of 
life among infants born to HIV-uninfected pregnant women who took part in a double-blind, 
randomised, controlled trial of monthly IPTp with DP (a highly effective regimen) versus SP (a 
less effective regimen). During pregnancy, IPTp-DP was superior to IPTp-SP for reducing the 
incidence of clinical malaria and prevalence of asymptomatic parasitaemia during pregnancy, 
and the prevalence of placental malaria at delivery [9]. Children born to mothers enrolled in this 
study did not receive chemoprevention during infancy.  
Methods 
Study setting and participants 
This study was conducted from September 6, 2016 to December 4, 2018, in Busia district, south-
eastern Uganda, an area of high malaria transmission intensity. The study was conducted in two 
phases; the pregnancy phase, which involved enrolment and follow-up of pregnant women 
through delivery, and the infancy phase which involved follow-up of infants through 12 months 
of age. Details of the pregnancy phase of the study have been published elsewhere [9]. In brief, 
HIV-uninfected pregnant women were eligible for enrolment if they were 12-20 weeks of 
gestation, 16 years or older, agreed to come to the study clinic for any illness, had no history of 
taking IPTp-SP or any other antimalarial therapy during the current pregnancy, and provided 
written informed consent. Women were excluded if they had a history of serious adverse events 
to SP or DP. The infancy phase involved the follow-up of all live births among women enrolled 
in the pregnancy phase of the study. 
Study design, randomisation, and masking 
This was a double-blind, randomised, controlled trial designed to assess the impact of monthly 
IPTp with DP versus SP in HIV-uninfected pregnant women, on the incidence of malaria during 
infancy (Trial registration, ClinicalTrials.gov; NCT02793622). At enrolment, pregnant women 
were randomly assigned in a 1:1 ratio to receive IPTp-DP or IPTp-SP. A randomisation list was 
computer generated using permuted blocks of 4 or 8 by a staff member not directly involved in 
patient care. To achieve allocation concealment, sealed envelopes, each containing a treatment 
allocation number and treatment group assignment, were prepared following the sequence of 
the randomisation list, prior to enrolment. Treatment allocation was done by a study pharmacist 
not involved in daily patient care by picking the next available sealed envelope, recording the 
participant’s identification number on the envelope, and opening it to reveal the assigned 
treatment. The treatment allocation number, the participant’s identification number, and the 




lockable place only accessible by the study pharmacist. Study drugs for each enrolled participant 
were pre-packaged by the study pharmacist and labelled with the participant’s identification 
number. Study drugs were administered every 4 weeks starting at 16 or 20 weeks of gestation. 
Each dose of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine; Duo-
Cotexin, Holley-Cotec, Beijing, China) consisted of 3 tablets given once a day for 3 consecutive 
days. Each dose of SP (tablets of 500 mg of sulfadoxine and 25 mg of pyrimethamine; Kamsidar, 
Kampala Pharmaceutical Industries) consisted of 3 tablets given as a single dose. To achieve 
blinding, participants randomised to DP also received SP placebos, and participants randomised 
to SP received DP placebos every 4 weeks. All 1st daily doses of study drugs were administered 
directly observed in the clinic. The 2nd and 3rd daily doses were dispensed to the mother for 
self-administration at home. Adherence to the 2nd and 3rd daily doses was assessed by self-
reporting during the visits following routine visits. 
Study procedures 
Study procedures for pregnant women have been previously described in detail [9]. Briefly, at 
enrolment, all participants received a long-lasting insecticide treated net and underwent a 
standard history and physical examination. Pregnant women were encouraged to come to a 
dedicated study clinic any time they were ill and to attend routine visits conducted every 4 weeks 
for study drug dispensing and laboratory testing. Pregnant women diagnosed with symptomatic 
malaria detected by microscopy at any visit were treated with artemether-lumefantrine. 
Asymptomatic parasitaemia detected during routine visits was not treated. At delivery, a 
standardised assessment was completed including evaluation of birth weight, gestation age 
based on ultrasound dating, and collection of biological specimens including placental tissue and 
placental blood.  
Following delivery, all live births were followed up to 12 months of age. Mothers were 
encouraged to bring their infants to a dedicated study clinic open every day for all their medical 
care and were provided transport refund. Routine assessments were conducted every 4 weeks 
including collection of blood for the detection of parasites by microscopy. Infants who presented 
with a history of fever in the past 24 hours or with a documented tympanic temperature > 38.0˚C 
had blood collected for a thick blood smear. If the thick blood smear was positive, infants were 
treated for malaria according to the Uganda Ministry of Health guidelines which consisted of 
artemether-lumefantrine for uncomplicated malaria and intravenous artesunate for 
complicated malaria. Non-malarial illnesses were treated according to the integrated 
management of childhood illnesses guidelines. At 12, 28, and 52 weeks of age, blood was 





Presence of malaria parasites in dried placental blood spots was detected by loop-mediated 
isothermal amplification as previously described [18]. Placental malaria by histology defined as 
presence of malaria parasites or malaria pigment was detected from placental tissue as 
previously described [19]. Blood smears were stained with 2% Giemsa and read by experienced 
microscopists. A blood smear was considered negative when the examination of 100 high power 
fields did not reveal asexual parasites. All blood smears were read by two independent 
microscopists. Blood smears with discrepant results between the first and second reader were 
read by a third reader as a tie breaker. Haemoglobin measurements were made using a portable 
spectrophotometer (Hemocue, Angelholm, Sweden).  
Study outcomes 
The primary outcome was the incidence of malaria from birth to 12 months of age. An incident 
episode of malaria was defined as the presence of fever (history of fever in the past 24 hours or 
a tympanic temperature ≥ 38.0˚C) with a positive thick blood smear not preceded by another 
malaria episode in the last 14 days. Secondary outcomes included time to a first episode of 
malaria; incidence of complicated malaria defined as an episode of malaria with danger signs 
(any of the following, less than 3 convulsions over 24 hours, inability to sit or stand, vomiting 
everything, unable to breastfeed or drink) or meeting standardised criteria for severe malaria; 
incidence of all cause hospitalisations; infant mortality; incidence of non-malarial febrile 
illnesses; prevalence of malaria parasitaemia during routine visits; and prevalence of anaemia 
(haemoglobin <10g/dL) at 12, 28, and 52 weeks of age. 
Statistical analysis 
To test the hypothesis that infants born to mothers randomised to IPTp-DP would have a lower 
incidence of malaria during the first 12 months of life compared to infants born to mothers 
randomised to IPTp-SP, it was estimated that the incidence of malaria in infants born to mothers 
randomised to IPTp-SP would be 3-5 episodes per person year (using data from a prior study 
conducted in the adjacent district of Tororo [20] and a loss of 5% of follow-up time per year). 
With these assumptions, the study had 80% power to detect an 18-23% difference in the 
incidence of malaria (incidence rate ratio of 0.77-0.82) among infants born to mothers 
randomised to IPTp-DP compared to those born to mothers randomised to IPTp-SP with a two-
sided significance level of 0.05.  
Data were double entered and verified in Microsoft Access by two independent data entrants. 




population, which included all live births followed until they reached 12 months of age or 
premature study withdrawal. Comparisons of simple proportions were made using the chi-
square test or Fisher’s exact test. Comparisons of continuous variables were made using the t-
test. Comparisons of proportions with repeated measures were made with generalised 
estimating equations, with the use of log-binomial regression and robust standard errors to 
adjust for clustering. Comparisons of incidence measures were made using a negative binomial 
regression model. Incidence rate ratios (IRRs) were defined as the incidence in the IPTp-DP arm 
divided by the incidence in the IPTp-SP arm. Prevalence ratios were defined as the prevalence 
in the IPTp-DP arm divided by the prevalence in the IPTp-SP arm. Stratified analyses of our 
primary outcome according to infant sex and age, and maternal gravidity were planned a priori 
in the statistical analysis plan. The cumulative risk of the first episode of malaria was compared 
using a Cox proportional hazards model with the association expressed as the hazard ratio (HR). 
In all analyses, two-sided p-values of <0.05 were considered statistically significant. 
 
Results 
Study participants and follow-up 
Between September 2016 and May 2017, 879 pregnant women were screened and 782 were 
enrolled and randomised to receive either monthly IPTp with DP (N=391) or SP (N=391) (figure 
1) [9]. Among the 687 (87.9%) women who were followed through delivery, there were 678 live 
births from December 9, 2016 to December 5, 2017, 339 in the IPTp-DP group and 339 in the 
IPTp-SP group. Among the 678 live births, 581 infants (85.7%) were followed up to 12 months of 
age (Figure 5.1). Maternal characteristics at enrolment were similar between the two groups 
(Table 5.1). Mean age at enrolment was 23.9 years, 321 (47.3%) infants were born to 
primigravida or secundigravida mothers, and 399 (58.8%) infants were born to mothers enrolled 
at 12-16 weeks of gestation while 279 (41.2%) were born to mothers enrolled at >16-20 weeks 
of gestation. Three hundred fifty-three (52.1%) infants were born to mothers with parasitaemia 
detected by microcopy at enrolment. During pregnancy, the period prevalence of parasitaemia 
detected by microscopy during routine visits was significantly lower in mothers who received 
IPTp-DP (365/2324, 15.7%) compared to mothers who received IPTp-SP (828/2291, 36.1%, 
p<0.001). Similarly, the incidence of malaria during pregnancy was significantly lower in mothers 
who received IPTp-DP compared to mothers who received IPTp-SP (0.09 vs 0.59 episodes per 
person year, p<0.001). At delivery, compared to mothers who received IPTp-SP, mothers who 
received IPTp-DP had a significantly lower prevalence of placental parasitaemia detected by 




differences in characteristics of infants born to mothers who received IPTp-DP or IPTp-SP (Table 
5.1).  
Impact of IPTp with DP on incidence of malaria in infancy 
Overall, infants born into the cohort experienced 1131 episodes of malaria during 614 person 
years of follow-up. The incidence of malaria was lower among infants born to mothers who 
received IPTp-DP (1.71 episodes per person year) compared to infants born to mothers who 
received IPTp-SP (1.98 episodes per person year), but the difference was not statistically 
significant (incidence rate ratio (IRR) 0.87, 95% confidence interval (CI) 0.73-1.03, p=0.11; Table 
5.2). However, the association between IPTp and the incidence of malaria in infants was 
modified by infant sex. Among male infants, the incidence of malaria was significantly lower 
among infants born to mothers who received IPTp-DP compared to those born to mothers who 
received IPTp-SP (IRR 0.75, 95% CI 0.58-0.98, p=0.03). There was no difference in the incidence 
of malaria between female infants born to mothers who received IPTp-DP versus IPTp-SP (IRR 
0.99, 95% CI 0.79-1.24, p=0.93; Table 5.2). In addition, difference in malaria incidence between 
the IPTp regimens among male infants was only significant between >3 to 12 months of age (IRR 
0.73, 95% CI 0.56-0.96, p=0.02) but not between 0 to 3 months of age (IRR 0.89, 95% CI 0.48-
1.66, p=0.72). There were no differences between the IPTp regimens among female infants 
stratified by age (table 5.2). There was no significant difference in the time to first episode of 
malaria between infants born to mothers who received IPTp-DP and infants born to mothers 
who received IPTp-SP (hazard ratio (HR) 0.90, 95% CI 0.75-1.09, p=0.30). When stratified by 
infant sex, male infants born to mothers who received IPTp-DP had a lower rate of first episode 
of malaria compared to male infants born to mothers who received IPTp-SP but this did not 
reach statistical significance (HR 0.79, 95% CI 0.60-1.05, p=0.10) and there was no difference 
among female infants (HR 1.01, 95% CI 0.78-1.31, p=0.96; Figure 5.2).  
Impact of IPTp with DP on incidence of complicated malaria in infancy 
Overall, there were 68 episodes of complicated malaria among 59 different infants. For 60 
episodes of complicated malaria, only danger signs were present while 8 episodes met criteria 
for severe malaria (7 episodes of respiratory distress and 1 episode of severe anaemia). The 
incidence of complicated malaria was lower among infants born to mothers who received IPTp-
DP compared to those born to mothers who received IPTp-SP (IRR=0.54, 95% CI 0.32-0.92, 
p=0.02; Table 5.3). Again, effect modification by infant sex was observed. Male infants born to 
mothers who received IPTp-DP had a significantly lower incidence of complicated malaria 
compared to male infants born to mothers who received IPTp-SP (IRR 0.36, 95% CI 0.17-0.78, 




female infants born to mothers who received IPTp-DP or IPTp-SP (IRR 0.86, 95% CI 0.40-1.87, 
p=0.71).  
Impact of IPTp with DP on other secondary outcomes 
The incidence of all cause hospitalisations was lower among infants born to mothers who 
received IPTp-DP compared to infants born to mothers who received IPTp- SP, but this did not 
reach statistical significance (IRR 0.39, 95% CI 0.15-1.05, p=0.06). When stratified by sex, male 
infants born to mothers who received IPTp-DP had a statistically significantly lower incidence of 
all cause hospitalisations compared to male infants born to mothers who received IPTp-SP (IRR 
0.20, 95% CI 0.05-0.82, p=0.03), but there was no difference among female infants (IRR 1.01, 
95% CI 0.22-4.63, p=0.99). A total of 16 infants died, including 9 in the neonatal period. One 
infant born to a mother who received IPTp-DP died of malaria at 11 months of age. There was 
no significant difference in the mortality rate between infants born to mothers who received 
IPTp-DP or IPTp-SP (IRR 0.45, 95% CI 0.03-7.88, p=0.59). The incidence of non-malarial febrile 
illnesses was similar among infants born to mothers who received IPTp-DP or IPTp-SP. The 
prevalence of parasitaemia during routine visits and prevalence of anaemia 
(haemoglobin<10g/dL) measured at 12, 28, and 52 weeks of age were similar among infants 
born to mothers who received IPTp-DP or IPTp-SP. Considering time to first parasitaemia, there 
was no significant difference between infants born to mothers who received IPTp-DP and those 
born to mothers who received IPTp-SP (HR 0.92, 95% CI 0.76-1.10, p=0.37). When stratified by 
infant sex, male infants born to mothers who received IPTp-DP had a slightly lower rate of first 
parasitaemia compared to male infants born to mothers who received IPTp-SP but this did not 
reach statistical significance (HR 0.81, 95% CI 0.62-1.06, p=0.13) and there was no difference 
among female infants (HR 1.02, 95% CI 0.79-1.31, p=0.87). 
 
Discussion 
In this double-blind, randomised, controlled trial conducted in an area of high malaria 
transmission intensity, infants born to mothers randomised to IPTp-DP had a 13% lower 
incidence of malaria compared to infants born to mothers randomised to IPTp-SP, but the 
difference was not statistically significant. However, among male infants, IPTp-DP was 
associated with a lower incidence of malaria compared to IPTp-SP. This difference was primarily 
seen between >3-12 months of age. Similarly, male infants born to mothers who received IPTp-
DP had a lower incidence of complicated malaria and all cause hospitalisations compared to 




were no differences in the incidence of malaria, complicated malaria, and all cause 
hospitalisations between those born to mothers who received IPTp-DP versus IPTp-SP. For both 
sexes, there were no significant associations between maternal IPTp regimen and the risk of 
non-malarial febrile illness or anaemia during infancy.  
IPTp-DP remains an attractive alternative to IPTp-SP for the prevention of malaria in HIV-
uninfected pregnant women. Three randomised controlled trials conducted recently in East 
Africa have consistently shown that IPTp-DP is associated with significant reductions in the risk 
of maternal parasitaemia, maternal clinical malaria and placental malaria compared to IPTp-SP, 
yet, none of these studies has shown significant differences in the risk of adverse birth outcomes 
for infants born to mothers receiving DP or SP for IPTp [7-9]. Historically, IPTp policy 
recommendations have been driven by evidence supporting reductions in the risk of adverse 
birth outcomes, specifically low birth weight, and for this reason the WHO continues to 
recommend IPTp-SP [5]. However, improved protection from malaria infection during 
pregnancy may have longer term effects on infant health [21]. A wealth of immunologic 
evidence suggests that maternal malaria infection affects the development of the foetal and 
infant immune system, both by altering the immune graft received by the foetus (both maternal 
antibodies and cells) as well as exposing the foetus to parasite antigens that may alter both the 
innate and adaptive immune responses [22]. Indeed, infants born to mothers with placental 
malaria may be at an increased risk of malaria during infancy and it would be important to know 
if more effective IPTp regimens could reduce the risk of malaria in infants [13, 14].  
In this study, although there was no overall evidence of a reduced malaria incidence in infants 
born to mothers receiving IPTp-DP versus IPTp-SP, our overall findings suggest that IPTp-DP may 
be associated with a moderately lower incidence of malaria in infants. A recently published 
systematic review identified three randomised controlled trials which evaluated the impact of 
different IPTp regimens on malaria during infancy [23]. There were no significant differences in 
the incidence of malaria among infants born to mothers randomised to IPTp with mefloquine 
versus IPTp-SP [16], intermittent screening and treatment with AL versus IPTp-SP [15], or IPTp-
SP versus placebo [14]. However, these studies were limited by the failure of the alternative 
(non-SP) regimen to significantly reduce the risk of placental malaria. In a randomised controlled 
trial from Uganda, IPTp-DP was found to significantly reduce the risk of placental malaria 
compared to IPTp-SP [8]. But, surprisingly, the incidence of malaria during the first two years of 
life in infants born into this cohort was higher in infants born to mothers who received monthly 
IPTp-DP compared to those born to mothers who received IPTp-SP given every two months [17]. 
However, in that study all infants were also given DP every 3 months, and the association 




finding could largely be explained by the fact that female infants with in utero exposure to DP 
had lower piperaquine levels after receiving DP during infancy, which is strongly predictive of 
malaria risk [24]. In contrast, among male infants, in utero exposure to DP was not associated 
with piperaquine levels during infancy [17]. Furthermore, male infants born to mothers 
randomised to IPTp-DP had a trend towards a lower incidence of malaria compared to male 
infants born to mothers who received IPTp-SP, a similar finding to that reported in here (aIRR 
0.66, 95% CI 0.25-1.75) [17].  
In the present study, IPTp-DP was associated with a lower incidence of malaria, a lower incidence 
of complicated malaria and a lower incidence of all cause hospitalisations during infancy 
compared to IPTp-SP, but only among male infants. Although the precise mechanism by which 
infant sex modifies the relationship between maternal IPTp, maternal malaria infection and 
infant malaria risk remains uncertain, there is a growing body of evidence of sex-based 
differences in susceptibility to infectious diseases in infants [25, 26]. Male infants have been 
found to have an increased pre-disposition to more frequent and more severe manifestations 
of infectious diseases than females [26]. Similarly, several adverse pregnancy outcomes, 
including stillbirth, are more common in males than in females [27]. This suggests that in utero 
foetal exposures may have more severe consequences for male infants than female infants [28]. 
Several potential mechanisms for these sex-based differences have been described. These 
include genetic differences attributable to the heterogeneity of expression of X-chromosome 
encoded genes [29], sex-dependent differences in glucocorticoid receptor expression and 
foetal-placental responsivity to cortisol [30], and sex-specific differences in neonatal and infant 
immune responses to toll-like receptor ligands and induction of regulatory T cell populations 
[25, 31]. Given the reduced risk of malaria among male infants whose mothers received IPTp-DP 
compared to those whose mothers received IPTp-SP, we hypothesise that effective prevention 
of maternal malaria may prevent sex-specific adverse consequences of placental malaria. 
Our study had some limitations. The observed incidence of malaria in infants born to mothers 
who received IPTp-SP (1.98 episodes per person year) was lower than the assumed incidence of 
3-5 episodes per person per year which was used for sample size estimation. This limited the 
power of the study to detect a significant difference between the two IPTp arms if such a 
difference truly existed. Also, our study was not powered to conduct stratified analyses by infant 
sex and age, or to test for associations between IPTp-DP and secondary outcomes such as 
complicated malaria and all cause hospitalizations, which were relatively uncommon in our 
study. Therefore, statistically significant associations observed in stratified analyses and 
between IPTp-DP and secondary outcomes should be interpreted with caution. This study was 




mothers had malaria parasitaemia detected by microscopy or quantitative PCR [9]. This limits 
the generalisation of our findings to other areas with lower transmission intensity. Also, 
administration of all SP doses was directly observed while only the 1st daily dose of DP was 
directly observed. It is possible that some mothers did not take the 2nd and 3rd dose of DP which 
were dispensed for self-administration at home. This could have led to underestimation of the 
effect of IPTp-DP compared to SP on the incidence of malaria. Finally, we measured malaria 
incidence using passive surveillance which could have underestimated the true incidence of 
malaria if infants were treated for malaria at home or taken for care outside the study clinic. 
However, mothers were encouraged to bring their infants to the study clinic for care whenever 
they were sick and were provided transport refund.  
Conclusion 
In summary, our study findings show that in addition to reducing the burden of malaria during 
pregnancy and placental malaria at delivery compared to monthly IPTp-SP [9], monthly IPTp-DP 
was associated with a reduced incidence of malaria, complicated malaria and a trend towards 
reduced incidence of all cause hospitalisations among male infants born to HIV-uninfected 
pregnant women residing in a high malaria transmission setting. Improved prevention of malaria 
during pregnancy may have additional benefits beyond birth. These results provide additional 
support for replacing SP with DP for IPTp in areas with widespread antifolate resistance. Future 
studies of IPTp should consider follow-up of infants beyond the neonatal period to evaluate the 
potential impact of IPTp on infant outcomes, stratify results based on infant sex, and evaluate 
the impact of IPTp on infant outcomes in settings of moderate malaria transmission intensity.  
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Figure 1. Trial profile 
SP=sulfadoxine-pyrimethamine, DP=dihydroartemisinin-piperaquine 
 
Figure 2. Time to first episode of malaria stratified by infant sex 
Panel A= males, panel B= females 







Table 5.1 Characteristics of study participants and their mothers 
Characteristic 







Maternal characteristics at enrolment 
Age in years, mean (SD) 23.9 (5.9) 23.9 (5.7) 0.98 
Gravidity, n (%)    
 Primigravida 86 (25.4%) 73 (21.5) 
0.21  Secundigravida 72 (21.2%) 90 (26.6) 
 Multigravida 181 (53.4%) 176 (51.8) 
Gestation age categories, n (%)    
 12-16 weeks 195 (57.5%) 204 (60.2%) 
0.48 
 >16-20 weeks 144 (42.5%) 135 (39.8%) 
Parasite prevalence by microscopy, n (%) 170 (50.2%) 183 (54.0%) 0.32 
Maternal characteristics during pregnancy 






Incidence of malaria (episodes/PPY) 0.59 0.09 <0.001 
Measures of placental malaria 
Placental blood positive by microscopyb, n/N 
(%) 
29/326 (8.9%) 1/331 (0.3%) <0.001 
Placental blood positive by LAMPc, n/N (%) 71/320 (22.2%) 7/329 (2.1%) <0.001 
Positive placental histologyd, n/N (%) 
199/327 
(60.9%) 
93/329 (28.3%) <0.001 
Characteristics of infants at birth 
Preterm birth, n (%) 27 (8.0%) 17 (5.0%) 0.12 
Gestation age in weeks, mean (SD) 39.4 (1.9) 39.6 (1.6) 0.08 
Low birth weight, n (%) 34 (10.0%) 26 (7.7%) 0.28 
Birth weight in grams, mean (SD) 3052 (505) 3023 (408) 0.41 
Female sex, n (%) 166 (49.0%) 180 (53.1%) 0.28 
Abbreviations: DP dihydroartemisinin-piperaquine, IPTp intermittent preventive treatment of 
malaria in pregnancy, LAMP loop-mediated isothermal amplification, PPY per person year, SD 
standard deviation, SP sulfadoxine-pyrimethamine 
aDefined as number of positive blood smears during routine visits divided by total number of 
routine blood smears 
b Defined as detection of parasites in placental blood by microscopy 
c Defined as detection of parasites in placental blood by LAMP 
















IRR (95% CI) p-value 
All infants born alive 
SP 339 602 304.4 1.98  
0.87 (0.73-1.03) 0.11 
DP 339 529 309.2 1.71 
Sex 
Female infants 
SP 166 283 152.5 1.86 
0.99 (0.79-1.24) 0.93 
DP 180 303 164.8 1.84 
Male infants 
SP 173 319 151.8 2.10 
0.75 (0.58-0.98) 0.03 





0-3 months of age 
SP 166 30 40.1 0.75 
1.16 (0.72-1.89) 0.54 
DP 180 38 43.6 0.87 
>3-12 months of age 
SP 156 253 112.5 2.25 
0.97 (0.77-1.24) 0.83 




0-3 months of age 
SP 173 22 41.5 0.53 
0.89 (0.48-1.66) 0.72 
DP 159 18 38.2 0.47 
>3-12 months of age 
SP 160 297 110.3 2.69 
0.73 (0.56-0.96) 0.02 




SP 86 131 69.3 1.89 
0.84 (0.58-1.20) 0.33 
DP 73 102 64.6 1.58 
2 
SP 72 97 65.5 1.48 
1.04 (0.72-1.49) 0.85 
DP 90 124 81.1 1.53 
> 3 
SP 181 374 169.5 2.21 
0.84 (0.67-1.07) 0.15 
DP 176 303 163.5 1.85 
Abbreviations: CI confidence interval, DP dihydroartemisinin-piperaquine, IPTp intermittent preventive treatment of malaria in pregnancy,  




Table 5.3 Secondary outcomes 
Incidence measures Maternal IPTp arm Number of cases (incidence PPY) IRR (95% CI) p-value 
Complicated malaria 
SP 44 (0.145) 
0.54 (0.32-0.92) 0.02 
DP 24 (0.078) 
All cause hospitalisations  
SP 19 (0.062) 
0.39 (0.15-1.05) 0.06 
DP 8 (0.026) 
Infant mortality 
SP 9 (0.030) 
0.45 (0.03-7.88) 0.59 
DP 7 (0.023) 
Non-malarial febrile illnesses 
SP 1022 (3.36) 
1.01 (0.91-1.12) 0.87 
DP 1047 (3.39) 
Prevalence measuresa Maternal IPTp arm Prevalence (%) PR (95% CI) p-value 
Parasitaemiab 
SP 344/3879 (8.9%) 
1.02 (0.83-1.27) 0.84 
DP 357/3933 (9.1%) 
Anaemiac 
SP 222/878 (25.3%) 
0.96 (0.79-1.17) 0.70 
DP 216/892 (24.2%) 
Abbreviations: CI confidence interval, DP dihydroartemisinin-piperaquine, IPTp intermittent preventive treatment of malaria in pregnancy,  
IRR incidence rate ratio, PPY per person year, PR prevalence ratio, SP sulfadoxine-pyrimethamine 
aPrevalence measures are period prevalence 
bProportion of blood smears with parasitaemia measured routinely every 4 weeks starting at 4 weeks of age 










Figure 5.1 Trial profile 












Figure 5.2 Time to first episode of malaria 
IPTp, intermittent preventive treatment of malaria in pregnancy; SP, sulfadoxine-






CHAPTER 6 PLACENTAL MALARIA AND INTERMITTENT 
PREVENTIVE TREATMENT OF MALARIA IN PREGNANCY ON CORD 
BLOOD P. FALCIPARUM IGG ANTIBODY LEVELS 
6.1 Chapter introduction 
This chapter presents a manuscript which addresses Objective 3, to evaluate the effect of PM 
and IPTp on cord blood levels of IgG antibodies against P. falciparum blood stage antigens. 
Antibody levels specific to antigens; AMA1, EBA140, EBA175, EBA181, GLURP, MSP1, Rh2, Rh4, 
and Rh5 levels were measured in maternal and cord blood samples collected from mothers who 
participated in the main trial, a double-blind, randomised, controlled trial of monthly IPTp with 
DP versus SP. Maternal and cord blood levels of specific P. falciparum IgG antibodies were 
compared among infants born to mothers with PM and those born to mothers with no PM, and 
among infants born to mothers who received IPTp-DP and those born to mothers who received 
IPTp-SP. This manuscript will be submitted to the BMC Immunology journal for consideration for 
publication. 
6.2 Research paper 
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Infants born to mothers with placental malaria (PM) have been reported to have a higher risk of 
malaria than those born to mothers without PM, which may be due to reduced maternal-foetal 
transfer of immunity against Plasmodium falciparum, where immunoglobulin G (IgG) antibodies 
play a critical role. To explore this further, P. falciparum IgG antibody levels were measured in 
samples collected at delivery from infants born to HIV-uninfected pregnant mothers who 
participated in a double-blind, randomised controlled trial of monthly intermittent preventive 
treatment of malaria in pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) versus 
sulfadoxine pyrimethamine (SP). 
Methods 
Maternal and cord blood IgG antibody levels to P. falciparum antigens apical membrane antigen-
1 (AMA1), erythrocyte binding antigen-140 (EBA140), EBA175, EBA181, glutamate rich protein 
(GLURP), merozoite surface protein-1 (MSP1), reticulocyte-binding protein homologue-2 (Rh2), 
Rh4, and Rh5 were measured in 600 paired samples. Antibody levels and ratios of antibodies in 
maternal and cord blood samples were compared between mothers who had active PM, mild-
moderate PM, and severe past PM and those who had no PM; and between mothers 
randomised to receive IPTp-DP and those to IPTp-SP. The association between P. falciparum IgG 
antibody levels in cord blood and the incidence of malaria during infancy was assessed using 
negative binomial regression.  
Results 
From December 9, 2016 to December 5, 2017, 600 maternal and cord blood samples were 
collected and analysed. There were no significant differences in cord blood antibody levels to 
AMA1, EBA140, EBA175, EBA 181, MSP1, Rh2, Rh4 and Rh5 among samples of infants born 
mothers with active PM, mild-moderate past PM and severe past PM compared to those from 
infants born to mothers with no PM. Cord to maternal antibody ratios were similar among 
mothers in different categories of PM. Compared to IPTp-SP, cord blood levels of most measured 
IgG P. falciparum antibodies were similar except for Rh4 which was significantly lower in cord 
blood of infants born to mothers who received IPTp-DP compared to those who received IPTp-
SP. Lower cord blood levels of specific P. falciparum IgG antibodies were not associated with a 





Placental malaria was not associated with lower levels of IgG antibodies to P. falciparum 
antigens in cord blood. Similarly, effective IPTp with DP did not affect levels of most IgG 
antibodies in cord blood as compared to IPTp-SP. This suggests that PM and IPTp do not affect 
maternal-foetal transfer of antimalarial antibodies and that other factors might explain the 







During pregnancy, maternal immunoglobulin G (IgG) antibodies are actively transferred across 
the placenta to the foetus [1]. The transferred IgG antibodies are thought to provide the 
newborn with protection against infectious diseases during early life [2-4]. In sub-Saharan Africa, 
where most areas are endemic for Plasmodium falciparum, most pregnant women are exposed 
to P. falciparum infection [5] which may lead to placental malaria (PM). Placental P. falciparum 
infection is characterised the presence of parasites in intervillous spaces, infiltration of 
inflammatory cells in intervillous spaces, and thickening of the basement membrane [6, 7]. 
These pathological changes have been associated with adverse birth outcomes, including 
preterm births, low birth weight, and stillbirths [8-10]. Placental malaria is also thought to affect 
the maternal-foetal transfer of IgG antibodies to common infectious disease-causing agents. 
Several studies have reported an association between PM and reduced maternal-foetal transfer 
of IgG antibodies to common infectious diseases, including measles [11], tetanus [12], and 
malaria [13], which may impact on infant immunity to infectious diseases early in life. Indeed, 
infants born to mothers with PM have been reported to have a higher risk of malaria in the first 
months of life than infants born to mothers without PM [14, 15], but it is not well known whether 
this increased risk can be explained by reduced levels of P. falciparum IgG antibodies in cord 
blood.  
Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-
pyrimethamine (SP) remains one of the main interventions recommended by the World Health 
Organization for preventing PM and improving birth outcomes [16]. However, widespread 
antifolate resistance of P. falciparum in East and Central Africa is threatening the effectiveness 
of IPTp-SP [17]. Studies evaluating alternative drugs for IPTp have shown dihydroartemisinin-
piperaquine (DP) to be a promising alternative. Compared to IPTp-SP, IPTp-DP was associated 
with reduced risk of clinical malaria during pregnancy, parasitaemia during pregnancy, and PM 
at delivery [18-20]. We recently reported that infants born to mothers who received IPTp-DP 
had a reduced risk of malaria during the first year of life compared to infants born to mothers 
who received IPTp-SP, but this association was only observed in male infants [21]. Whether this 
reduced risk of malaria in infants born to mothers who received IPTp-DP can be explained by a 
greater maternal-foetal transfer of antimalarial antibodies is not known. 
To evaluate the association between PM, IPTp and P. falciparum IgG antibody levels in cord 
blood we compared cord blood P. falciparum antibody levels, and the ratio of cord and maternal 




without PM, and among infants born to mothers who received IPTp-DP to those born to mothers 
who received IPTp-SP.  
Methods 
Study design and collection of samples 
This study was part of a double-blind, randomised, controlled trial of monthly IPTp with DP 
versus SP in HIV-uninfected pregnant women and their infants conducted in Busia District, 
Uganda, between September 2016- December 2018. Details of the study have been previously 
described [19, 21, 22]. In brief, HIV-uninfected pregnant women were enrolled at 12-20 weeks 
of gestation and randomised to receive monthly DP vs SP. Women were reviewed monthly for 
routine assessment and administration of study drugs. Pregnant women were followed up 
through delivery. At delivery, maternal blood, cord blood, placental blood, and placental tissue 
were collected. Maternal and cord blood samples were collected in EDTA tubes, centrifuged, 
and the plasma was stored at -80°C. Infants born alive were followed-up to 12 months of age in 
a dedicated study clinic for all their medical and were reviewed monthly for routine assessment. 
Infants who presented to the study clinic with a history of fever in the past 24 hours or with a 
documented tympanic temperature of > 38.0˚C had an urgent thick blood smear done for 
detection of malaria parasites. Infants with a fever and a positive thick blood smear were 
diagnosed with malaria and treated according to the Uganda Ministry of Health guidelines. 
Diagnosis of placental malaria 
Placental malaria was diagnosed from placental blood by microscopy and loop-mediated 
isothermal amplification (detection of parasites), and from placental tissue by histology 
(detection of parasites or malaria pigment) as described previously [23, 24]. Severity of malaria 
was quantified by the proportion of high-power fields (HPF) with malaria pigment deposition in 
placental fibrin. 
Measurement of IgG antibodies in maternal and cord blood 
Levels of antibodies to specific P. falciparum antigens were measured on stored maternal and 
cord plasma samples collected at delivery using a multiplex antibody bead assay. Luminex bead 
conjugation was performed as previously described [25]. Thawed plasma (50 μl), in duplicate 
(1/200 dilution), was co-incubated with microsphere mixtures on a 96-well plate for one hour, 
washed, stained, and incubated with a secondary antibody, then washed and read by the 
MAGPIX system. Antibody levels were expressed in arbitrary units (AUs), calculated by dividing 




(SD) of samples from Europeans never exposed to malaria. Positive control samples from 
individuals with known antibodies to these antigens were pooled, and standard curves were 
generated through serial dilutions of the positive control pool. The antibodies measured 
included those to specific P. falciparum antigens that are expressed at the erythrocytic stage of 
the parasite life cycle, that have been shown to be protective against malaria or are promising 
vaccine candidates. These included apical membrane antigen-1 (AMA1) [26], erythrocyte 
binding antigen-140 (EBA140), EBA175, EBA181 [27], glutamate rich protein (GLURP) [26], 
merozoite surface protein-1 (MSP1) [28], reticulocyte binding protein homologue-2 (Rh2), Rh4, 
and Rh5 [29-32].  
Statistical analyses 
Data were double entered and verified into an Access database and analyses were conducted 
using Stata version 14.2. PM was categorised into four categories 1) no PM (no evidence of 
parasites or pigment), 2) active PM (evidence of parasites with or without pigment), 3) mild-
moderate past PM (no parasites detected but with <=20% of high-power fields with pigment 
deposition in fibrin), and 4) severe past PM (>20% of HPF with pigment deposition in fibrin with 
no parasites detected). 
The means of log transformed P. falciparum antibody levels in maternal and cord blood were 
compared among infants born to mothers randomised to receive IPTp-DP versus SP and among 
infants born to mothers with active PM, mild-moderate past PM, severe past PM versus no PM 
using linear regression and adjusted for maternal parasitaemia at enrolment, gravidity, maternal 
IPTp, and household type (modern house built with cement with nets in vents versus traditional 
house built with mud and wattle with open eaves).  
The association between cord blood P. falciparum IgG antibody levels and the incidence of 
malaria during the first year of life was assess using negative binomial regression. First the level 
of each specific IgG antibody in cord was fitted in the model as a continuous exposure variable 
to assess for a possible linear relationship. Because there was no linear relationship observed 
for any specific IgG antibody with the incidence of malaria during infancy, antibody levels were 
stratified into three subpopulations using percentiles; 1) ≤25th percentile, 2) >25-50th percentile 
and 3) >50th percentile. To increase statistical power, the >50-75% and the >75% categories were 
combined because the association between level of antibodies and the incidence of malaria had 
similar effect sizes comparing the >50-75% category with the ≤25% category, and the >75% 
category with the ≤25% category. The incidence of malaria during the first year of life among 
infants with specific P. falciparum IgG antibody levels in cord blood >25-50th percentile and >50th 




≤25th percentile adjusting for maternal IPTp arm, maternal parasitaemia at baseline, gravidity, 
and household type.  
To reduce the probability of type I error due to multiple hypothesis tests conducted, the level of 
significance was reduced by dividing the p-value of 0.05 by the number of hypothesis tests 
conducted, to p<0.002 (0.05/27) for the associations between IgG levels and PM categories, 
p<0.006 (0.05/9) for the associations between IgG levels and IPTp, and p <0.003 (0.05/18) for 




Of the 782 HIV-uninfected pregnant women enrolled, 687 were followed through delivery 
resulting in 678 live births, 339 born to mothers on monthly IPTp-DP and 339 born to mothers 
receiving IPTp-DP [21] (Figure 6.1). A total of 600 infants (297 born to mothers receiving monthly 
IPTp-SP, and 303 born to mothers receiving monthly IPTp-DP) had cord blood collected at 
delivery of which 584 were followed up to one year. Maternal characteristics at enrolment were 
similar between the two treatment arms (Table 6.1). At enrolment, 287 (48%) mothers were 
primigravidae or secundigravidae, 461 (77%) were residing in traditional houses, and 82% of 
mothers had parasitaemia detected by microscopy or qPCR at enrolment.  
Association between placental malaria and P. falciparum IgG antibodies in maternal and cord 
blood at delivery 
Overall, 600 cord blood samples were collected and analysed for levels of P. falciparum IgG 
antibodies. P. falciparum IgG antibodies were measurable in all cord blood samples. There were 
strong positive correlations between levels of specific P. falciparum IgG antibodies in maternal 
blood and levels of the same antibodies in cord blood (Table 6.2, Figure 6.2).  
In the analysis adjusted for maternal IPTp, gravidity, maternal parasitaemia at enrolment and 
household type, mothers with active PM (mean log MFI 10.04, SD 0.89, p=0.03), mild-moderate 
past PM (mean log MFI 10.03, SD 0.08, p=0.02) and severe past PM (mean log MFI 10.19, SD 
0.43, p=0.01) had higher levels of AMA1 antibodies compared to mothers with no PM (Table 
6.3), but the difference was not statistically significant at the level of p<0.002. Similarly, 
compared to no PM (mean log MFI 7.98, SD 1.37), active PM (mean log MFI 8.48, SD 1.35, 
p=0.03) and severe past PM (mean log MFI 8.63, SD 1.35, p=0.02) were associated with higher 




levels of GLURP antibodies were lower in mothers with severe past PM (mean log MFI 8.16, SD 
1.74) compared to those with no PM (mean log MFI 9.45, SD 1.56, p=0.03). There were no 
significant differences in maternal IgG antibody blood levels of EBA140, EBA175, EBA181, MSP1, 
Rh4, and Rh5 antibodies.  
Infants born to mothers with severe past PM had lower levels of antibodies to GLURP (mean log 
MFI 8.58, SD 1.85) than those born to mothers with no PM (mean log MFI 9.52, SD 1.24, p=0.006; 
Table 6.3). There were no significant differences in cord blood levels of AMA1, EBA140, EBA175, 
EBA181, MSP1, Rh4, and Rh5 antibodies among infants born to mothers with active PM, mild-
moderate past PM, and severe past PM compared to those born to mothers without PM (Table 
6.3). Cord to maternal blood ratios of all antibodies tested were similar among mothers with 
active PM, mild-moderate past PM, and severe past PM compared to mothers with no PM (Table 
6.3) and this relationship did not differ between male and female infants. 
Association between IPTp and P. falciparum IgG levels in maternal and cord blood at delivery 
We next considered the impact of different IPTp regimens on maternal IgG antibody levels. 
Maternal antimalarial antibody levels of Rh2, Rh4, and Rh5 were lower among mothers who 
received IPTp-DP compared to those who received IPTp-SP, but the difference was not 
statistically significant (Table 6.4). There were no significant differences in maternal antibody 
levels to AMA1, EBA140, EBA175, EBA181, GLURP, and MSP1 among mothers receiving monthly 
IPTp-DP compared to those receiving monthly IPTp-SP (Table 6.4, Figure 6.3), although the 
maternal IgG antibody levels for most antimalarial antibodies were slightly lower for mothers 
who received IPTp-DP compared to those who received IPTp-SP.  
There were no significant differences in cord blood levels of AMA1, EBA140, EBA175, EBA181, 
GLURP, MSP1, Rh2, and Rh5 among infants born to mothers who received IPTp-DP compared to 
those born to mothers who received IPTp-SP (Table 6.4). Cord blood levels of Rh4 antibodies 
were significantly lower in infants born to mothers who received IPTp-DP (mean log MFI 6.43, 
SD 1.49; Table 6.4) compared to mothers who received IPTp-SP (mean log MFI 6.81, SD 1.53, 
p=0.002, Figure 6.4). The cord-maternal ratios of all the measured P. falciparum IgG antibodies 
were similar among mothers who received IPTp-DP compared to those who received IPTp-SP. 
There was no effect modification by infant sex, observed in the association between IPTp and 
cord blood antimalarial IgG antibody levels. 
Association between cord blood antibody levels and malaria risk during the first year of life. 
We next assessed for the association between specific P. falciparum IgG antibody levels in cord 




association between IgG antibody levels and the incidence of malaria during the first 12 months 
of life at the level of p<0.003. Compared to IgG antibody levels within the 25th percentile, levels 
of antibodies above the 50th percentile to AMA1, EBA175, and Rh5 were associated with a higher 
incidence of malaria during infancy, after adjustment for maternal parasitaemia at enrolment, 
maternal gravidity, IPTp arm, and household type (AMA1 (Incidence rate ratio [IRR] 1.25, 95% 
confidence interval [CI] 1.03-1.59, p=0.02; Table 6.5), EBA175 (IRR 1.27, 95% CI 1.03-1.57, 
p=0.03), and Rh5 (IRR 1.30, 95% CI 1.06-1.60, p=0.01)) but the difference was not statistically 
significant (significance level p<0.003). No effect modification by infant sex was observed in the 
association between antimalarial antibody levels in cord blood and the incidence of malaria in 
infants. There were no significant differences in the rates of first malaria episode among infants 
with cord blood antimalarial antibody levels >25th -50th percentile or >50th percentile and infants 
with cord blood antimalarial antibody levels ≤ 25th percentile (Table 6.5) 
 
Discussion 
Maternally transferred antimalarial IgG antibodies may be important in providing protection 
against malaria in the infant during early life [33]. We evaluated for associations between PM, 
IPTp and levels of P. falciparum IgG antibodies in maternal and cord blood by comparing levels 
of P. falciparum IgG antibodies and foetal to maternal cord blood ratios among infants born to 
mothers with active PM, mild-moderate past PM, and severe past PM compared to those born 
to mothers with no PM; and among infants born to mothers who received monthly IPTp-DP vs 
those born to mothers who received IPTp-SP. Overall, there was no evidence of a difference in 
cord blood levels of most measured P. falciparum IgG antibodies in infants born to mothers with 
active PM, past PM (mild-moderate past PM and severe past PM) compared to infants born to 
mothers with no PM. Cord to maternal antibody ratios were similar among mothers with active 
PM, mild-moderate past PM, and severe past PM compared to those with no PM. There was no 
evidence of a difference in cord blood P. falciparum antibody levels (AMA1, EBA140, EBA175, 
EBA181, GLURP, MSP1, Rh2, Rh4, and Rh5) between infants born to mothers who received IPTp-
DP compared to those born to mothers who received IPTp-SP. These data suggest that other 
factors might explain the increased risk of malaria in infancy among infants born to mothers with 
placental malaria. 
In this study, there were no differences in cord blood levels of P. falciparum IgG antibodies 
measured and cord to maternal blood antibody ratios were similar, between infants born to 
mothers with active PM, mild-moderate PM, or severe past PM and those born to mothers 




antimalarial antibodies. Contrary to our study findings, some studies have previously 
demonstrated that PM was associated with a reduced maternal-foetal transfer of P. falciparum 
IgG antibodies [13, 34]. In a study conducted in Benin, PM was associated with reduced maternal 
to foetal transfer of IgG antimalarial antibodies to AMA1, MSP, and GLURP antigens [13]. 
However, similar to our study, the cord blood antimalarial antibody levels were not significantly 
different between infants born to mothers with PM and those born to mothers with no PM. In 
Mozambique, maternal parasitaemia (parasites detected in maternal peripheral blood or by PCR 
or microscopy, or parasites detected in placental tissue by histology or PCR) was associated with 
a reduced maternal-foetal transfer of IgG1 antimalarial antibodies to AMA1 and parasite lysate 
but not total IgG to these specific antigens [34] suggesting that maternal malaria may affect the 
transfer of some specific antimalarial IgG antibody subtypes and not others.  
Transfer of maternal IgG antibodies to the foetus is an active process which is mediated through 
foetal Fc receptors located in the syncytiotrophoblast [1] and PM is thought to reduce this 
transfer by altering placental integrity [35]. We had hypothesised that highly effective IPTp with 
DP, which has been shown to substantially reduce the risk of PM [18-20], would be associated 
with higher levels of antimalarial IgG antibodies in cord blood compared to IPTp-SP, by 
improving maternal-foetal transfer of antibodies. However, contrary to this hypothesis, in this 
study, IPTp-DP was not associated with higher antimalarial antibody levels in cord blood 
compared to IPTp-SP, similar to what was reported previously in a study conducted in Uganda 
[36]. Furthermore, there were no differences in cord to maternal blood antibody ratios among 
infants born to mothers who received IPTp-DP compared to those born to mothers who received 
IPTp-SP, indicating that IPTp-DP did not improve maternal-foetal transfer of antibodies. Our 
results suggest that in an area of high malaria transmission intensity, effective IPTp may not alter 
maternal-foetal transfer of antimalarial antibodies. 
In Ghana, IPTp was found to be associated with reduced maternal IgG antibodies to P. falciparum 
antigens, specifically GLURP [37], suggesting that IPTp with highly effective drugs may reduce 
maternal IgG antibody levels to P. falciparum antigens. However, in our study, despite IPTp-DP 
being associated with significant reduction in the risk of clinical malaria and asymptomatic 
parasitaemia during pregnancy compared to IPTp-SP [19], levels of most of the measured P. 
falciparum specific antibodies at delivery, including GLURP, were similar among mothers who 
received IPTp-DP compared to those who received IPTp-SP. Only maternal IgG antibody levels 
to Rh2, Rh4, and Rh5 tended to be lower in mothers who received IPTp-DP possibly indicating 
reduced exposure to merozoites due to the prophylactic effect of the DP. The difference in the 
findings of our study and the Ghanaian study could be related to differences in the level of 




transmission setting, supported by a very high baseline malaria parasitaemia [19], while the 
study in Ghana was conducted in a moderate malaria transmission setting [38]. Our findings 
suggest that in a setting of high malaria transmission intensity, highly effective IPTp with DP may 
not reduce maternal IgG antimalarial antibodies compared to IPTp-SP.  
Maternal IgG antibodies to P. falciparum transferred to the feotus are thought to provide 
protection against malaria to the infant during the first few months of life [4, 33, 39]. However, 
in this study, there was no evidence of an association between levels of P. falciparum specific 
IgG antibodies and the incidence of malaria in infants during the first three months of life or 
during the first 12 months of life similar to what was previously reported in Ghana [40]. In 
contrast, we observed that cord blood levels of antimalarial antibodies to AMA1, EBA175, and 
Rh5 greater than the 50th percentile were associated with a trend towards a higher incidence of 
malaria during the first year of life as compared to cord blood antibody levels within the 25th 
percentile, suggesting that levels of antimalarial IgG antibodies transferred may instead reflect 
the level of malaria transmission intensity [2].  
The lack of an association between PM, IPTp and maternal-foetal transfer of antimalarial 
antibodies suggests that altered maternal-foetal transfer of IgG antimalarial antibodies may not 
explain the observed association between PM, IPTp and the incidence of malaria in infant 
observed in chapter 4 and chapter 5 [21]. Other factors such as the influence of PM on cell-
mediated immunity [41, 42] and acquisition of antimalarial antibodies in the infant [43] 
following delivery may explain our observed results. 
This study had some limitations. First, a limited number of antimalarial IgG antibodies were 
measured in this study. Although our analysis may not reflect the full spectrum of malaria 
antigens, the panel we examined much broader than what was evaluated in prior studies [13, 
34]. Second, we did not differentiate between IgG subclasses. Although we found no differences 
in maternal-foetal transfer of antibodies among mothers with active or past PM compared to no 
PM, it is possible there could be differences in maternal-foetal transfer of different IgG sub-
classes. Indeed, PM has been previously reported to be associated with reduced maternal-foetal 
transfer of IgG1, IgG2, and IgG4 but not IgG3 antibodies to herpes simplex type 1 virus, 
respiratory syncytial virus, and varicella-zoster virus [44]. Third, in 12% of the infants, cord blood 
was not collected. This could have introduced bias if the infants who did not have cord blood 
samples collected were systematically different from the ones whose samples were collected. 
However, in this study, there were no differences in infants that had cord blood collected and 
those whose cord blood was not collected suggesting that bias due to missing data is unlikely. 
Fifth, multiple statistical tests were carried out in this study. It is possible that some of the 




caution. Finally, we did not test the functionality of the antibodies transferred from mother to 
the newborn. It is possible that other functional features of malaria-specific IgG were impacted 
by PM and/or IPTp and could be associated with protection from malaria in infancy.  
In conclusion, in this study conducted in an area of very high malaria transmission intensity, 
there was no evidence of an association between PM, IPTp and maternal-foetal transfer of 
antibodies to specific P. falciparum antigens. Furthermore, we did not find any evidence to 
suggest that lower levels of IgG antibodies to specific P. falciparum antigens are associated with 
a higher risk of malaria during infancy. Future studies should evaluate the impact of PM and IPTp 
on foetal antimalarial immunity, including cell-mediated immunity and acquisition of antibodies 
to P. falciparum antibodies and whether this modifies the risk of malaria during infancy in areas 
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Figure 6.1 Study profile 
SP=sulfadoxine-pyrimethamine, DP=dihydroartemisinin-piperaquine 
Figure 6. 2 Correlations between maternal and cord blood IgG antibody levels for selected P. 
falciparum antibodies 
AMA1= Apical membrane antigen-1, EBA175=Erythrocyte-binding antigen, MSP1= Merozoite 
surface protein-1, Rh5= reticulocyte-binding protein homologue-5 
Figure 6.3 Maternal P. falciparum IgG antibody levels measured at delivery stratified IPTp 
arm 
AMA1= Apical membrane antigen-1, AU=Arbitrary units, DP= dihydroartemisinin-piperaquine, 
EBA=Erythrocyte-binding antigen, GLURP=Glutamate-rich protein, IPTp= intermittent 
preventive treatment of malaria in pregnancy, MSP1= Merozoite surface protein-1, Rh= 
reticulocyte-binding protein homologue, SP= sulfadoxine-pyrimethamine 
**P<0.05 
Figure 6.4 Cord P. falciparum IgG antibody levels measured at delivery stratified IPTp arm 
AMA1= Apical membrane antigen-1, AU=Arbitrary units, DP= dihydroartemisinin-piperaquine, 
EBA=Erythrocyte-binding antigen, GLURP=Glutamate-rich protein, IPTp= intermittent 
preventive treatment of malaria in pregnancy, MSP1= Merozoite surface protein-1, Rh= 




Table 6.1 Characteristics of study participants 
Abbreviations: DP, dihydroartemisinin-piperaquine; PM, placental malaria; qPCR, quantitative 
polymerase chain reaction; SD, standard deviation; SP, sulfadoxine-pyrimethamine 
aDefined as number of routine positive blood smears divided by total number of routine blood 
smears 
No PM=no parasites or pigment detected; active PM=parasites detected with or without 
pigment 
Past PM (Mild-moderate) = >0-20% of high-power fields with pigment but no parasites; Past 







Maternal IPTp arm 
Monthly SP (N=297) Monthly DP 
(N=303) 
Maternal characteristics at enrolment 
Age in years, mean (SD) 23.9 (6.0) 23.9 (5.7) 
Gravidity, n (%)   
 Primigravida/secundigravida 139 (46.8%) 148 (48.8%) 
 Multigravida 158 (53·2%) 155 (51·2%) 
House-hold type, n (%)   
 Modern House 70 (23.6%) 69 (22.8%) 
 Traditional House 227 (76.4%) 234 (77.2%) 
Parasite prevalence by microscopy or qPCR, n (%)   
 No parasites 49 (16.5%) 58 (19.1%) 
 Sub-microscopic parasitemia 97 (32.7%) 81 (26.7%) 
 Microscopic parasitemia 151 (50.8%) 164 (54.1%) 
Maternal characteristics during pregnancy 
Parasite prevalence by microscopy, n/N (%)a  723/2019 (35.8%) 326/2078 (15.7%) 
Incidence of malaria (episodes per person-year) 0.61 0.09 
Placental malaria status 
Placental malaria status, n (%)   
 No PM 111 (37.6%) 213 (70.8%) 
Active PM 62 (21.0%) 5 (1.7%) 
Past PM (Mild-moderate pigment) 87 (29.5%) 77 (25.6%) 
Past PM (Severe pigment) 35 (11.9%) 6 (2.0%) 
Characteristics of infants at birth 
Preterm birth, n (%) 17 (5.7%) 14 (4.6%) 
Low birth weight, n (%) 25 (8.4%) 23 (7.6%) 




Table 6.2 Correlation between maternal and cord blood IgG antibody levels 
Antibody 
Mean IgG antibody levels (SD) 
Correlation coefficient 
Maternal blood Cord blood 
AMA1 9.92 (0.77) 10.13 (0.73) 0.62 
EBA140 7.25 (1.72) 7.33 (1.78) 0.90 
EBA175 8.44 (1.36) 8.54 (1.40) 0.83 
EBA181 7.29 (1.28) 7.38 (1.44) 0.80 
GLURP 9.30 (1.30) 9.35 (1.37) 0.85 
MSP1 8.92 (1.24) 9.17 (1.32) 0.73 
Rh2 8.16 (1.38) 8.65 (1.31) 0.83 
Rh4 6.58 (1.32) 6.62 (1.52) 0.81 
Rh5 6.35 (1.02) 6.43 (1.22) 0.66 
AMA1= Apical membrane antigen-1, EBA=Erythrocyte-binding antigen, GLURP=Glutamate rich 











Placental malaria status  
No PMa 
Mean (SD), N=323 
Active PM 
Mean (SD), N=67 
p-value 
Mild-mod past PM 
Mean (SD), N=164 
p-value 
Severe past PM 




Maternal 9.79 (0.80) 10.04 (0.89) 0.03 10.03 (0.08) 0.02 10.19 (0.43) 0.01 
Cord 10.02 (0.83) 10.20 (0.86) 0.15 10.26 (0.43) 0.07 10.32 (0.31) 0.12 
Cord/Maternal 1.03 (0.08) 1.03 (1.00) 0.80 1.03 (0.09) 0.19 1.01 (0.02) 0.42 
EBA140 
Maternal 7.26 (1.74) 7.47 (1.70) 0.35 7.17 (1.71) 0.99 7.14 (1.69) 0.99 
Cord 7.35 (1.84) 7.45 (1.81) 0.78 7.25 (1.70) 0.75 7.22 (1.64) 0.68 
Cord/Maternal 1.02 (0.11) 1.01 (0.22) 0.57 1.02 (0.14) 0.58 1.02 (0.11) 0.56 
EBA175 
Maternal 8.41 (1.39) 8.50 (1.49) 0.29 8.50 (1.24) 0.15 8.25 (1.33) 0.79 
Cord 8.51 (1.50) 8.48 (1.51) 0.78 8.67 (1.17) 0.17 8.30 (1.34) 0.77 
Cord/Maternal 1.02 (0.12) 1.02 (0.24) 0.76 1.03 (0.12) 0.87 1.01 (0.08) 0.34 
EBA181 
Maternal 7.36 (1.33)  7.36 (1.14) 0.74 7.15 (1.24) 0.21 7.18 (1.31) 0.49 
Cord 7.46 (1.50) 7.33 (1.36) 0.35 7.30 (1.40) 0.29 7.23 (1.30) 0.37 
Cord/Maternal 1.02 (0.13) 1.01 (0.23) 0.70 1.02 (0.12) 0.93 1.02 (0.13) 0.82 
GLURP 
Maternal 9.45 (1.56) 9.14 (1.38) 0.37 9.21 (1.32) 0.88 8.61 (1.74) 0.03 
Cord 9.52 (1.24) 9.11 (1.51) 0.13 9.27 (1.37) 0.49 8.58 (1.85) 0.006 
Cord/Maternal 1.01 (0.08) 1.01 (0.21) 0.61 1.01 (0.15) 0.41 1.00 (0.10) 0.21 
MSP1 
Maternal 8.97 (1.15) 8.82 (1.46) 0.60 8.94 (1.14) 0.34 8.53 (1.79) 0.29 
Cord 9.20 (1.32) 9.16 (1.41) 0.78 9.21 (1.17) 0.46 8.77 (1.72) 0.17 
Cord/Maternal 1.03 (0.12) 1.07 (0.33) 0.15 1.04 (0.10) 0.79 1.04 (0.12) 0.92 
Rh2 
Maternal 7.98 (1.37) 8.48 (1.35) 0.03 8.28 (1.37) 0.12 8.63 (1.35) 0.02 
Cord 8.48 (1.36) 8.91 (1.21) 0.08 8.74 (1.27) 0.43 9.06 (1.18) 0.09 
Cord/Maternal 1.08 (0.16) 1.07 (0.19) 0.41 1.06 (0.11) 0.09 1.06 (0.12) 0.19 
Rh4 
Maternal 6.64 (1.38) 6.60 (1.27) 0.61 6.56 (1.26) 0.98 6.30 (1.32) 0.25 
Cord 6.64 (1.60) 6.60 (1.34) 0.47 6.69 (1.47) 0.52 6.23 (1.36) 0.15 
Cord/Maternal 1.00 (0.15) 1.02 (0.23) 0.90 1.02 (0.14) 0.59 1.00 (0.14) 0.56 
Rh5 
Maternal 6.33 (1.04) 6.48 (0.99) 0.72 6.36 (0.95) 0.73 6.18 (1.13) 0.31 
Cord 6.36 (1.24) 6.55 (1.22) 0.55 6.53 (1.16) 0.35 6.32 (1.32) 0.65 
Cord/Maternal 1.01 (0.16) 1.02 (0.16) 0.78 1.03 (0.14) 0.61 1.03 (0.17) 0.64 
aThe No PM group is the reference group for all p-values calculated. All p-values adjusted for maternal IPTp arm, gravidity, maternal parasite status at enrolment, and house type. 




Table 6.4 Comparison of cord blood IgG antibody levels in infants born to mothers on 
different maternal IPTp arm 
IgG antibody 










Maternal 9.94 (0.79) 9.89 (0.76) 0.41 
Cord 10.12 (0.83) 10.13 (0.61) 0.85 
Cord/maternal 1.02 (0.13) 1.02 (0.07) 0.67 
EBA140 
Maternal 7.34 (1.77) 7.16 (1.66) 0.21 
Cord 7.43 (1.85) 7.23 (1.70) 0.16 
Cord/maternal 1.02 (0.15) 1.01 (0.12) 0.54 
EBA175 
Maternal 8.48 (1.36) 8.39 (1.35) 0.41 
Cord 8.57 (1.45) 8.52 (1.35) 0.66 
Cord/maternal 1.02 (0.16) 1.02 (0.11) 0.87 
EBA181 
Maternal 7.38 (1.27) 7.20 (1.28) 0.08 
Cord 7.45 (1.46) 7.32 (1.42) 0.26 
Cord/Maternal 1.02 (0.16) 1.02 (0.12) 0.71 
GLURP 
Maternal 9.31 (1.33) 9.28 (1.25) 0.71 
Cord 9.34 (1.46) 9.35 (1.28) 0.98 
Cord/Maternal 1.01 (0.16) 1.01 (0.07) 0.95 
MSP1 
Maternal 8.96 (1.29) 8.88 (1.19) 0.43 
Cord 9.25 (1.39) 9.09 (1.25) 0.16 
Cord/Maternal 1.04 (0.20) 1.03 (0.10) 0.26 
Rh2 
Maternal 8.29 (1.37) 8.03 (1.38) 0.02 
Cord 8.75 (1.33) 8.54 (1.29) 0.06 
Cord/maternal 1.07 (0.16) 1.07 (0.13) 0.53 
Rh4 
Maternal 6.71 (1.32) 6.46 (1.32) 0.02 
Cord 6.81 (1.53) 6.43 (1.49) 0.002 
Cord/maternal 1.02 (0.17) 1.01 (0.15) 0.15 
Rh5 
Maternal 6.45 (1.05) 6.25 (0.97) 0.01 
Cord 6.52 (1.27) 6.34 (1.17) 0.07 
Cord/maternal 1.02 (0.16) 1.02 (0.15) 0.78 
aThe IPTp-SP group is the reference group for all p-values calculated 
AMA1= Apical membrane antigen-1, DP= dihydroartemisinin-piperaquine, EBA=Erythrocyte-
binding antigen, GLURP=Glutamate-rich protein, MSP1= Merozoite surface protein, Rh= 









Table 6.5 Association between cord blood IgG antibody levels and infant malaria during the first 12 months of life  
IgG antibody Categories of antibody in 
percentiles 
Incidence rate ratio (95% 
CI)* 
p-value 
Time to first malaria 
episode, HR (95% CI)* 
p-value 
AMA1 
≤25th percentile reference group  reference group  
>25-50th percentile 1.25 (0.98-1.59) 0.07 1.18 (0.88-1.59) 0.25 
>50th percentile 1.28 (1.03-1.59) 0.02 1.21 (0.94-1.57) 0.14 
EBA140 
≤25th percentile reference group  reference group  
>25-50th percentile 0.97 (0.77-1.24) 0.83 1.00 (0.75-1.34) 0.99 
>50th percentile 1.17 (0.95-1.45) 0.14 1.05 (0.82-1.35) 0.69 
EBA175 
≤25th percentile reference group  reference group  
>25-50th percentile 1.07 (0.83-1.37) 0.61 1.02 (0.76-1.36) 0.91 
>50th percentile 1.27 (1.03-1.57) 0.03 1.12 (0.87-1.44) 0.87 
EBA181 
≤25th percentile reference group  reference group  
>25-50th percentile 0.91 (0.72-1.16) 0.46 0.98 (0.73-1.31) 0.89 
>50th percentile 0.99 (0.80-1.22) 0.90 1.02 (0.79-1.32) 0.86 
GLURP 
≤25th percentile reference group  reference group  
>25-50th percentile 1.11 (0.86-1.42) 0.42 1.07 (0.79-1.44) 0.65 
>50th percentile 1.16 (0.94-1.44) 0.17 1.18 (0.91-1.54) 0.22 
MSP1 
≤25th percentile reference group  reference group  
>25-50th percentile 0.95 (0.75-1.21) 0.16 0.97 (0.73-1.30) 0.85 
>50th percentile 1.04 (0.85-1.29) 0.26 1.02 (0.79-1.31) 0.87 
Rh2 
≤25th percentile reference group  reference group  
>25-50th percentile 1.16 (0.92-1.47) 0.20 1.12 (0.84-1.50 0.43 
>50th percentile 1.03 (0.82-1.29) 0.79 1.02 (0.79-1.32) 0.87 
Rh4 
≤25th percentile reference group  reference group  
>25-50th percentile 0.94 (0.74-1.19) 0.62 0.89 (0.66-1.19) 0.42 
>50th percentile 0.94 (0.76-1.15) 0.55 0.93 (0.72-1.19) 0.56 
Rh5 
≤25th percentile Reference group  reference group  
>25-50th percentile 1.00 (0.78-1.29) 0.95 0.93 (0.69-1.25) 0.61 
>50th percentile 1.30 (1.06-1.60) 0.01 1.17 (0.91-1.51) 0.22 
*Adjusted for maternal IPTp arm, maternal parasitaemia at enrolment, gravidity, and household type 














Figure 6.2 Correlations between maternal and cord blood IgG antibody levels for selected P. 
falciparum antibodies 
AMA1= Apical membrane antigen-1, EBA175=Erythrocyte-binding antigen, MSP1= Merozoite 
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Figure 6.3 Maternal P. falciparum IgG antibody levels measured at delivery stratified IPTp 
arm 
AMA1= Apical membrane antigen-1, AU= Arbitrary units, DP= dihydroartemisinin-piperaquine, 
EBA=Erythrocyte-binding antigen, GLURP=Glutamate-rich protein, IPTp= intermittent 
preventive treatment of malaria in pregnancy, MSP1= Merozoite surface protein-1, Rh= 
reticulocyte-binding protein homologue, SP= sulfadoxine-pyrimethamine 












































Figure 6.4 Cord blood P. falciparum IgG antibody levels measured at delivery stratified IPTp 
arm 
AMA1= Apical membrane antigen-1, AU= Arbitrary units, DP= dihydroartemisinin-piperaquine, 
EBA=Erythrocyte binding antigen, GLURP=Glutamate-rich protein, IPTp= Intermittent 
preventive treatment of malaria in pregnancy, MSP1= Merozoite surface protein, Rh= 










































CHAPTER 7 DISCUSSION 
7.1 Chapter introduction 
This chapter summarises the main findings from this thesis, discusses their implications, 
highlights the study strengths and limitations, and provides an overall conclusion with 
recommendations for future research. This chapter has 8 sections. The first section summarises 
the study findings for each thesis objective; section 2 discusses the association between PM and 
the incidence of malaria infants; section 3 discusses association between IPTp or PM and 
secondary outcomes including infant mortality, non-malaria febrile illnesses, and anaemia; 
section 4 discusses the results of the impact of delivering IPTp DP vs SP to pregnant women on 
the incidence of malaria in their infants during the first 12 months of life; section 5 discusses the 
impact of IPTp and PM on P. falciparum IgG levels in umbilical cord blood; section 6 presents the 
thesis strength; section 7 addresses the limitations of the thesis; and section 8 provides the 
overall conclusion with recommendations for future research. 
7.2 Summary of study findings 
The systematic literature presented in chapter 2 highlighted that evidence on the association 
between MiP, or IPTp, and the risk of malaria in infants is lacking [1]. The majority of the studies 
included in the systematic literature review were observational studies, which suggested that 
MiP was associated with an increased risk of malaria during infancy. However, these studies 
were limited by potential confounding by malaria exposure which is shared by both the mother 
and the infant [2]. The best way to address this limitation would be to compare the risk of 
malaria in infants born to mothers randomised to different IPTp regimens where one of the 
regimens is more efficacious than the alternative regimen, however, few randomised controlled 
trials were included in the systematic literature review and these were limited by the failure to 
show a considerable difference in the risk of MiP between IPTp-regimens [3-6]. To address these 
limitations, this thesis used data collected from a birth cohort of infants born to HIV-uninfected 
pregnant women living in an area of high malaria transmission intensity, who participated in a 
double-blind randomised controlled trial of monthly IPTp with DP versus SP, to evaluate the 
impact of MiP on the risk of malaria in infancy. In this RCT, compared to IPTp-SP, IPTp-DP was 
associated with a 96% lower risk of malaria and 98% lower risk parasitaemia during pregnancy, 
and a 97%, 90%, and 54% lower risk of PM detected at delivery by microscopy, LAMP, or 
histology respectively [7]. The thesis had 3 main aims: 1) To compare the incidence of malaria 
during the first year of life among infants born to mothers with PM and those born mothers 




born to mothers randomised to IPTp with monthly DP and those born to mothers randomised 
to IPTp with monthly SP; and 3) To compare P. falciparum IgG antibody levels in cord blood of 
infants born to mothers who received monthly IPTp-DP vs those born to mothers who received 
monthly IPTp-SP. 
The results of this thesis can be summarised in three key findings (Table 7.1): 1) Active PM and 
severe past PM were associated with an increased risk of malaria during infancy. However, 
active PM was only marginally associated with an increased risk of malaria in all infants, while 
severe past PM was associated with an increased risk of malaria, but only in male infants; 2) 
IPTp-DP was associated with a lower risk of malaria during infancy compared to IPTp-SP, but 
only in male infants; 3) There was no evidence of an association between PM or IPTp and infant 
mortality, non-malaria febrile illnesses or anaemia; 4) PM and IPTp were not associated with 
altered levels of P. falciparum IgG antibodies in cord blood. These key findings are discussed in 





Table 7.1 Summary of thesis objectives and main findings 
Thesis objective Key findings 
Objective 1: To compare the incidence of 
malaria in infants during the first year of 
life among infants born to mothers with 
PM detected by microscopy, LAMP, or 
histology and those born to mothers 
without PM. 
• Compared to infants born to mothers with no PM, infants born to mothers with active PM (parasites detected by microscopy, 
LAMP or histology) had a higher incidence of malaria during the first year of life, but the difference was of marginal significance 
• In the analysis stratified by infant sex, severe past PM (>20% HPF with malaria pigment deposition) was associated with a higher 
incidence of malaria, higher rate of first malaria episode, a higher incidence of complicated malaria and a higher prevalence of 
asymptomatic parasitaemia compared to no PM, but only in male infants 
• There was no evidence of an association between PM and incidence of all-cause hospitalisations, incidence of non-malaria 
febrile illnesses, and prevalence of anaemia 
• 89.7% of the effect of IPTp-DP vs SP on the incidence of malaria among male infants was mediated through prevention of PM 
Objective 2: To compare the incidence of 
malaria during the first year of life in 
infants born to mothers who were 
randomised to receive monthly IPTp-DP 
versus monthly IPTp-SP. 
• Overall IPTp-DP was associated with a 13% lower incidence of malaria in infants during the first year of life compared to IPTp-SP, 
but this difference was not statistically significant 
• IPTp DP was associated with a lower incidence of malaria and complicated malaria among male, but not female, infants 
• IPTp-DP was associated with a lower risk of hospitalisations, but only in male infants 
• IPTp-DP was not associated with the incidence of non-malaria febrile illnesses or prevalence of anaemia (Hb<10g/dL) 
Objective 3: To compare P. falciparum 
antibody levels in cord blood of infants 
born to mothers who received monthly 
IPTp-DP vs those born to mothers who 
received monthly IPTp-SP. 
• There was no association between PM and cord blood antibody levels or maternal-foetal transfer of P. falciparum IgG antibodies 
• There was no significant difference in cord blood levels of P. falciparum IgG antibodies among infants born to mothers who 
received IPTp-DP compared to those born to mothers who received IPTp-SP. IPTp-DP did not improve maternal-foetal transfer of 




7.3 Key finding 1: Placental malaria was associated with a higher 
incidence of malaria during infancy in male infants 
We conducted a secondary analysis to assess for the association between PM and the incidence 
of malaria during infancy using data collected from a birth cohort of infants born to HIV-
uninfected mothers who participated in the main trial, a double-blinded randomised controlled 
trial of monthly IPTp with DP versus SP. The incidence of malaria during the first 12 months of 
life was compared between infants born to mothers with active PM, mild to moderate past PM, 
or severe past PM, and infants born to mothers with no PM. In addition, mediation analysis was 
carried out to estimate what proportion of the observed association between IPTp-DP and the 
risk of malaria in infancy was mediated through the prevention of PM.  
The results of the secondary analysis suggest that overall, active PM was associated with a higher 
incidence of malaria during infancy compared to no PM, although the difference was of 
borderline statistical significance, possibly due to the small sample size given that few infants 
were born to mothers who had active PM. An association between active PM and higher risk of 
malaria in infants has been previously reported in several studies in Uganda, Benin, Tanzania 
and Gabon [8-11]. However, most of these studies were observational studies and did not adjust 
for potential confounding by malaria exposure which is shared by the mother and her infant. 
Only one study, conducted in Benin, adjusted exposure to anopheles mosquitoes [9]. In this 
study PM detected by microscopy was associated with a higher risk of first parasitaemia during 
infancy, but only in infants who were resident in houses with insecticide-treated nets. In our 
study, we adjusted for malaria exposure using proxy measures of malaria exposure including 
maternal parasitaemia at enrolment, and household type (modern house with closed eaves vs 
traditional house built with mud and wattle with open eaves). Our study, together with previous 
studies suggest that active PM may be associated with a higher incidence of malaria in infancy, 
and that interventions that reduce the risk of active PM may be protective of malaria during 
infancy. 
Importantly, we observed an association between severe past PM and the risk of malaria during 
infancy in male, but not female, infants. This association was consistent for all malaria outcomes 
including incidence of malaria, rate of first malaria episode, incidence of complicated malaria, 
and parasite prevalence. To our knowledge, this is the first study to report an association 
between severe past PM and the risk of malaria in male infants. Infants born to mothers with 
past PM have been previously reported to have a higher risk of malaria during the first year of 




infant sex has been previously reported. In our study, unlike severe past PM, mild-moderate 
past PM was not associated with a higher risk of malaria in male infants, suggesting that the 
severity of the past placental infection rather than the mere absence or presence of PM, may 
be more important. Our study findings suggest that in a setting of high malaria transmission 
intensity, the consequences of PM on the infant later in life may differ by sex and appear to be 
worse in male infants. Highly effective drugs for IPTp, which reduce the severity of PM, may be 
protective, but only in male infants.  
The exact mechanisms through which PM may be acting to increase the risk of malaria during 
infancy are not well understood. However, reduced maternal-foetal transfer of antimalarial IgG 
antibodies and modulation of the foetal cell-mediated immune system following in-utero foetal 
exposure to malaria have been suggested as potential mechanisms. Previous studies have 
reported an association between PM and reduced maternal-foetal transfer of antimalarial IgG 
antibodies [13, 14]. However, there was no sex modification reported in this association. In-
utero exposure to malaria antigens has been shown to be associated immune tolerance which 
may affect infant immunity to infectious diseases including malaria [15-17]. Furthermore, male 
infants exposed to malaria including PM in-utero have been reported to have a higher 
proportion of regulatory T-cells in cord blood compared female infants with similar exposure 
[18] suggesting that in-utero malaria exposure may result in immune tolerance in male but not 
female infants. The findings of this thesis add to the growing literature of sex-disparities in risk 
of adverse birth outcomes and infectious diseases suggesting that male infants are at a higher 
risk [19-21].  
The observed association between severe past PM and the risk of malaria supports the 
hypothesis that IPTp with highly efficacious drugs, which may reduce the severity of PM, 
particularly in high malaria transmission settings where pregnant women are at risk of recurrent 
P. falciparum infections, may be protective against malaria during infancy in male infants. This 
is further supported by the results of the mediation analysis which suggested to that a large 
proportion (89.7%) of the protective effect of IPTp-DP, compared IPTp-SP, against malaria during 
infancy was mediated through prevention of PM among male infants, though this was not 
statistically significant.  
7.4 Key finding 2: IPTp-DP is associated with a lower risk of malaria, 
complicated malaria, and all-cause hospitalisations in male infants 
Recent studies have shown that DP is a highly effective and promising alternative to SP for IPTp. 




parasitaemia during pregnancy, and reduce the risk of PM at delivery; but no clear difference in 
the risk of adverse birth outcomes has been shown [7, 22, 23]. Several observational studies 
have reported an association between MiP and malaria in infancy suggesting that highly 
effective interventions, such as IPTp-DP which reduce the burden of MiP, including PM, may 
protect the infant against malaria in early life. This may have implications on the choice of 
alternative drugs to replace SP for IPTp. To confirm this observation, the incidence of malaria 
during infancy was compared among infants born to mothers randomised to monthly IPTp with 
DP vs SP. 
This is the first double-blind, randomised, controlled trial to compare the incidence of malaria 
in infants born to mothers randomised to monthly IPTp-DP compared to those born to mothers 
randomised to monthly IPTp-SP. The second hypothesis was that infants born to mothers 
randomised to monthly IPTp-DP would have a lower incidence of malaria during the first year of 
life compared to those born to mothers randomised to monthly IPTp-SP. The results of this 
analysis presented in chapter 5 suggest that monthly IPTp-DP is associated with a lower 
incidence of malaria during infancy, compared to monthly IPTp-SP [24]. However, this difference 
was not statistically significant, possibly due to a lower-than-expected incidence of malaria in 
infants born to mothers in the control arm (IPTp-SP). To my knowledge, this is the first study to 
show that IPTp with highly effective drugs may be associated with a lower incidence of malaria 
in infants compared to the standard of care. Previous studies that compared the incidence of 
malaria in infants born to mothers randomised to different IPTp regimens found no evidence of 
a difference in malaria in infants. There was no difference in the incidence of malaria in infants 
born to mothers randomised to IPTp with MQ compared to those born to mothers who received 
IPTp-SP in Benin, Gabon, Tanzania, and Mozambique [25], in infants born to mothers 
randomised to IPTp-SP compared to placebo in Mozambique [12], in infants born to mothers 
randomised to intermittent screening and treatment with AL compared to those born to 
mothers who received IPTp-SP in Ghana [26], or in infants born to mothers randomised to 
monthly community-scheduled screening and treatment of malaria during pregnancy plus IPTp-
SP (CSST/IPTP-SP) compared to IPTp-SP in Burkina Faso [27]. These studies were limited by the 
failure to show a substantial difference between the chemoprevention interventions on the risk 
of MiP [3-6]. 
Interestingly, the association between IPTp regimens and the incidence of malaria was modified 
by infant sex, such that the reduction in the incidence of malaria associated with IPTp-DP, as 
compared to IPTp-SP, was only observed in male infants. Consistent with this observation, the 
incidence of complicated malaria was also lower in male infants born to mothers who received 




previous study reported a lower incidence of malaria during the first two years of life, in male 
children receiving chemoprevention with DP born to mothers randomised to monthly IPTp-DP 
versus IPTp-SP given every two months [28]. However, this difference was not statistically 
significant, possibly due to a limited sample size. This difference in the effect of IPTp-DP on the 
incidence of malaria among male and female infants could be explained by the effect of severe 
past PM, which in chapter 4, was reported to be associated with a higher incidence of malaria 
and complicated malaria in male but not female infants. IPTp-DP may be acting by reducing the 
risk of severe past PM, which may have negative consequences in male but not female infants.  
Similarly, the association between IPTp and the incidence of all-cause hospitalisations was also 
modified by infant sex. The rate of all-cause hospitalisations was lower in male infants born to 
mothers received IPTp-DP than in male infants born to mothers who received IPTp-SP, but no 
difference was observed among female infants [24]. This could possibly be partly be explained 
by the observed lower incidence of complicated malaria among male infants born to mothers 
who received IPTp-DP compared to male infants born to mothers who received IPTp-SP. All 
together, these findings suggest that compared to IPTp-SP, IPTp-DP may be protective against 
malaria and hospitalisations in male infants. 
7.5 Key finding 3: No evidence of an association between IPTp or PM and 
infant mortality, non-malaria febrile illnesses, and anaemia  
Previous studies have reported increased mortality in infants born to mothers with PM [12, 29] 
and that prevention of malaria in pregnancy may improve infant survival [30]. However, in this 
study there was no strong evidence of improved survival in infants born to mothers receiving 
IPTp-DP compared to those born to mothers receiving IPTp-SP, although the infant mortality 
was lower (but not significantly so) among infants born to mothers on IPTp-DP. The reasons for 
the lack of association in this study could be due to a small number of deaths observed during 
follow-up possibly due to close follow-up and access to better health care, which resulted in 
type II error. 
No associations between IPTp-DP or PM and the risk of non-malaria febrile illnesses during 
infancy were observed in this study, suggesting that effective prevention of MiP may have no 
effect on the risk of non-malaria illnesses. In contrast to these findings, previous studies 
conducted in Burkina Faso [27] and Benin [31] reported an association between prevention of 
MiP and PM, and the risk of non-malaria febrile illnesses in infants. Prevention of MiP with 
community-based screening and testing, in addition to IPTp-SP was found to be protective 




compared to IPTp-SP alone [27]. However, no association was observed between MiP and the 
risk of non-malaria febrile illnesses in infants in that study, contrary to the reported association 
between PM and a higher risk of non-malaria febrile illnesses during infancy reported by Rachas 
et al in Benin [31].  
Moreover, there was no association between IPTp or PM and the risk of anaemia during infancy, 
in this study, which is in contrast to a previous study in Benin, which reported a higher risk of 
anaemia during infancy among infants born to mothers with PM than in those born to mothers 
without PM [32]. In agreement with our study findings, there was no association between IPTp 
or PM and the risk of anaemia in infants in a study conducted in Ghana [26]. Together, these 
data suggest that IPTp and PM may have a greater impact on malaria specific outcomes than 
non-malaria outcomes in infants. 
7.6 Key finding 4: Placental malaria and IPTp were not associated with 
levels of P. falciparum IgG antibodies and both did not affect maternal-
foetal transfer of IgG antibodies. 
In this study, in chapter 4, we observed that infants born to mothers with severe past PM had a 
higher risk of malaria during the first 12 months of life compared to infants born to mothers with 
no PM. This association was observed only in males. We also observed that male infants born to 
mothers who received monthly IPTp DP had a lower risk of malaria compared to those born to 
mothers who received monthly IPTp-SP [24]. Using maternal and cord blood samples collected 
at delivery from HIV-uninfected pregnant women who had taken part in a randomised 
controlled trial, we assessed whether PM and IPTp may affect P. falciparum IgG antibody levels 
in cord blood or maternal-foetal transfer of P. falciparum IgG antibodies.  
Previous studies reported that PM is associated with a reduced maternal-foetal of IgG antibodies 
to P. falciparum which may affect the newborn’s immunity to P. falciparum [13, 14]. Contrary to 
findings from previous studies, there was no evidence that PM is associated with reduced cord 
blood levels or maternal-foetal transfer of P. falciparum IgG antibodies to AMA1, EBA140, 
EBA175, EBA181, GLURP, MSP1, Rh2, Rh4, and Rh5. Our findings suggest that in a setting of high 
malaria transmission intensity, PM may not affect the transfer of these measured P. falciparum 
IgG antibodies from the mother to the foetus. The reason for the observed differences in the 
findings of this study and previous studies could be due to differences in study design, and 
malaria transmission intensity setting. In our study, women were randomised to receive monthly 
IPTp-SP vs DP, while the study conducted in Mozambique was a randomised trial of 2 dose IPTp 




malaria transmission intensity [13], our study was conducted in a very high transmission 
intensity where most of the adult residents in this area usually have high levels of circulating 
antibodies to P. falciparum antigens and therefore pregnant women will be more likely to 
transfer antibodies to the foetus.  
IPTp-DP has been previously shown to reduce the burden malaria during pregnancy including 
reducing the risk of PM during pregnancy compared to IPTp-SP [7, 22, 23] suggesting that IPTp-
DP may improve the maternal-foetal transfer of IgG antibodies to P. falciparum antigens. In this 
study, maternal-foetal transfer was similar among infants born to mothers who received IPTp-
DP compared to infants born to mothers who received IPTp-SP suggesting that effective IPTp 
may not improve maternal-foetal transfer of P. falciparum IgG antibodies. This is possibly 
because effective IPTp may reduce the level of maternal P. falciparum IgG antibodies [33] due 
to reduced exposure to blood-stage parasite forms which reduces the quantity of antibodies 
transferred such that the increase of maternal-foetal transfer of P. falciparum IgG due to the 
reduced risk of PM is cancelled out by a decrease in the level of the maternal antibodies available 
for transfer to the foetus. Nevertheless, in this study, levels of IgG antibodies in maternal blood 
at delivery were similar among mothers who received IPTp-DP compared to mothers who 
received IPTp-SP. 
It is widely believed that maternal antibodies transferred to the foetus protect the newborn 
against malaria during the first months of life [34]. However, in this study, like previous studies 
conducted in Ghana and Burkina Faso [35, 36], higher levels of IgG antibodies to P. falciparum 
antigens were not associated with protection against malaria during the first 12 months of life. 
Instead, higher levels of some P. falciparum IgG antibodies were associated with a trend towards 
a higher incidence of malaria during the first year of life suggesting that higher levels of P. 
falciparum IgG antibodies in cord blood may be an indicator of malaria exposure [36].  
Together, these results suggest that in an area of high malaria transmission intensity PM does 
not affect maternal-foetal transfer of P. falciparum IgG antibodies and effective IPTp with DP 
may not increase maternal to foetal transfer of antibodies. 
7.7 Implication of the study findings 
Overall, our study findings show that in an area of high malaria transmission intensity, the 
severity of PM, detected by the quantity of malaria pigment deposited in placental fibrin, rather 
than the mere presence or absence of PM that, was associated with a higher incidence of malaria 




severity of PM may be protective against malaria in male infants resident in a high malaria 
transmission intensity setting.  
The results of the comparison of incidence of malaria during infancy among infants born to 
mothers who were randomised to receive monthly IPTp with DP vs those born to mothers 
randomised to receive monthly IPTp-SP suggested that IPTp was associated with a moderate 
protective effect against malaria during the first 12 months of life among male infants [24]. This 
could be due largely to its impact on reducing the severity of past PM which was shown to be 
associated with a higher risk of malaria in male infants. This is supported by results of the 
mediation analysis which showed that a greater proportion of the effect of IPTp-DP versus IPTp-
SP on the incidence of malaria in male infants was mediated through reduction of PM. 
In this study, the observed association between PM, IPTp and the incidence of malaria could not 
be explained by the suggested reduced maternal-foetal transfer of P. falciparum IgG antibodies 
which was reported in previous studies [13, 14]. Both PM and IPTp did not impact on the 
maternal-foetal transfer of specific P. falciparum IgG antibodies and therefore did not impact on 
the level of these antibodies in cord blood. This suggests that the effect of PM on other factors 
such as cell-mediated immunity [37, 38] and IgG antibody acquisition during infancy [39], may 
explain the observed reduced incidence of malaria among male infants born to mothers with 
severe past PM. 
Altogether, the findings of this thesis suggest that in a setting of high malaria transmission 
intensity, where pregnant women are more likely to get multiple infections, severe PM is 
associated with a higher risk of malaria in male infants and that IPTp with monthly DP, a highly 
effective drug compared to SP, which reduces the severity of PM may be protective against 
malaria in male infants during the first year of life.  
7.8 Thesis strengths 
This study had several strengths including a rigorous study design, and diagnosis and 
classification of PM. The randomised, blinded design of this study reduced the potential effect 
of confounding factors and other biases which would have been difficult to adjust for during 
analysis. The substantial differences in efficacy between IPTp-DP and IPTp-SP on the risk of MiP, 
including PM, made it possible to test the hypothesis that highly effective interventions which 
substantially reduce the risk of MiP are protective against malaria during infancy. In addition, 
the birth cohort nature of the study, with monthly follow-up of infants at a dedicated study 
clinic, allowed for assessment of both asymptomatic parasitaemia and clinical malaria right from 




Diagnosing PM has been a challenge for previous studies that assessed associations between 
PM and malaria risk in infancy [1]. To address this, we used a combination of different methods 
to diagnose PM. In this thesis, PM was diagnosed from placental blood by microscopy and LAMP, 
and from placental tissue by histology. The advantage of using microscopy is that it is 
inexpensive and relatively easy to use, however, it only detects active or chronic infection and 
has limited sensitivity for detecting PM compared to molecular methods like LAMP, and 
histology [40]. In this study, 9% of the mothers had PM detected by microscopy, compared to 
22% which were detected by LAMP [7]. Like microscopy for detecting PM, LAMP detects active, 
or chronic infections, but not past infections. Placental histology is more sensitive than both 
microscopy and LAMP; in this study over 60% of the mothers had PM detected by histology 
compared to only 22% by LAMP [7]. The main limitation for histology is that it requires advanced 
technical skills which are not widely available. 
Leveraging on the different methods for detection of PM, this thesis used a modified system for 
classifying PM based on Muehlenbachs et al [41] and Ismail et al [42] which included four 
categories of PM: 1) no PM, 2) active PM, 3) mild-moderate past PM, and 4) severe past PM. 
This allowed us to evaluate severity of PM as shown by the quantity of malaria pigment 
deposition which has been shown to be associated with adverse birth outcomes [43], and in this 
study, was found to be associated with a higher incidence malaria in male infants. Future studies 
evaluating the association between PM and infant outcomes in high malaria transmission 
intensity settings should consider including PM categories based on severity of past infection. 
7.9 Thesis limitations 
This study also had several limitations which have been briefly discussed in the results chapters. 
Here, the limitations are discussed in detail. First, IPTp is recommended in pregnant women in 
both moderate and high malaria transmission settings [44]. However, this study was conducted 
in a setting of very high malaria transmission intensity, which limited the generalisation of the 
thesis findings to settings of moderate malaria transmission intensity. 
Second, the study had a limited sample size which reduced power to detect a significant 
difference, if one truly existed. It was expected that the incidence of malaria during infancy 
among infants born to mothers who received IPTp-SP would be at least 3 episodes per person 
year. However, in this study the incidence of malaria among infants born to mothers who 
received IPTp-SP was approximately 2 episodes per person year, which reduced the power of 
the study. Furthermore, stratified analyses, including those stratifying for infant sex and age, 
although planned a priori, were not put into consideration at study inception. This too limited 




Third, in this study, administration of all doses of IPTp-SP was directly observed while, for IPTp-
DP, only the 1st daily doses of the three daily doses given monthly, were administered directly 
observed. This could have limited the adherence of IPTp-DP if some mothers did not take their 
2nd or 3rd daily doses leading to under estimation of the effect of IPTp-DP on the risk of malaria 
in infancy compared to IPTp-SP. However, the approach of administering IPTp-DP with partial 
directly observed therapy is what would be done in routine care settings as administration of all 
three daily doses by direct observation would be very challenging. 
Fourth, in the assessment of the association between PM and the incidence of malaria in infancy, 
it is important to measure malaria transmission intensity at the level of the household so that 
this potential confounding by malaria exposure shared by both the mother and her infant can 
be adjusted for. However, we were unable to directly measure malaria transmission intensity 
using entomological measures (such as entomological inoculation rate) and epidemiological 
measures (such as parasite prevalence) due to resource limitations. Nonetheless, maternal 
parasitaemia detected at enrolment by microscopy and qPCR, and household type (whether 
modern house with nets in ventilators or traditional house with open eaves) were considered as 
proxy measures of malaria transmission intensity and these were adjusted for in the analysis. 
Fifth, in this study, placental inflammation was not included the grading of PM. The extent of 
placental inflammation has been shown to be associated with adverse birth outcomes similar to 
the level of malaria pigment deposition [41], but there is currently no data on the effect of 
placental inflammation on the incidence of malaria during infancy. Future studies should 
consider evaluating the effect of placental inflammation on the incidence of malaria during 
infancy. 
Finally, the mediation analysis performed for this study was limited by confounding. In this 
analysis, it was assumed that all confounding factors in the association between IPTp and the 
risk of PM, and between PM and the incidence of malaria were measured or controlled for. This 
assumption is valid for the association between IPTp and the risk of PM because the IPTp 
interventions were randomised which allowed control of both known and unknown 
confounders. However, in the association between PM and the incidence of malaria in infants 
only maternal parasitaemia status at enrolment, gravidity, house-hold type, and maternal IPTp 






Overall, this thesis found that in a setting of high malaria transmission intensity, severe past PM 
was associated with a higher incidence of malaria, complicated malaria, and parasitaemia in 
male infants. Monthly IPTp-DP, which has been shown to significantly reduce the risk of malaria, 
parasitaemia and PM during pregnancy compared to monthly IPTp-SP [7, 22, 23], was associated 
with a lower incidence of malaria, and complicated malaria, during infancy, but only among male 
infants. This suggests that IPTp with highly effective drugs could be protective against malaria in 
infants. Future IPTp studies conducted in both settings of moderate and high malaria 
transmission intensity, should consider follow-up of infants to evaluate the benefits of IPTp to 
the infant beyond the neonatal period, and assess the role of infant sex. Future studies in high 
malaria transmission settings evaluating the association between PM and infant outcomes 
should consider the severity of PM based on the proportion of HPF with malaria pigment 
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